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Abstract 
 
Background: Chronic obstructive pulmonary disease (COPD) is emerging as 
the third largest cause of human mortality worldwide, killing over more than 3 
million people annually. It is a defined as a chronic inflammatory lung disease 
characterized by airflow limitation that is not fully reversible. Tobacco smoking 
is the single most important causative factor for the development of COPD, 
especially in developed countries. Colonization/infection of the lower 
respiratory tract with microorganisms in COPD is likely to be one of the 
important factors driving inflammatory processes in the airways, possibly 
leading to long-term progression and exacerbations of the disease. Non-
typeable Haemophilus influenzae (NTHi) and Streptococcus pneumonia (S. 
pneumoniae) are the most important pulmonary bacteria during both stable 
phase of disease and exacerbations of COPD, but the underlying 
mechanisms for their prominence in these conditions remain elusive. 
Exposure to cigarette smoke has been shown to significantly increase 
pulmonary tissue bacterial infections (with both NTHi and S. pneumoniae) in 
cell culture and animal models, as well as human lung samples. Bacterial 
adherence to lung epithelium and subsequent tissue invasion is known to be a 
crucial step in the pathogenesis of respiratory infections. Notably, platelet 
activating factor receptor (PAFr) has been established as the primary 
attachment molecule for both NTHi and S. pneumoniae. Moreover, 
intercellular adhesion molecule-1 (ICAM-1) serves as an entry receptor for not 
only the majority (~60%) of human rhinoviruses (HRVs), but also for NTHi. 
Although the expression of these microbial receptors have been investigated 
in smokers, the expression pattern of these adhesion molecules in COPD has 
not been reported till date. 
 
Aims: I have investigated the expression pattern of airway epithelial PAFr and 
ICAM-1 in both the large and small airways, as well as lung parenchyma in 
tissues from: smoker with normal spirometry, COPD subjects (smokers and 
ex-smokers), and a group with small dysfunction only. I have also investigated 
whether blocking PAFr reduces the bacterial adherence to bronchial cells pre-
treated with cigarette smoke. 
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Methodology: I evaluated the expression of PAFr and ICAM-1 cross-
sectionally in both large (bronchial biopsies, EBB and resected lung tissue, 
RT) and small airways (RT) from: 16 EBB/8 RT smokers with normal lung 
function (NLFS); 10 with smoking-related small airway narrowing only; 15 
EBB/8 RT COPD smokers; 12 EBB/10 RT COPD ex-smokers, and compared 
these with 15 EBB/9 RT control tissues (NC). Anti-PAFr/ICAM-1 
immunostaining on paraffin-embedded tissue was quantified using computer-
aided image analysis. Moreover, human cultures bronchial epithelial BEAS-2B 
cells were exposed to cigarette smoke extract (CSE). PAFr and ICAM-
1 expression levels were determined using immunocytochemistry and qPCR. 
The epithelial cells were challenged with either NTHi or S. pneumoniae 
labeled with FITC, and bacterial adhesion was measured using 
immunofluorescence. The effect of a well-evaluated antagonist of PAFr, WEB-
2086, on binding of the bacterial pathogens to BEAS-2B cells was then 
assessed. With collaborators, I also carried out in-silico studies of the tertiary 
structure of PAFr and the binding pocket for PAF and its antagonist WEB-
2086. 
 
Results: Large airway epithelium showed markedly enhanced expression of 
PAFr in COPD-smokers especially (p<0.005) and also COPD-ex-smokers 
(p<0.002) compared to smokers with normal lung function. Moreover, 
significantly increased PAFr expression in small airway epithelium of all 
clinical groups was found compared with controls (p<0.01), but with no 
difference between smokers with or without COPD. Smoking history (pack-
year) correlated significantly with PAFr expression in the currently smoking 
individuals, especially in NLFS (r=0.9; p<0.002). An increase above normal in 
PAFr-expressing cells in the airway sub-epithelial Rbm was only significant in 
COPD smokers (p<0.007). A lesser increase in PAFr-expressing cell in 
alveolar epithelium (compared to airway epithelium) was uniformly found in all 
clinical groups compared with normal controls (p<0.01). In vitro analyses 
showed that PAFr expression by bronchial epithelial cells was upregulated by 
CSE, and significantly associated with increased bacterial (both NTHi and S. 
pneumoniae) adhesion. WEB-2086, a known PAFr-antagonist, reduced the 
epithelial adhesion by both NTHi and S pneumoniae to levels observed for 
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non-CSE exposed control cells. Furthermore, WEB-2086 was non-toxic 
towards the bronchial epithelial cells. Moreover, in silico analyses allowed 
identification of the binding pocket for PAF/WEB-2086 in the predicted PAFr 
tertiary structure.  
 
Significantly increased ICAM-1-positive cells were found in the epithelium of 
the both large (p<0.006) and small airways (p<0.004) of all clinical groups, 
compared to control tissue. Moreover, epithelial ICAM-1 expression was 
especially upregulated in the airway obstruction (CAL) group compared to 
smokers with normal lung function (p<0.007, for large airway expression; 
p<0.02, for small airway expression). Smoking history (pack-year) correlated 
significantly with ICAM-1 expression in both the large and small airway 
epithelium in the currently smoking individuals (r=0.49; p<0.03). In the sub-
epithelial Rbm, increase in ICAM-1 expressing cells was only significant in 
small airways in the CAL group (p<0.02). The staining patterns were quite 
intriguing: in the CAL group especially, both basal and luminal areas of 
epithelial cells stained heavily for ICAM-1, but so did goblet cells and sub-
mucosal glands. These features were little evident in either normal controls or 
NLFS subjects. 
 
Conclusion: The expression of epithelial PAFr and ICAM-1 is upregulated in 
both the large and small airways in smokers, but markedly so in COPD. 
Increased expression of these microbial receptors in the respiratory tract 
could be crucial in viral and bacterial infections known to be important during 
the course of the disease. 
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Chapter 1  	
COPD: An introduction 
 
1.1 Characteristics of COPD 
1.1.1 Clinical  
In the current perspective, the widely used functional definition of COPD 
drafted by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) 
defines COPD as "a disease state characterized by airflow limitation that is 
not fully reversible. The airflow limitation is usually both progressive and 
associated with an abnormal inflammatory response of the lungs to noxious 
particles or gases” (GOLD 2015). Although the definition includes 
‘inflammatory’ response as a hallmark of COPD, the data on inflammatory 
cellular profile in the airway wall is contradictory. Based on our laboratory 
findings (Figure 1.1), we conclude that the classic inflammation may not play 
a central role in COPD, at least in the early stages of the disease and in the 
airway wall (Sohal et al. 2015).  
 
Common signs and symptoms of COPD include chronic cough, shortness of 
breath and mucus hypersecretion. The major pathologic changes of COPD 
are observed in the airways. Lung parenchyma and pulmonary vasculature 
could also show significant pathological manifestations. 
 
The tracheobronchial tree is a highly branched system of conducting tubes, 
which can be divided schematically into large airways (airways with cartilage 
in their walls, usually >2mm in internal diameter) and small airways or 
bronchioles (no cartilage in their walls, usually <2mm in internal diameter) 
(Bohadana, Teculescu & Martinet 2004). The landmark study by Hogg et al. in 
late 1960s suggested that earliest pulmonary changes and airflow obstruction 
in smoking-related COPD occurs mainly at the level of the small conducting 
airways and surrounding alveoli, which become the major site of airflow 
obstruction (Hogg, Macklem & Thurlbeck 1968). Briefly, various cellular and 
biochemical processes in the lung result in progressive thickening of the wall 
in small airway with luminal narrowing, fibrosis and small airway obliteration 
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(~50%) (Belperio et al. 2003; Hogg et al. 2004; Hogg, McDonough & Suzuki 
2013). These changes increase airway resistance and airflow obstruction. 
Previous experimental measurements suggest that as high as 30-40% of 
airway resistance could be attributed to small airways (Takishima, Yanai & 
Sasaki 1991), which is considerably higher than what was estimated earlier 
(~20%) (Hogg, Macklem & Thurlbeck 1968).  
 
Airway inflammation has become something of a dogma in COPD literature 
but is really a phenomenon of the airway lumen until the disease is very 
severe (Hogg et al. 2004). More marked in the airway wall is remodeling in the 
form of epithelial goblet cell hyperplasia (bronchitis), epithelial squamous 
metaplasia and submucosal gland hyperplasia in majority of patients, 
emphysema develops only in a subset of individuals, possibly as secondary 
phenomena. 
 
The dilatation and destruction of the gas-exchanging tissue beyond the 
terminal bronchioles is termed “emphysema” (McDonough  et al. 2011). 
Emphysema is defined in pathologic terms as "alveolar wall destruction with 
irreversible enlargement of the air spaces distal to the terminal bronchioles 
and without evidence of fibrosis” (Snider et al. 1985), and in general, occurs a 
decade later than airway narrowing (Dunnill 1969). Morphologically, there are 
two main subtypes of emphysema (Kim, WD et al. 1991). The centrilobular (or 
centriacinar) emphysema is most closely associated with cigarette smoking, 
causing more severe small airways obstruction. The panlobular (or panacinar) 
emphysema is associated with α1-antitrypsin deficiency, resulting in an even 
dilatation and destruction of the entire acinus (Litmanovich, Boiselle & Bankier 
2009). 
 
Changes in the pulmonary vasculature include intimal hyperplasia and smooth 
muscle hypertrophy/hyperplasia, likely attributed to chronic hypoxic 
vasoconstriction of the small pulmonary arteries (Harkness et al. 2014). 
Emphysema can lead to loss of the associated areas of the pulmonary 
capillary bed and pruning of the distal vasculature, which can be detected 
radiographically. 
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Figure 1.1. Clinical characteristics of COPD. 
Primary phenomena include fibrosis and obliteration of small airways, as well 
as other airway remodeling changes such as squamous metaplasia, mucus 
hypersecretion and goblet cell hyperplasia in large airways. Airway luminal 
inflammation becomes prominent as the disease progresses, with 
inflammatory cells probably related to chronic infections with ‘respiratory 
pathogens’. These changes are associated increased risk of acute 
exacerbations of COPD, decreased quality of life and accelerated decline of 
lung function. Basal cells in the airway epithelium are increasingly regarded 
as extremely important in airway remodeling. One manifestation of this is the 
change on the features of the epithelium, but also include epithelial-
mesenchymal transition (EMT), type II or III, categorized on the basis of 
presence (type III) or absence (type II) of angiogenesis.  
 
Secondary phenomena include emphysema (enlargement and destruction of 
terminal bronchioles and alveoli), and lung cancer, potentially related to EMT, 
especially type III with angiogenesis in the reticular basement membrane 
(Rbm) and epithelium (Mahmood et al. 2015). 
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1.1.2 Physiological (Spirometric classification) 	
By standard definition, diagnosis of COPD requires the presence of poorly- 
reversible airflow obstruction using an objective spirometry assessment 
(Global Strategy for the Diagnosis 2015). The introduction of an obstructive 
index, i.e., the ratio of forced expiratory volume in 1 second (FEV1) to the 
forced expiratory vital capacity (FVC) (Hyatt & Black 1973), and its more 
modern equivalent of scalloping out of the expiratory limb of the maximal flow-
volume curve (Johns, Walters & Walters 2014) have become pivotal 
diagnostic indices in clinical medicine. Forced expiratory volume in 1 second 
(FEV1) indicates the volume of air exhaled under forced conditions in the first 
second. Forced vital capacity (FVC) is the determination of the vital capacity 
from a maximally forced expiratory effort. Both are measured after a full 
inspiration. Spirometry is a safe, non-invasive, practical and reproducible 
breathing test that can be performed quickly. Modern spirometers have the 
added advantages of yielding immediate computer-generated feedback to the 
operator on the quality and repeatability of the test, as well as real-time 
graphical display of the flow-volume curve. Spirometry is performed both 
before and after bronchodilator administration to confirm whether airflow 
limitation is present and whether it is partially-, fully- or non-reversible. The 
ratio of these two measures, i.e., FEV1/FVC is termed the forced expiratory 
ratio (FER), and a FER of <0.7 confirms the presence of airway obstruction, 
while FEV1% predicted is used to classify COPD severity (mild ≥80%, 
moderate 50-80%, severe 30-49%, very severe <30%).  
 
The social and economic burden of COPD occurs predominantly in Stages II 
and higher. However, the confirmation of COPD based on specific post-
bronchodilator FER of <0.7 has has certain limitations. The fixed ratio 
excludes normal age-related changes in airflow limitation (Ito & Barnes 2009). 
Evidently, there is a decline in FER associated with normal ageing. In healthy 
non-smoking adults, the decrease in FEV1 is about 30 mL/year with an upper 
limit of about 50 mL/year (Kerstjens et al. 1997). As a consequence, even in 
normal people, the lower limit of normal for FER also decreases with age and 
should be accounted for to confirm COPD (Hankinson, Odencrantz & Fedan 
	 5	
1999). Therefore, establishing COPD based solely on FER is likely to 
misclassify some healthy elderly as diseased (Stanojevic et al. 2008; Vaz 
Fragoso et al. 2010). More appropriate classification rules for COPD 
classification based on a lower limit of normal (LLN) i.e., more than 1.64·SD 
below the predicted level (5th percentile for age) has been proposed 
(Schermer & Quanjer 2007). This has not been widely accepted and many 
clinicians argue that it is important to accept that accelerated ageing of the 
airways/lungs even in non-smokers is a significant issue clinically, and if 
symptomatic, should be indeed treated as COPD. 
 
Detection of small airways function by spirometry is by measuring the forced 
expiratory flow over the middle half of the FVC (FEF25-75%) and forced 
expiratory flow at 75% of the FVC (FEF75%) (McFadden & Linden 1972). 
However, these measures do not contribute to clinical decision-making due to 
the dependency on the measurement of FVC and lack of repeatability 
(Quanjer et al. 2014). This area is currently being reconsidered with better 
indices of spirometric small airway function being proposed (Johns, Walters & 
Walters 2014). In addition, newer technology has been proposed (Milne & 
King 2014). It is worth emphasizing that major pathological damage has to 
take place in small airways well before dynamic lung function indices become 
abnormal. With current measurements, at this stage, COPD often advances to 
a moderate stage (Hogg, McDonough & Suzuki 2013) before detection 
(Johns, Walters & Walters 2014).   
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Table 1. Staging of disease severity. 
 
 
Despite the availability of all these measures, COPD still remains substantially 
under-diagnosed in the primary care settings, particularly due to underuse of 
spirometry and poor interpretation of spirometric data (Walters, JA et al. 
2008). Recently, Johns et al. summarized the data on use of spirometry in 
current perspective and stressed on the importance of early diagnosis of 
COPD based on quantification of the degree of concavity in the spirometric 
expiratory flow-volume curve (Figure 1.2) (Johns, Walters & Walters 2014).  
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Figure 1.2. Variables used to quantify global and peripheral concavity. 
A novel way of interpreting the expiratory limb of the F-V curve. Measured 
FEF50% and measured FEF75% are the forced expired flows when 50% and 
75% of the FVC has been expired. Reference FEF50% and Reference FEF75% 
are the reference flows that would be obtained if the flow-volume curve had 
zero curvature i.e., a linear descending limb (dotted line). The variable, y, is 
the volume to peak expiratory flow (PEF); a value of 0.6 L can be assumed for 
this. In this example, global concavity is approximately 50 Units and 
peripheral concavity is approximately 65 Units. Such an analysis may 
markedly improve the pick-up of early COPD (by perhaps 25%).  
From Johns, Walters and Walters (2014) with permission from AME 
Publishing Company.  
 
In most specialist practice, a further assessment of lung physiology in COPD 
also takes into account lung hyper-inflation (emphysema or just air-trapping 
due to small airway disease) using a body-plethysmograph, and also the lung 
diffusion capacity (oxygen-absorbing capacity) as a sensitive measure of 
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extent of emphysema. The diffusing capacity for carbon monoxide (DLCO) is 
an index of the degree of anatomic emphysema in smokers with airflow 
limitation, but is not needed for routine assessment of COPD. The DLCO 
decreases in proportion to the severity of emphysema; however, it can be 
difficult to detect mild emphysema because it is neither a sensitive nor a 
specific test (Bailey 2012). 
 
1.2 Epidemiology of COPD 
1.2.1  Global burden of COPD 	
The highly cited global burden of disease study (GBD) highlights COPD as 
being the sixth leading cause of death in 1990, increasing to fourth since 
2000, and projected to become the third by 2020 (Lopez et al. 2006). The 
Burden of Obstructive Lung Disease (BOLD) initiative was designed to be 
somewhat more accurate and develop standardized methods for estimating 
COPD prevalence world-wide that would be practical for use in countries with 
differing economic development profiles and also to then estimate the 
economic burden of COPD (Buist et al. 2005). BOLD study data from 12 sites 
(n=9425; in China, Turkey, South Africa, Austria, Iceland, Germany, Poland, 
Norway, Canada, USA, Philippines and Australia), up to 2006, reported the 
estimated population prevalence of COPD GOLD Stage II and higher as 
10.1±4.8%(SE) overall (11.8±7.9% for men and 8.5±5.8% for women). The 
prevalence of COPD increased with age and pack-years of smoking, although 
other risk factors, such as biomass use for heating and cooking, chronic 
occupational exposure to dusty environments and tuberculosis, could also 
contribute to location-specific variations in disease prevalence (Buist et al. 
2007).  
 
Halbert and colleagues (Halbert et al. 2006) conducted a systematic review 
and random effects meta-analysis quantified the global prevalence of COPD 
(62 studies published during 1990-2004 from 28 different counties). The 
prevalence of physiologically defined COPD (GOLD criteria) in adults (≥40 
years) was again approximately 9–10%. The authors also report the 
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prevalence of chronic bronchitis alone (6.4%, 38 studies) and emphysema 
alone (1.8%, 8 studies).  
 
Rycroft et al. reviewed 133 studies published between 2000-2010 the trends 
in the COPD prevalence (80 articles), incidence (15 articles), and mortality (58 
articles) in Australia, Canada, France, Germany, Italy, Japan, The 
Netherlands, Spain, Sweden, the United Kingdom, and the USA (Rycroft et al. 
2012). COPD prevalences ranged from 0.2% (Japan) to 37% (USA), but 
varied widely across countries and populations reported, COPD diagnosis and 
classification methods and age groups reported. The burden of COPD was 
more commonly reported in older populations (>75 years). Moreover, the 
prevalence of COPD has increased over time, although the rate of increase 
has declined in recent years, particularly among men.  
 
Similar to prevalence, the overall mortality rate varied between countries, 
ranging from 3–9 deaths per 100,000 in Japan to 7–111 deaths per 100,000 
in the USA (Rycroft et al. 2012). Respiratory diseases, including asthma and 
COPD, were the third leading non-communicable diseases (NCDs) causing 
4.2 million deaths globally in 2008 and are expected to become more severe 
in near future (WHO 2014b). Globally, COPD affects approximately 329 
million people, which accounts for nearly 5 percent of the total population (Vos 
et al. 2012). In terms of mortality, COPD resulted in 2.9 million deaths in 2013 
alone, which increased from 2.4 million deaths in 1990, which was published 
as an international collaborative global burden of disease project ('Global, 
regional, and national age-sex specific all-cause and cause-specific mortality 
for 240 causes of death, 1990-2013: a systematic analysis for the Global 
Burden of Disease Study 2013'  2015).  
 
In addition to mortality and morbidity burden of COPD, understanding the 
economic implications associated with the disease and its treatments is as 
important as understanding their clinical impact. Medical expenditures for 
treating COPD (chronic medication needs, frequent exacerbations, 
hospitalization and ambulatory oxygen therapy required by those with 
advanced COPD) and the indirect opportunity-lost costs of morbidity can 
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represent a substantial economic and social burden (Ramsey & Sullivan 
2003). In terms of global expenditure on COPD, the cost is expected to rise 
from US$2.1 trillion in 2010 to US$4.8 trillion in 2030, half of which is 
expected to arise in developing countries (Lomborg 2013). Of the US$2.1 
trillion expenditure in 2010, approximately US$1.9 trillion accounted for direct 
costs such as medical care, while US$0.2 trillion was spent as indirect 
productivity losses, such as absence from work (Bloom 2011).  
1.2.2 National burden of COPD in Australia 	
In Australia, the death rates due to COPD have approximately halved 
between 1979 and 2011 among males, although it increased between 1979 
and 1997 among females before starting to decline (Figure 1.3). Moreover, 
deaths due to COPD are higher among people of indigenous origin compared 
to non-indigenous Australians (AIHW 2012). All of this reflects current and 
legacy of smoking rates.  
 
Despite falling death rates, COPD is still a leading cause of death and disease 
burden, after heart disease, stroke and cancer. The principal risk factor for 
COPD in Australia is indeed cigarette smoking, like other developed and 
probably under-developed countries. Chronic respiratory diseases (including 
COPD) are the fourth leading cause of deaths annually (approximately 6% of 
total deaths in 2008) (AIHW 2012). COPD alone is the fifth leading cause of 
mortality, causing 6,122 deaths in 2011 (AIHW 2012). However, the median 
age of death from COPD was reported to be 81 years in 2007–2011. 
Moreover, data from The Sax Institute’s 45 and Up Study (n= 204,953; aged 
≥45 years) has found not only that two-thirds of deaths in current smokers can 
be directly attributed to smoking, which is much higher than the earlier 
international estimates of 50%, but in addition, current smokers are estimated 
to die an average of 10 years earlier than non-smokers (Banks et al. 2015). 
The age of 45 seems to be something of a watershed: if a smoker stops 
smoking, then they are largely unscathed, but beyond that real trouble starts. 
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Australian BOLD study estimates that approximately 14.5% (one in seven) 
Australians >40 years have airflow limitation of their lungs, which increases to 
29.2% in Australians >75 years. Moreover, around 7.5% Australians (>40 
years) have subjective symptoms and it is estimated that about half of them 
are under-diagnosed (Toelle et al. 2013).  
 
 
Figure 1.3. COPD death rates in Australia. 
The data is presented on a 3-year moving average, and smoking rates, 1945 
to 2010. The two are obviously closely linked, albeit with about 20 years lag-
phase. Source: (AIHW 2012).  
 
In terms of total costs, COPD is more costly per case than cardiovascular 
disease (CVD), osteoporosis or arthritis and therefore exerts a huge economic 
burden on Australia. COPD is Australia’s second leading cause of avoidable 
hospital admission (Glover et al. 2007). In 2008 alone, the total economic 
impact of COPD was estimated to be AU$98.2 billion. AU$8.8 billion was 
attributed to direct financial costs and AU$89.4 billion to the loss of wellbeing 
and productivity. Annually, the direct cost to the Australian health care system 
is estimated to be $900 million with hospital use contributing the largest share 
of health spending ($473 million) ('Access Economics’  2008).  
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1.3 Risk Factors for COPD 	
The risk factors for COPD can be broadly categorized as exposures and host-
related factors (Figure 1.4). Various strategic steps could be employed to 
minimize the exposures, at least partially, for each exposure category. 
However, host-related (genetic) factors possibly leading to lung pathology and 
appearance of symptoms are extremely difficult to control. These factors are 
briefly summarized here, with a major focus on cigarette smoke exposure.  
 
 
Figure 1.4. Known risk factors for COPD. 
1.3.1 Exposure 	
As mentioned earlier, under ideal conditions, pulmonary function increases 
during childhood and adolescence (FEV1), up to the age of 18–22 years and 
then plateaus before starting to decline as a normal process of ageing (Eisner 
et al. 2010), probably after about age 30-35. Various exposures that affect the 
normal lung growth phase leading to decreased maximal FEV1, shorten the 
plateau period, or increase the subsequent decline in pulmonary function 
could lead to COPD. In this section, the role of various exposures will be 
reviewed briefly.  
 
1.3.1.1 Cigarette Smoke (Active and passive smoking) 	
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Exposure to cigarette smoking (direct or indirect) is the principal causal factor 
for COPD. There are approximately 1.1 billion daily smokers globally, which 
could increase to 1.6 billion daily smokers by 2025 (Bilano et al. 2015). 
Currently, WHO estimates about 6 million annual deaths due to tobacco use 
(both smoking and smokeless). This total also includes about 600,000 people, 
estimated to die from the exposure of second-hand smoke. Mathers and 
Loncar (Mathers & Loncar 2006) project total tobacco-attributable deaths to 
rise from 5.4 million in 2005 to 6.4 million in 2015, which will further increase 
to 8.3 million in 2030 (7.4 million to 9.7 million). Tobacco-attributable deaths 
are projected to decline by 9% between 2002 and 2030 in high-income 
countries, but to double from 3.4 million to 6.8 million in low- and middle-
income countries. This is attributed to increasing total and smoking 
populations, lack of awareness and ineffective tobacco control policies in 
developing countries. In a systematic review with meta-analysis of the 
epidemiological evidence relating smoking to COPD, chronic bronchitis (CB; 
chronic cough and sputum production) and emphysema, Forey et al. analyzed 
218 studies (133 for COPD, 101 for CB and 28 for emphysema) (Forey, 
Thornton & Lee 2011). The authors reported that relative risk estimates are 
elevated for ever smoking (RR for COPD: 2.89; 95%CI: 2.63-3.17, n=129; 
RR for CB: 2.69; 95%CI: 2.50-2.90, n=114; RR for emphysema: 4.51; 95%CI: 
3.38-6.02, n=28), current smoking (COPD: 3.51; 95%CI: 3.08-3.99; CB: 
3.41; 95%CI: 3.13-3.72; emphysema: 4.87; 95%CI: 2.83-8.41) and ex-
smoking (COPD: 2.35; 95%CI: 2.11-2.63; CB: 1.63; 95%CI: 1.50-1.78; 
emphysema: 3.52; 95%CI: 2.51-4.94).  
 
Ng et. al. estimated the prevalence of daily smokers by age and sex and the 
number of cigarettes/smoker/day for 187 countries from 1980 to 2012. The 
authors show that the number of daily smokers (>15 years) increased 
significantly, from 721 million (95% uncertainty interval [UI], 700 million–742 
million) in 1980 to 967 million (95%UI, 944 million–989 million) in 2012 (Ng et 
al. 2014). Although the numbers are predicted to increase, due to population 
growth, the prevalence of daily tobacco smoking in the same population 
decreased from 41.2% (95%UI: 40.0%-42.6%) in 1980 to 31.1% (95%UI: 
30.2%-32.0%) in 2012 for men and from 10.6% (95%UI: 10.2%-11.1%) to 
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6.2% (95%UI: 6.0%-6.4%) for women (Ng et al. 2014). Substantial variation 
was observed across age, sex, number of cigarettes per smoker per day and 
various countries. A recently published study evaluating participants 
(n=1,389) from Tasmanian Longitudinal Health Study cohort (TAHS) 
concluded that heavy maternal smoking (>20 cigarettes/day) during childhood 
increases the prevalence of post-bronchodilator (BD) airflow obstruction in the 
middle-age (9.3%; n=123). Maternal smoking was also associated with a 1.8-
fold increase in the odds of airflow limitation for 7-year-old children, which was 
independent of gender and asthma severity. For the sub-group that was 
studied in middle age, heavy maternal smoking was associated with a 2.7-fold 
(95%CI: 1.3-5.7) increase in the odds of having post-BD airflow obstruction 
compared to individuals without exposure (Perret et al. 2016). 
 
The association between current smoking and death from COPD is 
significantly higher than non-smokers among individuals >55 years (Men: 
relative risk= 27.8; 95%CI: 24.1-32.0; Women: relative risk= 25.0; 95%CI: 
21.2-28.1). Among former smokers, the relative risk for mortality declined as 
the number of years since quitting increased (Carter et al. 2015). Moreover, 
the continuation of smoking is strongly associated with an increased rate of 
decline in lung function (FEV1) over time, compared to ex-smokers or non-
smokers (figure 1.5). This emphasizes the importance of smoking cessation 
for patients with chronic conditions such as COPD (Vestbo et al. 2011). In 
addition, second hand smoke exposure and children with smoking parents are 
also prone to development of airflow obstruction in non-smokers (Salvi & 
Barnes 2009). In smokers (>10 cigarettes/day), the decline in lung function 
can be much more rapid and frequently twice as great as in non-smokers 
(Rennard 1998). Evidence also highlights that active maternal smoking during 
pregnancy causes alterations in lung development and is responsible for both 
poor lung function and asthma in children (Gilliland et al. 2002). 
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Figure 1.5. Decrease in forced expiratory volume in 1 second, according to 
smoking status.  
Reproduced with permission from Fletcher & Peto (1977). Copyright BMJ 
publishing group. 
 
A number of potentially genetically controlled mechanisms have been 
suggested for explaining the role that cigarette smoke (CS) plays on lung 
tissue and parenchyma. Bronchial biopsies from mild to moderate COPD 
patients show significantly increased concentrations of CD8+ lymphocytes in 
proximal airways. The concentration of neutrophils in sputum also increases 
markedly (Keatings et al. 1996). CS mediates the production of inflammatory 
cytokines by directly stimulating epithelial cells and immune cells, particularly 
macrophages (Lim et al. 2000; Takizawa et al. 2001). CS appears to play an 
important role in the remodeling of the airways by interacting with epithelial 
cells, extracellular matrix and bronchial smooth muscle cells (Chung 2005). 
An imbalance in proteases/antiproteases is thought to lead to the destruction 
of compounds in the extracellular matrix, in particular elastin. A 40% alteration 
in the function of an antiprotease, α1-antitrypsin (ATT), has been reported in 
smokers compared to nonsmokers (Gadek, Fells & Crystal 1979). In addition, 
In another study published by BARR et al. [29], among 1,003
patients with COPD, 61% reported moderate or severe dyspnoea
and 41% reported a prior hospitalisation for COPD. The most
prevalent comorbid diagnoses were hypertension (55%),
hypercholesterolaemia (52%), depression (37%), cataracts (31%)
and osteoporosis (28%).
MORTALITY ATTRIBUTABLE TO COPD
According to the World Health Organization, COPD is the
fourth leading cause of death in the world, with approximately
2.75 million deaths per annum, or 4.8% of deaths. In Europe,
mortality rates vary from country to country: ,20 per 100,000
population in Greece, Sweden, Iceland and Norway, up to
more than 80 per 100,000 population in Ukraine and in
Romania. In France, the mortality rate is approximately 40
deaths per 100,000 population [30]. In developing countries,
mortality is also on the increase, in relation to the increase in
cigarette smoking. In China, tobacco is responsible for 12% of
deaths, with projections which show that this rate could reach
30% in 2030 [31].
Mortality from COPD is higher in males and increases with age
in those over 45 yrs old. Mortality also increases with severity
of disease. In the USA, within the framework of the National
Health and Nutrition Examination Survey (NHANES I), 1,301
deaths were analysed in a cohort of 5,542 adults. The presence
of COPD at various GOLD stages was associated with the
following risk of death, as defined by hazard ratio (HR). Stage
I: HR 1.4, 95% CI 1.31–1.70; stage II: HR 2.04, 95% CI 1.34–3.11;
severe COPD: HR 2.7, 95% CI 2.1–3.5 [32].
Several factors have been found to be predictive of mortality in
patients with COPD: severity of airflow obstruction, nutritional
status (body mass index), exercise capacity using the 6-min
walk test and severity of dyspnoea (the BODE index). This
index appears to predict mortality better than the FEV1 alone
[33]. The mortality rate during hospitalisation for exacerbation
of COPD is estimated to be 2.5–10%. The mortality rate after
hospitalisation varies between 16% and 19% in the 3 months
following hospitalisation, between 23% and 43% at 1 yr and is
55–60% at 5 yrs. After classifying patients by GOLD stage,
mortality rate at 5 yrs was 17% for stage I, 42% for stage II, 49%
for stage III and 73% for stage IV [23].
In France, an analysis of cause of death in subjects aged over
45 yrs revealed that in 2002 COPD represented 3% of deaths. The
diagnosis of COPD was associated in 48% of subjects with other
causes of death. Between 1979 and 1999, the trend in rate of
mortality remained stable in males and increased in females [34].
The only factors having demonstrated a reduction in mortality
in COPD are cessation of smoking [35] and oxygen treatment
[36] for patients with chronic respiratory failure (fig. 1).
RISK FACTORS FOR COPD
Risk factors are directly related to the interaction existing between
genetic predisposition and exposure to environmental factors.
The clinical manifestations resulting from this interaction will
also depend on the existence of associated comorbidities.
Active and passive smoking
Active smoking is the main risk factor for COPD. The risk
attributable to active smoking in COPD is thought to vary from
40% to 70% according to the country. Figure 2 shows that the
prevalence of chronic bronchitis increases with smoking and
with age. It should be noted that, at the time of this study, there
was a small proportion of patients with chronic bronchitis
despite the fact that they were nonsmokers [15].
Active smoking by females during pregnancy will also alter
fetal lung development and be responsible for asthma in
predisposed children [38]. In addition, consequence of passive
smoking is the lateness in lung development of the fetus.
The mechanisms of action of the components of cigarette
smoke on lung tissue and parenchyma are probably multiple.
Many arguments arising from in vitro and ex vivo experiments
are in favour of an inflammation of the airways, where the cell
and molecular agents differ from those present in asthma.
Histological analyses of bronchial biopsies from patients with
mild to moderate COPD show the presence of an infiltrate of
CD8+ lymphocytes in proximal airways. Neutrophils are
present in high concentrations in the sputum of patients with
COPD [39]. In addition, cigarette smoke directly stimulates
various types of cells, in particular macrophages [40, 41] and
epithelial cells of the airways [42], thus contributing to
increased production of mediators and cytokines that partici-
pate in maintaining the inflammatory reaction. Through their
interactions with the epithelium and extracellular matrix, the
bronchial smooth muscle cells would also appear to play an
important role in the remodelling of the airways observed in
COPD [43].
Other theories have been established to try and explain the
irreversible histological lesions caused by tobacco components.
For example, an imbalance in proteases/antiproteases is
thought to lead to the destruction of compounds in the
extracellular matrix, in particular elastin. This concept remains
controversial and is based on an original study demonstrating
a 40% alteration in the function of an antiprotease, a1-
antitrypsin, in subjects who were smokers, in comparison to
those who were nonsmokers [44]. Finally, there is a permanent
antagonism between the toxicity of oxidants present in
cigarette smoke and the antioxidant immune system. The
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FIGURE 1. Decrease in forced expiratory volume in 1 s (FEV1) according to
smoking status. Adapted from [37].
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the upset in the oxidant (present in CS) and antioxidant (immune system) 
balance results in oxidative stress and is a likely factor for chronic 
inflammation (MacNee & Rahman 2001).  
 
Validation of self-reported current smoking history by analyzing biomarkers 
associated with smoking increases the reliability and accuracy of both 
epidemiological and clinical analyses. We routinely performed exhaled CO 
measurements. Overall lifetime tobacco exposure is chiefly measured in pack-
years and is frequently collected by surveys/questionnaires/personal 
interviews, and relies on the participants’ responses (Florescu et al. 2009). 
Smoking habits vary greatly and are likely driven by changes in public health 
policies, as well as individual-associated factors such as occupational setup, 
socio-economic status (SES), and family-associated emotional incidents (e.g. 
death in family) (Hammond 2005). Inaccurate assessment of pack-years 
smoking may arise due to a number of reasons, such as poor recall of start 
age, failure of the participant to recall accurate exposure periods, false 
reporting, recall-bias, or loss of memory (Jaakkola & Jaakkola 1997). In 
addition, variable smoking habits for short periods are often either unreported 
or forgotten (England et al. 2007).  
However, although debatable, there is evidence that self-reported smoking 
behavior during an individual’s life-course is fairly reliable in most clinical 
studies (Kenkel, Lillard & Mathios 2003). Patrick and colleagues (Patrick et al. 
1994) conducted a meta-analysis of published studies (n=26) and concluded 
that self-reports are mostly accurate, with an high average sensitivity (87.5%) 
and specificity (89.2%). The authors also recommend validation of current 
self-reported smoking status/duration by biochemical markers of tobacco 
exposure, such as cotinine, a major metabolite of nicotine (Al-Delaimy 2002; 
Kvalvik et al. 2012; Montalto & Wells 2007) or exhaled CO measures as 
performed by our research nurse. 
 
Smoking cessation is the most effective and cost-effective intervention to 
prevent development and slow the progression of COPD. In terms of curbing 
the menace of tobacco smoking, Schauer and colleagues recently published 
that more than 50% of current smokers with a diagnosis of COPD were 
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offered cessation assistance counseling during their last clinic visit (Schauer 
et al. 2016). Healthcare professionals around the world should continue to 
provide tobacco cessation counseling, assistance and treatment to smokers 
with COPD in order to reduce the burden of smoking-related diseases, 
including COPD. The strategies for smoking cessation at a personal and 
community level are beyond the scope of this account, but a combination of 
limiting access (e.g. price), public media campaigns, quit facilities and 
potentially limiting supplies (e.g. Tobacco Free Generation legislation in 
Tasmania) are all important (Walters & Barnsley 2015). 
 
1.3.1.2 Environmental exposure to noxious particles and gases (air 
pollution) 	
Although it is less potent than the smoking effect, high levels of air pollution 
have also been implicated as risk factors for the development of COPD. 
Approximately 25–45% of COPD patients are never-smokers (Salvi & Barnes 
2009), in developing countries. Increasing population, urbanization, economic 
profile and pollution are a few of the factors and contribute substantially. The 
role of outdoor air pollution (including traffic-related fine particulate matter) as 
a causative factor for airflow limitation is gaining attention in recent times, due 
to increased vehicular pollution, as well as industrialization of the two most 
populated countries, China and India (Eisner et al. 2010).  
 
Particulate matter with a diameter of 2.5 microns or less (PM2.5), is 
considered to be the most health-damaging particles, as they could penetrate 
the deep lung tissue and initiate deleterious effects on the airway including but 
not limited to airway oxidative stress, pulmonary and systemic inflammation, 
ciliary dysfunction, amplification of infections, and increases in bronchial 
reactivity (Donaldson et al. 2002). The main components of PM10 are sulfate, 
nitrates, ammonia, sodium chloride, black carbon, mineral dust and water 
(WHO, 2014).  
 
Several investigators have assessed the effect of air pollution as a potential 
risk factor for COPD. In children and young adults, cross-sectional studies 
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have shown a relationship between higher outdoor pollutant levels (especially 
traffic related pollution) and lower lung function (Holguin et al. 2007; Janssen 
et al. 2003). Kulkarni et al. reported a likely causative dose-dependent inverse 
association between the carbon content (as a biomarker of particulate matter 
exposure, PM10) of airway macrophages with lung function in children 
(Kulkarni et al. 2006). Furthermore, exposure to traffic-related pollution, 
characterized by the residential distance from a highway, was associated with 
impaired lung growth and lung function deficits at 18 years of age 
(Gauderman et al. 2007). Also, higher traffic density and proximity to 
highways was significantly associated with lower lung function (FEV1) and 
FVC, but only in females (Kan et al. 2007), who are also at a greater risk of 
COPD than for those living farther away (Schikowski et al. 2005).  
 
Long-term exposure to airborne particles and particulate matter is significantly 
associated with the risk of premature death and acute care hospitalizations, 
especially in patients with severe disease (Wordley, Walters & Ayres 1997; 
Zanobetti, Bind & Schwartz 2008). Moreover, daily variation in exposure to 
outdoor air pollution (mainly the particulate matter) significantly correlates with 
acute exacerbations of COPD (Sunyer 2001). The mechanisms that underlie 
obstruction due to air pollution are likely to be the same or/and similar to those 
due to cigarette smoking, but we do not yet have evidence for this, in spite of 
the importance of the issue.  
 
1.3.1.3 Occupational exposure to dusts and fumes 	
Several longitudinal studies have shown an association between certain dusty 
occupational exposures and COPD, i.e., coal mining (Attfield 1985), gold 
mining (Holman et al. 1987), work related to tunnel-construction (Ulvestad et 
al. 2001), low levels of concrete dust containing crystalline silica exposure 
(concrete production industries) (Meijer, Kromhout & Heederik 2001), 
exposure to cotton in textile industries (Niven et al. 1997), workers exposed to 
welding fumes (Bradshaw et al. 1998), grain handlers and postal workers 
(exposure to endotoxins) (Schwartz et al. 1995) and animal feed industry 
(Post, Heederik & Houba 1998). In addition, exposures to chemical vapors, 
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irritants and fumes can also contribute to accelerated loss of airflow 
(Boschetto et al. 2006). One study involving railroad workers reported a 
positive association between COPD mortality and occupational exposure to 
diesel exhaust (Hart et al. 2006). 
 
A population-based study found positive associations between several 
occupational exposure measures (mineral dusts, metal dusts and fumes, 
organic dusts, irritant gases or vapors, sensitizers, organic solvents, diesel 
exhaust, and environmental tobacco smoke) with COPD, among both ever-
smokers and never-smokers (Weinmann et al. 2008). 
 
Experimental studies in animal models have demonstrated that exposures to 
several agents, such as sulphur dioxide, mineral dusts, vanadium and 
endotoxin, are capable of inducing chronic obstructive bronchitis (Boschetto et 
al. 2006). Intratracheally instilled silica (quartz) produces airflow obstruction 
(functional change), which correlate with the presence of both emphysema 
and small-airway lesions (Wright et al. 1988). Inorganic dusts containing silica 
is associated with neutrophil and macrophage accumulation and 
morphological changes in rat lung. These morphological changes in small 
airways and lung parenchyma were similar to those in rats treated with 
elastase (Churg, Hobson & Wright 1989). 
 
1.3.1.4 Biomass smoke inhalation 	
Various forms of biomass fuel (mostly animal dung, crop residues, and wood) 
are commonly used as sources of energy and constitute around 50% of total 
global household fuel consumption (cooking and heating in developing 
countries). Combustion of biomass fuel generates a large amount of smoke 
(>250 organic compounds, varying mainly by the type of fuel burnt and the 
combustion conditions) and adds to indoor and local air pollution (Naeher et 
al. 2007). Repeated and prolonged exposures to such biomass smoke with 
high emission factors (very low energy efficiencies; ~5‒10%), while cooking or 
heating in poorly ventilated houses, have been associated with increased 
mortality and morbidity worldwide (de Koning, Smith & Last 1985). The 
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percentage of population using such solid fuels varies greatly among various 
countries and regions. It ranges from 77% in sub-Saharan Africa to 16% in 
Latin America and the Caribbean and in Central and Eastern Europe. In the 
majority of industrialized countries, solid biomass fuel use is below <5% 
(Rehfuess, Mehta & Prüss-Üstün 2006). A study of 12,000 slum dwellers from 
Pune (India) revealed an overall COPD prevalence of 6.5% (8.5% in males 
and 4.5% in females). Of those diagnosed with COPD, 69% were never 
smokers (Brashier 2005). 
 
Hu et al. reviewed the available evidence up to 2010 in a meta-analysis and 
found a significant elevation in risk of developing COPD has been reported in 
people exposed to biomass smoke, compared with those without the 
exposure (OR: 2.44; 95% CI: 1.79-3.33). Biomass smoke was a significant 
risk factor for developing COPD in both males (OR: 4.30; 95%CI: 1.85-10.01) 
and females (OR: 2.73; 95%CI: 2.28-3.28) (Hu et al. 2010). Similarly, 
exposure to solid fuel (principally wood) smoke is consistently associated with 
COPD (OR: 2.80; 95%CI: 1.85-4.0) and chronic bronchitis (OR: 2.32; 95%CI: 
1.92-2.80) (Kurmi et al. 2010). Exposure to biomass smoke from an early age 
is likely to result in impaired lung growth in later life. In a Nepalese study, the 
prevalence of airflow obstruction (FEV1/FVC) in the biomass smoke-exposed 
group (20%) was twice that in the unexposed controls (11%) (Kurmi et al. 
2013). 
 
Animals exposed to wood smoke, at varying concentrations and times, 
showed reduced carbon monoxide diffusing capacity and increased airway 
resistance high-exposure group. Moreover, mild chronic inflammation and 
squamous metaplasia were also observed in the larynx of the wood-smoke 
exposed groups (Tesfaigzi et al. 2002). Similarly, guinea pigs subjected to 
wood smoke showed increased alveolar-capillary permeability, microvascular 
permeability, and histological injury scores in both airways and parenchymal 
tissues (Lin et al. 2001). In graded wood smoke exposure in Sheep, lung 
myeloperoxidase (MPO) activity was found to be higher (~19-fold) in smoke-
exposed animal’s lung tissue than in controls. A dose-dependent injury to 
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tracheobronchial epithelium and lung parenchyma in response to smoke was 
also reported (Park et al. 2004). 
 
Women (and children) who spend most of their time indoors, especially in 
rural areas of developing countries, are exposed for 4-6 hours daily to higher 
concentrations of solid biomass fuel smoke that are produced by inefficient 
open fires. Ramírez-Venegas et al. reported that such women develop clinical 
characteristics of COPD, with reduced quality of life, and increased mortality 
comparable to that of tobacco smokers (Ramirez-Venegas et al. 2006), mainly 
characterized by greater small airway fibrosis (Rivera et al. 2008). The 
prevalence of COPD in non-smoking females living in rural areas in China 
was estimated to be three times higher than those living in urban areas (Liu et 
al. 2007).  In a Mexican study, women exposed to biomass smoke had more 
air trapping but less frank emphysema than subjects who were exposed to 
tobacco smoke, implying an airway-predominant phenotype (Camp et al. 
2014). 
 
Better home ventilation and home design, and change from biomass to 
cleaner fuels is urgently needed in order to reduce biomass smoke-induced 
mortality and morbidity. Furthermore steps should be taken to increase 
awareness about the health effects of biomass fuel smoke inhalation among 
physicians and health administrators, which may improve diagnosis and 
treatment of affected patients and trigger preventive actions through 
education, research, and policy change (Silva, Oyarzun & Olloquequi 2015). 
1.3.2 Host factors 
 
1.3.2.1 Age 	
Global demographic projections suggest that the proportion of population over 
the age of 60 years will double from around 11% in 2000 to 22% in 2050, with 
the absolute number of people >60 years estimated to increase from 605 
million to 2 billion by 2050. More than 80% of this demographic group will live 
in less-developed countries, compared with about two-thirds at present (WHO 
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2014). Ageing is associated with a progressive degeneration of the lung 
tissues, which has a negative impact on the structure and function of lungs, 
and is an independent predictor for COPD (Decramer & Rossi 2001). These 
inherent changes coupled with other risk factors (exposures) may potentially 
lead to symptomatic airflow limitation. Thus, COPD is reported to be three-
times higher in the elderly (>60 years), than other age groups (Fukuchi et al. 
2004). In an international multisite survey, the overall prevalence of COPD 
was approximately 10% for people >40 years, nearly doubling with every 10-
year increment of age, and so estimated to reach 19–47% for men and 6–
33% for women aged 70 years and older (Buist et al. 2007). In individuals 
over 60 years, COPD is the third-most burdensome disease after ischaemic 
heart disease (IHD) and stroke, accounting for 43·3 million disability adjusted 
life years (DALYs) globally, with again 86% of this estimated burden arises in 
under-developed regions ('Global, regional, and national age-sex specific all-
cause and cause-specific mortality for 240 causes of death, 1990-2013: a 
systematic analysis for the Global Burden of Disease Study 2013'  2015).  
 
The process of ageing also has profound effects on the cellular, organ and 
organismal level. The aging-associated inflammation/structural change is the 
results of several factors, such as failure of reactive oxygen species (ROS) 
elimination, impaired repair of damaged DNA, reduction in anti-ageing 
molecules (histone deacetylases and sirtuins) and/or stimulation of pro-ageing 
molecules and telomere shortening (Ito & Barnes 2009). Natural ageing of the 
lung is also associated with dilatation of alveoli with an enlargement of 
airspaces and decrease in gas exchange surface area, together with a loss of 
supporting tissue for peripheral airways (termed as “senile emphysema”), 
resulting in decreased static elastic recoil of the lung and increased residual 
volume and functional residual capacity (Janssens, Pache & Nicod 1999). 
However the changes in structure and functional characteristics caused by 
isolated airspace enlargement seen in the elderly lung (>60 years) could be 
differentiated from pathological (smoking-related) emphysema by the absence 
of alveolar wall destruction (Verbeken et al. 1992).  
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Functionally, vital capacity is reduced with ageing, although the total lung 
capacity remains unchanged (Chan & Welsh 1998). Respiratory muscle 
strength has been shown to decrease in 65 to 85-year-old healthy males. 
Thus, diaphragm strength is reduced by approximately 25% in healthy elderly 
individuals compared with young adults (Enright et al. 1994). There is a 
decline in the diffusing capacity of the healthy nonsmoker lung for carbon 
monoxide (DLCO) of 2.03 mL/min/mm Hg per decade from middle age onward 
for men and a decrease of 1.47 mL/min/mm Hg per decade for women (Neas 
& Schwartz 1996). A progressive decline in maximum oxygen consumption 
(Vo2 max) also occurs with advancing age, principally due to the loss of 
muscle mass and respiratory limitations with senescence (Fleg & Lakatta 
1988).  
 
1.3.2.2 Genetic Factor 	
Although inconsistent, several population studies have suggested a shared 
genetic risk of COPD. The strongest genetic risk factor is the hereditary 
deficiency of α1-antitrypsin (ATT, encoded by SERPINA1) (Stoller & 
Aboussouan 2005), which accounts for around 5% of cases of COPD, yet 
only a minority (~4%–5%) of ATT-deficient individuals are identified 
(Lieberman, Winter & Sastre 1986), that too at a delay of around 5 to 10 years 
(Stoller et al. 2005). Large-scale genome-wide studies (GWAS) have 
identified key polymorphisms linked to COPD, including a-nicotinic 
acetylcholine receptor (CHRNA 3/5), TNS1, GSTCD, HTR4, AGER and 
THSD4 (Pillai et al. 2009; Repapi et al. 2010; Soler Artigas et al. 2011). In a 
recently published meta-analysis of COPD, Cho and coworkers (Cho et al. 
2014) confirmed associations at three known loci and found additional 
genome-wide significant associations with moderate-to-severe COPD near 
RIN3 and with severe COPD near MMP12 and TGFB2.  
 
Data from current and former smokers participating in the COPDGene Study 
indicate that subjects with mild airflow obstruction showed substantial clinical 
heterogeneity, with FAM13A and BICD1 associated with emphysematous 
subjects and HHIP and CHRNA3 associated with the lowest FEV1 %predicted 
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cluster (Lee et al. 2014). The recent advances in GWAS in identifying the 
genomic regions associated with COPD have certainly improved our 
understanding. Given the large differences in genetic background of different 
ethnic populations, fairly large-scale studies in genetically diverse populations 
are warranted. 
 
1.3.2.3 Gender 	
Historically, COPD has been considered as a disease of males who started 
smoking several decades before women. Indeed, growing epidemiologic data 
since late 90s suggest that females may be more susceptible than males to 
the effects of cigarette smoking and development of COPD. The interaction of 
gender and smoking on development of COPD was assessed in two 
population studies, the Copenhagen City Heart Study (CCHS) and the 
Glostrup Population Studies (GPS) (n=13,897). The participants were 
followed for 7-16 yrs. Smoking had greater impact on the lung function of 
females than males in both the studies. Moreover, the risk of hospitalization 
for COPD was higher in females than in males (Prescott et al. 1997).  
 
Among current smokers, males and females differ in their susceptibility to 
developing COPD. In a systematic review and a meta-analysis (11 studies; 
n=55,709), Gan et al. presented additional evidence that smoking women 
have more decline in lung function, especially over the age of 45–50 years 
(Gan et al. 2006), 0.98%/pack-year in men vs. 1.21%/pack-year for women 
(Dransfield et al. 2006). In another similar study of COPD patients, Sorheim et 
al. reported that women had a lower FEV1 (48.7% predicted for women vs. 
55.8% predicted for men) and higher prevalence of GOLD COPD stage (III 
and IV) in both the low and high smoke exposure subgroup (Sørheim et al. 
2010). Again, with a different approach in a longitudinal study of COPD 
patients participating in the Evaluation of COPD Longitudinally to Identify 
Predictive Surrogate Endpoints (ECLIPSE) study (n=1928), the annual 
decline in CT lung density was more rapid in women than in men and in 
current smokers (additional-0·29 [SE 0·14] g/L per year) than in former 
smokers (Coxson et al. 2013).  
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Females also report more symptoms, such as dyspnea, depression and lower 
health-related quality of life, and appear to have an airway predominant 
disease phenotype (Allen-Ramey, Gupta & DiBonaventura 2012; Martinez et 
al. 2007).  
 
The effects of hormones on COPD are still largely unknown. One study 
demonstrated no difference in the incidence of COPD in women on hormone 
replacement therapy (Barr et al. 2004), while another study showed that 
hormone replacement therapy did significantly improve lung function in post-
menopausal women (Carlson et al. 2001). Although its mechanisms are yet to 
be fully elucidated, it is likely to be a dose response as women are smaller in 
size and their lungs are subjected to a greater stress for the same 20 
cigarettes/day compared to men (Prescott et al. 1997). The notable sex 
disparity in COPD may have potential diagnostic, therapeutic and prognostic 
implications and are crucial for effective management of female patients with 
airway diseases. 
 
1.3.2.4 Asthma (bronchial hyper-responsiveness, BHR) 	
Many individuals share characteristics of both asthma and COPD, and have 
largely excluded from pharmaceutical studies. This Asthma-COPD overlap 
syndrome (ACOS) occurs in patients with fixed airways obstruction 
characteristic of COPD and presence of typical symptoms and features 
associated with asthma (eosinophilic bronchial and systemic inflammation, 
increased reversibility of airflow obstruction, and increased response to 
inhaled corticosteroids). In terms of prevalence of ACOS, Vonk et al. studied 
228 adults (13-44 years at baseline) who were followed up for 26 years, and 
reported that approximately 16% of asthmatic patients developed fixed airway 
obstruction (reduced FEV1, and poor reversibility of airway obstruction), as 
well as symptoms characteristic of COPD (cough, phlegm, dyspnoea) at 
follow (Vonk et al. 2003).  
 
	 26	
Compared to COPD individuals, patients with ACOS have more rapid disease 
progression and experience more frequent exacerbations as well as more 
wheezing and dyspnoea (Barrecheguren, Esquinas & Miravitlles 2015). 
Clinically, asthmatics with fixed airflow obstruction have distinct clinical 
characteristics compared with patients with smoking-related COPD, and have 
significantly more eosinophils in peripheral blood, sputum, bronchoalveolar 
lavage, and airway mucosa; fewer neutrophils in sputum and bronchoalveolar 
lavage fluid; a higher CD4+/CD8+ ratio of T cells infiltrating the airway 
mucosa; and a thicker reticular layer of the epithelial basement membrane 
(Fabbri et al. 2003). In a 5 years follow-up study, patients with COPD (n=21) 
and asthmatics with irreversible airflow obstruction (n=16) had a greater rate 
of lung function decline as well as significantly increased exacerbation rates, 
compared to the asthma group with fully reversible airflow obstruction (n=15) 
(Contoli et al. 2010). Data from our group (n=1,389) from the population-
based Tasmanian Longitudinal Health Study (TAHS), shows that both active 
smoking and current clinical asthma contribute substantially to fixed airflow 
obstruction in middle age (overall prevalence: 6.0%; 95%CI; 4.5–7.5%), 
especially among those with atopy (Perret et al. 2013). 
 
1.3.2.5 History of respiratory infections (Pneumonia and Tuberculosis) 	
Childhood lower respiratory tract infections (LTRIs), especially tuberculosis 
(TB) and pneumonia, could damage the respiratory tract and possibly lower 
lung function permanently. With increasing age it may lead to accelerated 
decline in airflow and increase the risk for COPD (Svanes et al. 2010). The 
European Community Respiratory Health Survey assessed a total of 9,175 
individuals (20-44 years) and concluded that childhood serious respiratory 
infections potentially have a detrimental effect on adulthood lung function 
(FEV1/FVC ratio: -1.2%; 95%CI: -1.8 to -0.6), and could influence 
development and persistence of adult respiratory morbidity (Dharmage et al. 
2009). 
We have recently published a review on the overlap of TB and COPD, in 
which we discussed the increased risk of developing airflow obstruction 
characteristic of COPD, post successful treatment of TB (O'Toole, Shukla & 
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Walters 2015). It is suggested that active TB disease can lead to localised 
bronchial fibrosis, and/or parenchymal destruction (emphysema), with loss of 
elastic recoil (Jordan, Spencer & Davies 2010). However, TB itself, if treated 
early, does not alter the major multiplicative effect with smoking on COPD.  
 
In addition to TB, epidemiological evidence exists suggesting an association 
between childhood pneumonia and obstruction (loss of lung function) in adult 
life. This certainly raises the question of whether childhood pneumonia is a 
risk factor COPD. As a part of United States COPDGene Study, Hayden and 
colleagues collected data from 10,192 individuals (45-80 years) and 
concluded that individuals who reported pneumonia during childhood are at 
greater risk of smoking-related COPD, chronic bronchitis, frequent episodes 
of COPD exacerbations, and lower lung function (OR: 1.40; 95%CI: 1.17-
1.66) (Hayden et al. 2015). Recently published data from a longitudinal study 
as a part of Tucson Children’s Respiratory Study in 44 subjects, the authors 
conclude that radiographically diagnosed pneumonia before the age of 3 
years was associated with small but persistent lung function deficits (mean: -
2.5%; SE: -0.8% in post-bronchodilator FEV1/FVC) up to age 26. Other lower 
respiratory infections (n=294) at an early age were also associated with very 
mild loss of lung function (mean: -1.1%; SE: -0.5%; post-bronchodilator 
FEV1/FVC) (Chan et al. 2015). Recent statistical data from our group 
(n=1,389, TAHS study) suggest that childhood measles significantly worsens 
the adverse association of having current asthma and smoking on chronic 
airflow limitation in the middle age. Moreover, childhood pneumonia was 
associated with reductions in adult total lung capacity (Jennifer et al. 2014).  
 
1.3.2.6 Socioeconomic status (SES)    	
Socioeconomic status (SES), commonly measured by education, occupation, 
and/or income has a profound impact on health and longevity. Once COPD 
has developed, SES may also influence the prognosis of the disease 
(Miravitlles et al. 2011; Pena et al. 2000). Various factors such as differences 
in COPD-treatment, varying smoking habits, unemployment rates, lack of 
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social relations and living alone, are frequently present in individuals with low 
SES and could negatively influence prognosis (Lange et al. 2014). 
 
A social class gradient in the prevalence of respiratory symptoms in adults 
(cough and sputum) was first reported in early studies in the UK (Speizer & 
Tager 1979). In a study conducted in two British towns based on mortality 
rates from respiratory diseases (high mortality: Caerphilly; Bath: low 
mortality), the overall mean FEV1 and FVC was found to be significantly 
higher in Bath than Caerphilly (Burr & Holliday 1987). Individuals at the lowest 
SES are twice as likely to have poor COPD outcomes compared to those of 
the highest SES. In addition, there is a significant negative correlation 
between lung function (FEV1 reductions of >300 mL in men and >200 mL in 
women) and SES (Hegewald & Crapo 2007). Yin et al. showed that subjects 
with low educational level had a significantly increased risk of COPD. 
Similarly, increased risk was observed for household income and COPD (OR: 
1.64; 95%CI: 1.28-2.09), but only in urban setting (Yin et al. 2011).  
 
In Victoria (Australia), subjects living in the most disadvantaged areas had a 
significantly greater COPD burden (r=-0.39), disease readmissions (r=-0.49) 
and mortality (r=-0.51). Moreover, Gershon et al. found that COPD-mortality 
declined faster in people with the highest SES (38%) compared with the 
lowest SES (30%), causing increased disparity between rich and poor 
(Gershon et al. 2014).  
 
1.3.2.7 Nutrition 	
Different dietary factors (dietary-patterns, foods, nutrients, vitamin D etc.) 
have been associated with the respiratory function in COPD along with 
complex interplays between environmental and genetic factors (Berthon & 
Wood 2015). Several studies have reported that fruits and vegetables exert 
beneficial effects on lung health (Keranis et al. 2010). Dietary fiber intake was 
also independently associated with higher pulmonary function and reduced 
prevalence of COPD in a study conducted in the USA (Kan et al. 2008). 
Moreover, frequent consumption of cured meats (high in nitrites) was 
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associated with higher prevalence and incidence of COPD among men in the 
USA (Varraso et al. 2007). It has also been suggested that subjects deficient 
in certain nutrients such as magnesium, omega(ω)-3 fatty acids, and lower 
fish intake had lower FEV1 than those who had sufficient nutrient intake 
(Britton et al. 1994; Shahar et al. 1994). Epidemiological studies have shown 
promising associations between vitamin D and lung health. Foong and Zosky 
reviewed the role of vitamin D deficiency in disease onset, progression and 
exacerbation of COPD, and concluded that vitamin D plays a key role in the 
immune function and/or lung growth, although only reversing vitamin D 
deficiency is promising (Martineau et al. 2015). The effect of vitamin D on 
microbe-induced exacerbations is less clear (Foong & Zosky 2013). Holistic 
management for these patients should be revisited, which could include 
nutritional modulation. Moreover, metabolic syndrome must be considered in 
the management of COPD, with recent evidence indicating that obesity itself 
can increase BHR (Byrne et al. 2015). 
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Chapter 2  
 
Respiratory infections in smokers and COPD 
 
2.1 Cigarette smoke (CS) exposure and risk of respiratory infections 
2.1.1 Components of CS 	
CS is recognized as a crucial factor for increased risk of respiratory infections, 
as well as host immunity in healthy individuals. Various ingredients, including 
the tobacco blend, the cigarette paper, the type and efficiency of the filter, and 
the degree of tip ventilation determine the chemical composition of cigarette 
smoke. More than 4,500 different substances have been identified in fresh 
CS. Chemical entities include neutral gases, carbon oxides, nitrogen oxides, 
amides, imides, lactames, carboxylic acids, lactones, esters, aldehydes, 
ketones, alcohols, phenols, amines, volatiles N-nitrosamines, N-heterocycles, 
hydrocarbons, nitriles, anhydrides, carbohydrates, ethers, nitro-compounds, 
metals and short- and long-living radicals. The quantities of the components in 
the mainstream smoke of a single cigarette vary greatly (Borgerding & Klus 
2005).  
 
In addition to chemicals, the bacterial metagenomic data from a cigarette-
based study revealed 15 different classes of bacteria and a broad range of 
potential pathogens in >90% of all cigarette samples (Acinetobacter, Bacillus, 
Burkholderia, Clostridium, Klebsiella, Pseudomonas aeruginosa, Serratia, 
Campylobacter, Enterococcus, Proteus and Staphylococcus) (Sapkota, 
Berger & Vogel 2010). Although several studies have documented the 
presence of microbial toxins (both bacterial and fungal), the risk of infection by 
potential pathogens from inhaling the burnt CS remains unclear (Larsson et 
al. 2008).  
 
Inhaled particulate matter from CS is deposited in the respiratory tract in a 
particle-size dependent manner. Larger particles (diameters >0.1 µm) are 
deposited in the upper and larger airways, and smaller particles (<0.1 µm) 
penetrating deep into the alveolar spaces, as well as more rapid uptake into 
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cells, and into circulation (Oberdorster et al. 2002). Impaired clearance of this 
particulate matter causes particle retention in lung tissues, resulting in a 
chronic, low-grade inflammation that may be important in the progression of 
chronic lung diseases associated with long-term smoking (Ling & van Eeden 
2009).  
2.1.2 CS exposure and risk of LRTI 	
Lower airway bacterial colonization (assessed in BAL sample) was found in 
approximately 60% of asymptomatic smokers (Qvarfordt et al. 2000). 
Bacterial colonization of the human respiratory mucosal surface is a dynamic 
process in which bacteria are acquired, replaced, and reacquired many times 
in a lifetime. Data from both prospective and retrospective studies have 
shown increased bacterial and viral infections among cigarette smokers 
compared with non-smokers (Sherman 1992).  In a study of 867 individuals 
(both males and females), the authors found that smoking significantly 
increases the likelihood of having a lower respiratory tract illness, as well as 
severity of acute respiratory tract infections by bacterial pathogens when they 
occur, resulting in morbidity and lost productivity (Aronson et al. 1982). A 
recent study also showed that current smoking status is associated with a 
higher mortality from various infections (relative risk: 2.3; 95%CI: 2.0-2.7) 
(Carter et al. 2015).  
 
Bensenor et al. reported an increased risk of prolonged ‘colds’ in women who 
were heavy smokers, while nonsmoking women passively exposed to CS had 
both more frequent and longer duration of such colds (Bensenor et al. 2001). 
As documented extensively, the most frequent microorganisms isolated from 
the lower respiratory tract of smokers and of persistently colonized patients 
are non-typeable H. influenzae (NTHi), S. pneumoniae and P. aeruginosa (the 
latter only in more severe stages of COPD). Furthermore, NTHi is also the 
most frequently isolated bacterial pathogen from patients with acute 
exacerbations of COPD (Sethi & Murphy 2008). 
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Zalacain et al. found current smoking to be significantly associated (OR: 3.17; 
95%CI: 2.50–8.00) with pulmonary infection with pathogenic bacteria, with H. 
influenzae, S. pneumoniae and M. catarrhalis being the most frequently 
cultured species (Zalacain et al. 1999). Exposure to cigarette smoke also 
increased invasive pneumococcal infections in adult smokers (Nuorti et al. 
2000). Futher cross-sectional surveillance study of nasopharyngeal and 
oropharyngeal carriage of S. pneumoniae and H. influenzae in 208 children 
aged <60 months and their mothers found higher S. pneumoniae carriage rate 
not only in actively smoking mothers, but also the children exposed to CS, 
compared to nonsmoking mothers and non-exposed children respectively. 
However, smoking or exposure to smoke did not increase upper airway H. 
influenzae carriage rates either in children or mothers (Greenberg et al. 2006). 
 
Gaschler et al. observed increased pulmonary inflammation and lung damage 
in CS-exposed NTHi-challenged mice as compared with control NTHi-
challenged mice. The authors reported that NTHi-challenge in CS-exposed 
mice resulted in a noticeable upregulation of the inflammatory mediators, such 
as monocyte chemotactic protein (MCP)-1, MCP-3, MCP-5, interferon 
gamma-induced protein (IP)-10, and macrophage inflammatory protein (MIP)-
1γ, while control NTHi-challenged mice showed a different profile of elevated 
levels of tumor necrosis factor (TNF)-α, interleukin (IL)-6, (MIP-2), and 
KC/GROα (Gaschler et al. 2009).  
 
The effect of tobacco smoking on the occurrence of pneumonia in the adult 
community was provided by a population-based case-control study (controls: 
475; patients: 205) in Barcelona (Spain). The authors found that smoking any 
type of tobacco had an increased risk of CAP for ever-smokers (OR: 2.0; 
95%CI: 1.24-3.24), current smokers (OR: 1.88; 95%CI: 1.11-3.19); and ex-
smokers (OR: 2.14; 95%CI: 1.26-3.65). A positive trend for increased risk of 
CAP was observed for an increase in the duration of the habit, the average 
number of cigarettes smoked daily, and cumulative cigarette consumption. 
This shows that giving-up smoking is still a big risk factor, though former 
smokers did have 50% reduction in the OR 5 years after the cessation of 
smoking (Almirall et al. 1999). In a prospective study during the period of 1997 
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to 2011 (n=1387), current smoking was also significantly associated with 
elevated risk of invasive pneumococcal disease, even in young adults (Grau 
et al. 2014). In another multicenter, prospective cohort study (n=4,288), Bello 
et al. reported that current smokers with pneumococcal community acquired 
pneumonia (CAP) often developed severe sepsis and require hospitalization 
at a younger age, despite fewer comorbid conditions. In consequence, 
continued smoking increased the risk of 30-day mortality independent of 
tobacco-related comorbidity, age, and other comorbid conditions (Bello et al. 
2014).  
 
The relative risk of development of tuberculosis for heavy smokers compared 
with nonsmokers is also significantly higher (RR: 2.17; 95%CI: 1.29-3.63) (Yu, 
Hsieh & Peng 1988). In a case-control study of the smoking habits of 27,000 
urban and 16,000 rural men in India, Gajalakhsmi et al. found higher 
tuberculosis prevalence risk ratio 2.9 (95%CI; 2.6-3.3) for ever-smokers 
compared with never-smokers. The authors also found that the smoking 
attributable fraction of deaths from tuberculosis was 61%, which was more 
than smoking-attributable deaths from vascular disease or cancer 
(Gajalakshmi et al. 2003). 
 
A number of studies have established that CS is also associated with 
significantly increased risk of pulmonary viral infections. Using in-vivo mice 
models, it has been shown that CS indeed affects inflammatory processes, 
viral clearance and secondary immune protection post-influenza virus 
infection (Gualano et al. 2008). It has been suggested that CS mainly affects 
primary antiviral inflammatory processes, whereas secondary immune 
protection remains intact (Robbins et al. 2006). Moreover, smokers exhibited 
higher incidence of non-acute viral infection (clinical ‘cold’) than nonsmokers 
(OR: 2.23; 95%CI: 1.03-4.82), to specific viruses (Rhinovirus, Respiratory 
Syncytial Virus or Coronavirus) (Cohen et al. 1993). 
 
2.1.3 Second-hand smoke (SHS) exposure and risk of LRTI 	
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There is robust evidence that exposure to SHS has similar (although 
quantitatively less) adverse effects to active smoking on lung infections, both 
in children (Kum-Nji, Meloy & Herrod 2006; Nandi et al. 2001) and adults 
(Jaakkola & Jaakkola 2002). Chronic exposure of mice to SHS resulted in 
significantly higher loads in the lungs, of both NTHi and S. pneumoniae, two 
most common respiratory bacterial pathogens (Voss et al. 2015).  One study 
(n=46 followed up to 14 weeks) found that the exposure to SHS increases the 
incidence of chronic respiratory symptoms, such as sneezing, sore throat and 
cough in non-smoking adults (Segala et al. 2004). 
 
A recent in vitro study reported reduced phagocytic activity of murine 
macrophages pretreated with SHS (and direct CS), which resulted in 
increased bacterial (P. aeruginosa) survival, compared to cells exposed to 
room-air control, possibly due to reduced phagocytosis by AMs (Ni, Ji & Vij 
2015).  
 
Although public health campaigns have focused at increasing the awareness 
of the dangers of SHS, and many jurisdictions worldwide have enacted 
legislation to restrict smoking in public places and at work, a large global 
population is frequently exposed to SHS, and this urgently needs to be better 
addressed. 
2.1.4 Mechanisms 	
Several mechanistic studies at molecular and cellular level on 
immunosuppressive effects of CS have been reported, mainly focusing on 
impairment of host immune system in healthy individuals. Mehta and 
colleagues (Mehta, Nazzal & Sadikot 2008) reviewed the immunosuppressive 
effects of CS and the mechanisms by which smoking affects host innate 
immunity including structural and functional changes in the respiratory tract 
(figure 2.1). 
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Figure 2. 1 The effects of smoking on epithelial, macrophage, neutrophils and 
lymphocytes.  
Reproduced with permission from Mehta et al. (2008). Copyright Springer. 
 
The specific mechanisms by which CS increases the risk of respiratory 
infections include structural changes in the respiratory tract and an impaired 
host-immune response. Exposure to CS results in structural changes in the 
respiratory airways, including luminal inflammation and wall fibrosis, increased 
mucosal permeability (disruption of tight junctions), impairment of the 
mucociliary clearance, and changes in pathogen adherence (Burns et al. 
1989; Dye & Adler 1994). CS also induces direct oxidative damage to 
membrane lipids and causes extensive DNA breaks, triggering repair and 
apoptotic cascades (Kim et al. 2004). Maunders et al. assessed the effects of 
cigarette smoke (determined at 1, 6, and 24 h post-exposure) on gene-
expression profiles associated with cell signaling and function in a three-
dimensional air-liquid interface model of tracheobronchial epithelium, which 
was grown from primary human lung epithelial cells. Genes associated with 
cellular adhesion decreased, and antioxidant and detoxifying genes were 
activated (Maunders et al. 2007). CS has been shown to decrease M. 
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catarrhalis-induced human β-defensin-2 (hBD-2) antimicrobial peptide 
expression and prostaglandin E2 induction, resulting in increased bacterial 
load on the bronchial epithelium of smokers (Zhang et al. 2011). 
 
Bronchoalveolar lavage fluid (BAL) studies have demonstrated a smoking-
dependent decrease in the absolute number of CD4+ cells, and an increase in 
CD8+ cells with a lower CD4+/CD8+ cell ratio in moderate smokers compared 
to nonsmokers, suggesting a deficit in cell-mediated immunity in the lung 
alveoli, which is the first-line defense against infection (Costabel et al. 1986). 
The retention of CD8+ T cells in the lungs may activate alveolar macrophages 
(AMs) to produce matrix metalloproteinase 12 (MMP-12), a potent elastin-
degrading enzyme that has been linked to emphysema (Hautamaki et al. 
1997). CS has also been shown to weaken the defensive ability of virus-
specific CD8+ memory effector T-cells in mice lung (Gualano et al. 2008). 
 
Although, CS increases the number of alveolar macrophages (AMs), it also 
activates them to produce pro-inflammatory mediators, reactive oxygen 
species and proteolytic enzymes, resulting in inflammation and tissue 
damage, which may make it more difficult to clear microbial pathogens 
(Sopori et al. 1998). It compromises the ability of AMs to phagocytose 
bacteria and apoptotic cells, as well as its ability to sense pathogen-
associated molecular patterns (PAMPs) (Berenson et al. 2006; Gaschler et al. 
2008; Hodge et al. 2007). CS exposure of alveolar macrophages (AMs) is 
shown to result in impaired NTHi ingestion, although not the ingestion of inert 
particles. Phosphoinositide 3-kinase (PI3K) signaling, including Akt 
phosphorylation, is essential for NTHi phagocytosis by AMs, and AMs 
exposed to CS show diminished phospho-Akt levels, which may account for 
sub-optimal phagocytic ability. Similar observations were made using 
immortalised macrophages and BAL macrophages from both smokers and 
COPD patients, compared with macrophages from never-smokers (Martí-
Lliteras et al. 2009).  
 
In terms of impaired pulmonary Pneumococcal clearance, CS has been 
shown to prevent complement-mediated phagocytosis of S. pneumoniae by 
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AMs in mice exposed to CS for 5 weeks followed by intratracheal bacterial 
challenge, although the ingestion of unopsonised bacteria or IgG-coated 
microspheres was not affected (Phipps et al. 2010).  
 
Woodruff et al. reported a distinctive state of activation of AMs in smokers that 
distinguished them from those in non-smokers (Woodruff et al. 2005). CS may 
induce phenotypic switching in macrophage population. Thus, CS may induce 
partial M1 deactivation or partial M2 activation of macrophages. The balance 
and intensity of this skewing has direct implications for the immune system 
and its response to disease because effective host defense requires a 
macrophage activation programme that is appropriate for the particular type of 
pathogen. The release of cytokines (e.g. TNFα, IL-1, IL-2 and IL-6) from 
macrophages may also be altered in smokers (McCrea, KA et al. 1994), which 
in turn could suppress neutrophil chemotaxis and migration (Corberand et al. 
1979). Several studies have also shown decreased natural killer (NK) cell 
numbers and activity in smokers compared with non-smokers (Swann et al. 
2007). Exposure to cigarette smoke attenuates the cytotoxic activity and 
cytokine production of NK cells in both humans and mice models (Mian et al. 
2008). 
 
Another important aspect of CS exposure is upregulation of microbial 
receptors on respiratory epithelial, which have been a focus of my studies. 
This interest in our group started with the observation that exposure to 
cigarette smoke extract (CSE) induces increased expression of 
pneumococcal adhesion receptor (PAFr) in lower airway epithelial cells in 
culture, as well as in living mice, which correlated with enhanced adhesion of 
S. pneumoniae (Grigg et al. 2012). There was also a suggestion of 
upregulation of PAFr on normal-smoker’s epithelium in biopsy material. 
2.1.5 Does cigarette smoke affect the respiratory Microbiome? 	
Smoking-related changes in the lung microbiome could be relevant for 
disease progression and exacerbations in a number of pulmonary diseases, 
including smoking-related COPD. But data on these issues are limited. 
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Results from a multicenter cohort study (n=64), based on modern culture-
independent techniques such as RT-qPCR (using 16S-rRNA) show that the 
oro-pharyngeal microbiome (oral wash) differed in nonsmokers and smokers, 
but no difference was found in lung microbial communities using BAL (Morris 
et al. 2013). Another study found that the nasopharyngeal microflora of 
smokers (n=20) contained more potential pathogens compared with those of 
non-smokers (n=20), especially S. pneumoniae, H. influenzae, Moraxella 
catarrhalis, and S. pyogenes (Brook & Gober 2005). The authors also noted 
fewer aerobic and anaerobic organisms with interfering capabilities against 
colonization by pathogenic bacteria. 
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2.2 Respiratory infections in patients with COPD 	
In the 1950s and 1960s, British investigators developed a hypothesis 
suggesting that recurrent bronchial infections were the primary reason in 
smokers for development of progressive airways obstruction (Fletcher 1959). 
Data from The Copenhagen City Heart Study (n=9435; men and women aged 
between 30 to 79 years, followed up to 10 years) suggested that smokers with 
chronic cough and sputum exhibited more accelerated decline in lung function 
(FEV1) than asymptomatic individuals. In the same study, chronic mucus 
hypersecretion was also associated with subsequent hospitalization due to 
COPD for both genders (Vestbo, Prescott & Lange 1996). Another study 
(n=30; followed up to 12 months) suggested a link between lung function 
decline and both bacterial counts and greater airway inflammation in sputum, 
as assessed by IL-8 levels. The authors found greater FEV1 decline in 
subjects who exhibited a change in the colonizing bacterial type compared 
with those with persistence of a single bacterial species over 12 months 
(Wilkinson et al. 2003). 
 
In the past two decades, our understanding of the pathogenesis of airway 
infections has increased substantially. In particular, novel molecular, cellular, 
and immunologic techniques used to study the host–pathogen interaction 
have been applied in assessing the role of microbial infections in COPD. It is 
also now acknowledged that airway infection is the predominant cause of 
exacerbations, which then contributes to the natural history of COPD. The 
prevalence and role of various microbial pathogens in both stable stages and 
exacerbations of COPD has been reviewed by Sethi and Murphy (Table 2) 
(Sethi & Murphy 2008).  
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Table 2. Microbial pathogens in COPD. Reproduced with permission from Sethi & Murphy 
(2008). Copyright Massachusetts Medical Society. 
Microbe Role in Exacerbations Role in Stable Disease 
Bacteria   
Haemophilus influenzae 20–30% of exacerbations Major role 
Streptococcus pneumoniae 
(Pneumococcus) 
10–15% of exacerbations 
Likely, still being studied 
(Domenech et al. 2012; 
Karin et al. 2015) 
Moraxella catarrhalis 10–15% of exacerbations Minor role 
Pseudomonas aeruginosa 
5–10% of exacerbations, prevalent in 
advanced disease 
Probably important in 
advanced disease 
Enterobacteriaceae 
Isolated in advanced disease, 
pathogenic significance undefined 
Undefined 
H. haemolyticus  
Isolated frequently (misdiagnosed), 
unlikely cause 
Unlikely 
H. parainfluenzae Isolated frequently, unlikely cause Unlikely 
Staphylococcus aureus Isolated frequently, unlikely cause Unlikely 
Viruses    
Rhinovirus  20–25% of exacerbations Unlikely 
Parainfluenza virus 5–10% of exacerbations Unlikely 
Influenza virus 5–10% of exacerbations Unlikely 
Respiratory syncytial virus 5–10% of exacerbations Controversial 
Coronavirus  5–10% of exacerbations Unlikely 
Adenovirus 3–5% of exacerbations 
Latent infection described, 
pathogenic significance 
undefined/unlikely 
Human metapneumovirus 3–5% of exacerbations Unlikely 
Atypical bacteria   
Chlamydophila pneumoniae 3–5% of exacerbations 
Commonly detected, 
pathogenic significance 
undefined 
Mycoplasma pneumoniae 1–2% of exacerbations Unlikely 
Fungi   
Pneumocystis jiroveci Undefined 
Commonly detected, 
pathogenic significance 
undefined/unlikely 
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2.2.1 Microbial colonization/infections in stable COPD 
 
Thus, persistence of bacteria in the lower respiratory tract, especially with 
NTHi in relatively stable COPD patients is characteristic of the disease, and is 
termed ‘colonization’, although that may well be a misnomer that 
underestimates the importance of what is in reality chronic infection (Robinson 
2004). Previously, ‘healthy’ lungs were considered relatively uninhabitable for 
microorganisms, especially bacteria, at least based on culture-detection 
techniques. Novel molecular techniques have recognized a wide range of 
bacteria that are likely to update our understanding of the role of 
microorganisms in the pathogenesis of COPD. It has been reported that lower 
respiratory tract is colonized by a ‘microbiome’ even in healthy individuals. 
One study reported that COPD is not associated with an alteration of the 
respiratory microbiome, whereas others have reported changes in relative 
abundance of specific microbial phyla and in microbial diversity (Cabrera-
Rubio et al. 2012; Erb-Downward et al. 2011; Han et al. 2012; Pragman et al. 
2012; Sze et al. 2012). In COPD patients; potentially pathogenic 
microorganisms (PPM) are culturable in lower airway fluids (sputum and 
bronchoalveolar lavage) in up to 65% of patients at any one time (Banerjee, 
Khair & Honeybourne 2004; Cabello et al. 1997; Garcha et al. 2012; Soler et 
al. 1999). Traditionally, this has been from an inadequate innate immune 
response of the host leading to airway bacterial colonization and subsequent 
invasion of the host tissue, i.e., overt bacterial infection (Hill et al. 2000; Sethi 
et al. 2006; Sethi et al. 2004; Weinreich & Korsgaard 2008). Moreover, qPCR 
has proven to be advantageous as it identifies a significant number of patients 
with potentially pathogenic bacteria as well as airway inflammation in COPD, 
which are not identified by traditional culture-based methods (Bafadhel et al. 
2015). 
 
COPD patients whose respiratory tracts are ‘colonized’ with bacteria 
experience increased daily respiratory symptoms (breathlessness, cough and 
sputum), an accelerated decline in lung function, increased airway and 
systemic inflammation, and impaired health related quality of life (Desai et al. 
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2014; Marin et al. 2012; Wilkinson et al. 2003). Thus, this is not a benign 
condition. 
 
The most common “colonizers” in the stable state of COPD are non-typeable 
Haemophilus influenzae (NTHi) (~60% of patients), Moraxella catarrhalis 
(~48% of patients) and Streptococcus pneumonia (~28% of patients) 
(Bafadhel et al. 2015; Barker et al. 2015). Moreover, bacterial colonization of 
the respiratory tract in COPD patients is believed to be dynamic, as the 
bacterial flora frequently changes in terms of both strains and species, but 
again predominantly with the above-mentioned bacteria (Marin et al. 2010; 
Wilkinson et al. 2003). These bacterial pathogens undoubtedly worsen a 
patient’s health over a long period of time and may be a major driver of airway 
luminal inflammation (Marin et al. 2012). For example, COPD patients 
chronically colonized with H. influenzae during stable phase also showed 
increased airway inflammation and reduced lung volumes when compared 
with non-chronically colonized patients (Tufvesson, Bjermer & Ekberg 2015). 
 
The persistence of viruses in the airway has also been reported in the stable 
clinical phase of COPD, most commonly Respiratory Syncytial Virus (RSV), 
which has been detected in up to 30% of patients in some reports (Borg et al. 
2003; Seemungal et al. 2001), but not others (Falsey et al. 2006). Thus, the 
role of RSV in COPD is still debated. The presence of the adenovirus hexon 
gene (as an index of presence of acute virus) has also been reported during 
both the stable phase in 6% of disease and during acute exacerbations in 7%. 
The presence of adenovirus 5 E1A (viral gene product, index of viral 
multiplication) in lung cells isolated from sputum samples in COPD patients 
occurred infrequently (~6%) (McManus et al. 2007); however, individuals 
positive for E1A had a lower FEV1 compared with E1A negative individuals 
(Kasuga et al. 2009).  
2.2.2 Infection in acute exacerbations of COPD (AECOPD) 
 
The risk of mortality and morbidity from COPD escalates when frequent 
exacerbations intervene, usually as the general severity of the COPD 
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worsens, and both are likely driven by infection (Miravitlles et al. 1999; Rosell 
et al. 2005; Sapey & Stockley 2006). COPD exacerbations are really nasty 
experiences for the individual patient, and the recovery is frequently slow, 
usually over weeks at least (Soler-Cataluna et al. 2005). Frequent 
exacerbations are also directly linked with further accelerated decline in lung 
function, increased local and systemic inflammation and decreased quality of 
life (Donaldson, GC et al. 2002; Osman et al. 1997; Papi et al. 2006; Patel et 
al. 2002). Thus, a vicious cycle is established once this phase of disease is 
reached (Figure 2.2) (Sethi & Murphy 2001). 
 
 
Figure 2. 2. The vicious-circle hypothesis of infection and inflammation in 
COPD. 
Reproduced with permission from Sethi & Murphy (2008). Copyright 
Massachusetts Medical Society. 
 
Both bacterial and viral pathogens have been implicated in AECOPD. A 
number of studies have reported that viruses are responsible for 40-60% of 
these episodes, with rhinovirus (RV) playing the major role (Mohan et al. 
2010). RV has been described as triggering approximately 60% of all virus-
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related exacerbations and 25% of all exacerbations (Hershenson 2013 
George et al. 2014).  
In addition to viral agents, bacteria have been implicated in up to 50% of 
exacerbations (Fagon et al. 1990), which is even higher (72%) in severe 
exacerbations requiring ventilatory support (Soler et al. 1998). Moreover 
approximately 25% of exacerbations of increased severity yielded bacterial-
viral co-infection (Papi et al. 2006). Acquisition of new bacterial species, 
increase in the pre-existing bacterial load and acquisition of a new strain of 
established colonizing bacteria are thought to be the key factors implicated in 
bacteria-triggered AECOPD (Sethi et al. 2002; Sethi et al. 2004). Again, S. 
pneumoniae, H. influenzae, and M. catarrhalis are the most common bacterial 
pathogens involved in an AECOPD. Patients with AECOPD and P. 
aeruginosa present higher severity of COPD, while those with S. pneumoniae 
present greater comorbidity (Boixeda et al. 2015). Even in virally induced 
exacerbations, subsequent bacterial infection within a few days is a common 
clinical experience (experimentally induced HRV infections, Mallia et al. 2012; 
naturally occuring HRV infections, George et al. 2014). 
 
A large USA-wide study (n=23,971) and reported that both current (light) 
smoking status and duration of smoking abstinence significantly reduced the 
risk of AECOPD (Au et al. 2009). Smoking cessation was also found to be 
associated with a reduced risk of hospitalization and total mortality in COPD 
patients (Anthonisen et al. 1994). Smoking history (pack-years) has been 
shown to be related to increased levels of lung/systemic inflammatory 
markers that could predict the risk of AECOPD, and inflammatory markers, 
including circulating C-reactive protein and TNF-α (Korani et al. 2016), soluble 
tumor necrosis factor receptor (sTNFR)-1 (Serapinas et al. 2011), and 
immune cells (predominantly macrophages in bronchial biopsies) (Willemse et 
al. 2005) have all been shown to be increased in COPD patients. However, 
the examiner is correct in that a strict relationship between smoking status 
and/or smoking history (pack-years) and exacerbation frequency has not 
always been observed (Cao et al. 2006; Donaldson et al. 2013; Gompertz et 
al. 2001; Han et al. 2013).  One possible explanation for this lack of 
consistency is that patients experiencing frequent exacerbations are more 
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likely to quit, and smoking cessation certainly aids in improving COPD 
prognosis, slows lung function decline and improves the quality of life (Criner 
et al. 2015). It could be, though, that differences between individuals reflect 
the virulence of airway bacteria that they chronically carry, and some of this 
may depend on the details of ChoP expression, in terms of amount and 
position in the bacterial wall, but also the ease with which rhinovirus is able to 
infect the epithelium. Further work on this is now needed. 
 
2.3 Mechanisms of chronic bacterial infection or ‘colonization’: general 
principles applicable to the respiratory tract 
 
As discussed in earlier sections, a number of mechanisms could contribute to 
frequent risk of respiratory tract infections (both bacterial and viral) in COPD 
patients throughout the clinical course. This includes impaired host defense, 
compromised airway epithelial integrity and increased microbial adhesion 
receptors in the susceptible host. I will be focusing mainly on two microbial 
receptors, which could be very relevant to smokers and patients with COPD. 
Firstly, platelet-activating factor receptor (PAFr), a major attachment site for 
important bacterial pathogens, including NTHi, S. pneumoniae and 
Pseudomonas aeruginosa. Secondly, intercellular adhesion molecule-1 
(ICAM-1), which is an important binding site for majority of human 
rhinoviruses (HRV-A and HRV-B) as well as NTHi. 
 
Theoretically, the first important step in the initiation of pathogenic infective 
disease is adherence of the pathogen to a host surface, followed by 
subsequent invasion and clinical manifestations (Kline et al. 2009). Epithelial 
adhesion is essential for colonization of mucous membranes, for example on 
large and small airway epithelium in chronic airway disease, and presumably 
also the alveolar epithelial surface as a prelude to pneumonia (Pizarro-Cerda 
& Cossart 2006).  
 
There is unlikely to be a sole “gold standard” mechanism of microbial 
colonization and invasion in host cells in the respiratory tract, reflecting the 
complex, dynamic and probably multifaceted nature of host-microbe 
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interactions. However, one relatively promising and potentially central 
approach relates to Platelet Activating Factor receptors (PAFr) (Grigg 2012). 
Notably, the two major respiratory pathogens in COPD, H. influenzae and S. 
pneumoniae, adhere to epithelial surfaces by physico-chemical interactions 
between phosphorylcholine [(CH3)3N+CH2CH2PO4-] or ChoP (a small 
zwitterionic/bipolar molecule and molecular mimic of PAF) on the bacterial cell 
wall surface with PAFr expressable on the luminal surface of respiratory tract 
epithelial cells (Cundell et al. 1995; Swords et al. 2000).  
 
The interaction between this bacterial wall ligand (ChoP) and epithelial 
surface PAFr seems to be quite specific as only pathogens expressing ChoP 
are able to “anchor” to PAFr. Indeed, there is now a growing body of evidence 
from both in vivo and in vitro studies that PAFr is an important host epithelial 
receptor used by specific respiratory bacterial pathogens to colonize and then 
invade respiratory epithelium and deeper tissue (Clementi & Murphy 2011; 
Iovino et al. 2013). In theory, therefore, any factor that upregulates either 
optimal ChoP presentation on bacterial surfaces or PAFr expression on 
epithelial surfaces could be very important in disease pathogenesis. I will now 
summarize the current evidence for this mechanism being relevant in COPD.  
2.3.1 Platelet Activating Factor receptor (PAFr) 
 
PAFr is a member of the G-protein coupled receptor (GPCR) superfamily, 
which is characterized by seven trans-membrane domains can be expressed 
on the surface of a range of cell types, including the majority of cells of the 
innate immune system (i.e., macrophages, polymorphonuclear leucocytes, 
mast cells etc.) but also potentially at the apical (luminal) surfaces of bronchial 
epithelial cells (Shukla 1992). The gene encoding PAFr in humans (PTAFR) 
has been mapped on chromosome 1. Like most GPCRs, PAFr becomes 
coupled as hetero-trimeric structures comprised of α, β and γ subunits on the 
cell plasma membrane (Izumi & Shimizu 1995).  
 
Physiologically, PAFr binds specifically to its natural ligand, platelet-activating 
factor (PAF) (Shukla 1992). PAF, 1-O-alkyl-2-acetyl-sn-glycero-3-
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phosphocholine, is a potent phospholipid ‘mediator’ of inflammation 
synthesized by various cells, including polymorphonuclear leucocytes 
(PMNs), macrophages, monocytes, endothelial cells, mast cells and platelets, 
which in turn can all carry surface PAF receptors (Nakamura et al. 1991). PAF 
is believed to be involved in numerous leucocyte functions, platelet 
aggregation and inflammation. Coupling of PAF to PAFr activates GTPase, 
triggering phospholipid turnover via phospholipases C, D and A2 pathways, 
which feed the various lipid mediator pathway (e.g. prostanoids and 
leukotienes), and thereby also produce more PAF. It also activates protein 
kinase C and tyrosine kinases (Iovino et al. 2013). PAFr plays a vital role in 
inflammatory processes, which can be blocked by specific PAFr antagonists 
(Chen et al. 2008).  
 
Localization of PAFr has been shown in lungs, brain, as well as platelets, 
endothelium and leucocytes. Previous publications have affirmed the role of 
PAFr in trafficking of leucocytes to remove inhaled respiratory pathogens 
(Cabellos et al. 1992) (Figure 2.3). Thus, PAF-PAFr binding may initiate a pro-
inflammatory cascade to eliminate inhaled bacteria (Cabellos et al. 1992). 
Other significant functions of PAF include upregulation of adhesion receptors 
in the host cells as well as epithelium. A time-dependent increase of ICAM-1 
expression on human eosinophils is also induced by PAF (Sagara et al. 
1996). PAF has also been reported to upregulate TLR-4 in intestinal epithelial 
cells, which again augments inflammation (Soliman et al. 2010). Whether PAF 
itself upregulates PAFr in lungs has not been investigated, but it remains a 
possibility, which needs further investigation; indeed little is known about PAF 
respiratory functionality. 
A wide variety of receptors, including platelet-activating factor receptor, 
present on the surface of macrophages can recognize bacterial pathogens 
(Mosser, DM 1994).  However, the persistence of microorganism (especially 
H. influenzae), both extracellular (in biofilms) and intracellular (within 
respiratory epithelial cells and macrophages) has been reported (Forsgren et 
al. 1994; St Geme & Falkow 1990). This is attributed to immunological 
impairments of alveolar macrophages (AM), including diminished 
inflammatory cytokine responsiveness and phagocytosis of NTHi (Berenson, 
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Garlipp, et al. 2006; Berenson, Wrona, et al. 2006). Defective phagocytosis by 
macrophages was found to be significantly greater for NTHi than other 
respiratory pathogens, including S. pneumoniae and Moraxella catarrhalis, in 
COPD (Berenson et al. 2013). However, the relevance of bacterial binding via 
ChoP to PAFr expressed on the surface of inflammatory cells is not fully 
understood, but certainly raises the possibility that evasion of effective 
clearance could be enhanced, i.e. an evolved way for certain bacteria to avoid 
other mechanisms of destruction, while at the same time enhancing the 
inflammatory response (Figure 2). The interaction between host PAFr and 
bacterial ChoP has been summarized and reviewed (Clark & Weiser 2013; 
Thornton, Durick-Eder & Tuomanen 2010), though not primarily in the context 
of lungs or COPD. 
 
Figure 2. 3. Potential role of PAFr in clearance of inhaled bacteria. 
PAFr probably plays a vital role in clearance of inhaled bacteria via interaction 
with PAF in healthy individuals. However, activated epithelium (e.g., cigarette 
smoke) with upregulated PAFr provides bacteria a possible escape 
mechanism from innate immune cells leading to chronic colonization, 
persistent inflammation and disease. For example in COPD, PAFr-expressing 
innate immune cells (macrophages) may also provide an escape mechanism 
especially for Haemophilus influenzae and lead to its persistence in the host. 
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Reproduced with permission from Shukla et al. (2015). Copyright Taylor & 
Francis. 
 
The first potential link between PAFr on lung structural cells and respiratory 
infections was provided by Cundell et al. (Cundell et al. 1995). They showed 
an interaction between S. pneumoniae and upregulated PAFr on cytokine-
activated respiratory epithelial A549 cells as well as human umbilical vein 
endothelial cells (HUVEC), which was blocked by a PAFr antagonist 
(L659989). They also showed that virulent strains of S. pneumoniae adhered 
to PAFr more than non-virulent strains and reported a decrease of 
approximately 50% in adherence and internalization of S. pneumoniae into 
cells with the PAFr antagonist. 
 
A strategic importance for PAFr expression specifically in airway colonization 
by the major respiratory pathogens S. pneumoniae and NTHi or in invasive 
pneumococcal disease has been previously suggested in both cultured cells 
and animal models (Iovino et al. 2013; Van Eldere et al. 2014). Further efforts 
to understand the interactive host-response mechanisms involved in airway 
respiratory infections in COPD are of vital importance. Upregulation of this 
PAF-PAFr system in other situations of chronic pulmonary infections, e.g., 
cystic fibrosis, or in response to environmental dust and fume exposure also 
needs to be investigated. Variation in both ChoP expression on bacteria and 
PAFr expression on epithelial cells, as well as their variable interactions could 
be important in the natural history of these diseases.  
 
2.3.1.1 Mechanistic in vitro studies; importance of PAFr in invasive 
pneumococcal disease 
 
In an animal “meningitis” model, Radin et al. reported co-localization of S. 
pneumoniae and PAFr in 82% of rat brain microvascular endothelial cells 
(BMEC) based on confocal microscopic analyses. A further noteworthy finding 
was increased expression of PAFr on endothelial cells in infection compared 
to non-infected animals. This suggests that S. pneumoniae may itself cause 
an upregulation of receptor expression once cells are activated and infection 
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has commenced (Radin et al. 2005). Whether PAF could be the intermediate 
mediator needs investigating. 
 
Going a step further, Ring et al. showed S. pneumoniae ‘navigating’ 
eukaryotic cell layers (human and rat) of brain microvascular endothelial cells 
via transcytosis (a process for transportation of macromolecules through cells 
in vesicles, which is mediated by highly specific signal cascades). This 
process is believed to be an essential mechanism in the development of 
invasive pneumococcal disease. They reported a decrease of 35% in the 
amount of intracellular bacteria on treating the cells with a PAFr antagonist 
(L659989) prior to infection accompanied by a 25%-30% decrease in 
transcytosed bacteria (Ring, Weiser & Tuomanen 1998).  
 
Although transcytosis as a process is well established, its exact mechanism is 
not entirely understood, and it needs more extensive investigation, perhaps 
especially in the human respiratory tract. However, the two major membrane 
receptors proposed to interact directly with pathogens are PAFr and polymeric 
immunoglobulin receptor (pIgR) (Iovino, Molema & Bijlsma 2014; Ring, 
Weiser & Tuomanen 1998), another putative bacterial receptor.  
 
Indeed, inflammatory cytokines have also been shown to upregulate the 
epithelial expression of cytokeratin 10, pIgR and laminin receptor, which have 
all been shown to enhance adherence of S. pneumoniae to human cells 
(Shivshankar et al. 2011). Therefore, it could be that activation of human cells 
(epithelial and endothelial) by inflammatory cytokines induces upregulation of 
several receptors; that all play some role in elevated bacterial adhesion and 
subsequent cellular uptake of Pneumococci (Chao & Olson 1993). However, I 
will initially focus on the role of PAFr in COPD, since it is still likely to be the 
most important respiratory pathogen adhesin. 
 
2.3.1.2 Importance of PAFr in non-typeable H. influenzae (NTHi) 
colonization and invasion 
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NTHi is a common commensal residing in the human nasopharynx, but it can 
cause opportunistic lower respiratory tract infection whenever an individual 
compromised by either other infections or disease (Clementi & Murphy 2011). 
The lower respiratory tract connects with the upper respiratory tract at the 
“guardian” vocal cords, but frequent micro-aspiration of secretions takes place 
normally (Gleeson, Eggli & Maxwell 1997). Further, it remains a possibility 
that NTHi is normally inhaled from the upper respiratory tract to the lower 
respiratory tract but is effectively cleared in health by normal host defenses 
(Murphy 2003). However, in the case of smokers and COPD patients, this 
clearance does not occur so efficiently probably for a number of reasons, but 
the relative importance of NTHi epithelial cell adherence leading to invasion 
may be especially important, but not yet well worked up (Sethi & Murphy 
2008). Bandi et al. reported the presence of intracellular NTHi in bronchial 
biopsies from 33% of stable chronic bronchitis patients, 87% of acutely ill 
chronic bronchitis patients but in no healthy tissue (Bandi et al. 2001). As 
already emphasized, NTHi is also an important cause of clinical acute 
exacerbations in COPD, and also in cystic fibrosis (Weinreich & Korsgaard 
2008).  
 
A limited number of studies of classical receptor-mediated adhesion and 
internalization NTHi have already provided some valuable insights about the 
potential role of PAFr epithelial colonization and invasion by this bacterium 
(Swords et al. 2000; Weiser, Shchepetov & Chong 1997). Similar to S. 
pneumoniae, NTHi adhesion to PAFr is facilitated by phosphorylcholine 
(ChoP) precisely positioned enzymatically in the outer lipo-polysaccharide 
layer of the bacterium (Clark et al. 2012; Schweda et al. 2000; Weiser et al. 
1998; Weiser, Shchepetov & Chong 1997). Variations in ChoP expression 
leads to variants of NTHi with modified virulence and function, such as 
variation in potency of bacterial LPS as an endotoxin, NTHi adherence, 
bacterial invasion, biofilm maturation, resistance to host antimicrobial peptides 
(such as cathelicidin LL-37) and resistance to pulmonary muco-ciliary 
clearance (Swords et al. 2000).  
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H. influenzae expresses ChoP ligand in the outer LPS layer (Schweda et al. 
2000). The variation in virulence of NTHi is enzymatically controlled through 
both the amount of ChoP and its precise localization on the outer LPS. Both of 
these variables are controlled by moduable expression of genes in lic 1 locus 
(McCrea, KW et al. 2010). There are four open reading frames, namely, lic A 
(choline kinase), lic B (choline permease), lic C (pyrophosphorylase) and lic D 
(diphosphonucleoside choline transferase) (figure 2.4) (Weiser, Love & Moxon 
1989). Lic A and lic B gene are believed to regulate the amount of choline 
incorporated from the outer medium (host environment) and the biosynthesis 
of ChoP inside the bacteria respectively (Michel et al. 2006). Lic C and lic D 
are involved in the variation in the ChoP presentation and precise localization 
in the LPS layer (Fan et al. 2003). In addition, there are multiple alleles of the 
ChoP transferase gene lic D in H. influenzae strains. These variables provide 
crucial ‘flexibility’ to NTHi to survive inside the host, either by increased 
adherence to host cells or potential survival inside PAFr-expressing innate 
inflammatory cells, e.g. macrophages (Craig et al. 2001). 
 
Figure 2. 4. Genetic control of phosphorylcholine in NTHi. 
It is worth mentioning that in case of S. pneumoniae, ChoP is incorporated 
into cell wall C-polysaccharide (teichoic acid) and F-antigen (lipoteichoic acid) 
moieties (Fischer et al. 1993). However, little is known about the mechanisms 
controlling variation in either amount or localization of ChoP in S. 
pneumoniae. 
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Swords et al. concluded that ChoP–PAFr binding initiated host cell signaling 
through a PTX (pertussis toxin)-sensitive G protein complex that was required 
for optimal and efficient cell/tissue invasion. Thus ChoP-negative NTHi strains 
exhibited significantly lower invasion of bronchial epithelial cells, suggesting 
that ChoP–PAFr-mediated invasion is more efficient than other alternative 
mechanisms (Swords et al. 2001).  
 
Human bronchial epithelial cells in culture infected by NTHi, likely using PAFr, 
showed a decreased bacterial load only after seven days from inoculation, 
implying that PAFr does aid in bacterial persistence in cells (Swords et al. 
2000). Moreover, intra-epithelial bacteria are protected from the detrimental 
effects of antibiotics as well as bactericidal antibodies for at least 24 hours in 
vitro (Clementi & Murphy 2011). Interestingly the turnover of pulmonary 
epithelium is approximately 180 days, which could therefore potentially 
harbour bacteria safely for a protracted period (Rawlins & Hogan 2008). Little 
research in patient material has been done on this area and the clinical 
relevance of these findings remains unknown. 
 
2.3.1.3 Mechanistic in vivo (mice) models of PAFr mediated lung 
infections 
 
Two studies have assessed PAFr expression in aged mice, a model that 
might mimic COPD. Hinojosa et al. performed intranasal TNF-α challenge of 
BALB/c mice and reported an increase in PAFr expression in the lungs; they 
also found increased susceptibility of these animals to pneumococcal infection 
(Hinojosa, Boyd & Orihuela 2009). Likewise, Shivshankar et al. showed that 
aged mice (BALB/c), after intranasal challenge with S. pneumoniae had more 
lung inflammation as well as increased PAFr expression in the lungs 
(Shivshankar et al. 2011). It is interesting that more inflammation does not in 
these circumstances lead to better clearance of bacteria but indeed are a 
marker of bacterial escape from usual innate clearance mechanisms; this is 
again reminiscent of COPD in humans. Although murine models of COPD 
have provided us with some exciting insights regarding mechanisms involved 
in bacterial infections, these experiments may not be optimal because of 
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dissimilar inflammatory responses, and receptor pharmacology, and lack of 
the classic structural changes seen in human airways in COPD. More human 
work to back up suggestive animal findings has been urgently required. 
 
2.3.1.4 Preliminary human tissue studies suggesting relevance of PAFr  
 
The expression pattern of PAFr in both in vitro cell cultures and animal 
models have been reported, its relevance in COPD patients is not yet clear, 
and was the focus of my project. Moreover, the available studies only studied 
either Pneumococcus or NTHi in their experiments, which further compelled 
us to investigate both the bacterial pathogens in my project, given all the other 
experimental conditions are kept alike. 
 
Until now, relatively few studies have assessed the possible role of PAFr in 
chronic or acute airway and lung colonization/infection in COPD. 
Paradoxically, the first study by Shirasaki and colleagues using northern blot 
assay in lung tissue obtained from smokers and asthmatics concluded that 
PAFr mRNA was significantly upregulated only in asthmatic individuals but 
decreased in the lung tissues of smokers (although chronic infection is only 
clinical characteristic in smokers) (Shirasaki et al. 1994). 
 
Human data also exist. Thus, tracheal epithelial cells exposed to acid showed 
upregulation of both PAFr mRNA and protein levels as well as increased 
adhesion of S. pneumoniae to cells. Moreover, pretreatment of acid-exposed 
cells to a PAFr antagonist (Y24180) resulted in an approximately 30-40% 
reduction in S. pneumoniae adherence to cells (Ishizuka et al. 2001).  
 
Perhaps more relevant to human environmental exposures, human-derived 
A549 cells as well as human primary bronchial epithelial cells exposed to 
urban pollution particulates showed elevated levels of PAFr mRNA transcript 
levels and PAFr protein expression. This was accompanied by an 
approximately threefold increase in pneumococcal adhesion. This effect was 
again attenuated by a PAFr antagonist (WEB2086) (Mushtaq et al. 2011); 
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whether the drug mainly works through blocking PAFr up-regulation by PAF, 
the receptor itself, or both, needs to be fully worked out. 
 
Conversely, McCullers and colleagues reported that PAFr is not required by 
S. pneumoniae to adhere to A549 cells in vitro. This opens the possibility of 
more emphasis being needed for PAFr-independent mechanisms for the 
adherence and invasion of epithelial cells by Pneumococcus (McCullers et al. 
2008). In addition, in culture studies, which have suggested a direct role of 
PAFr in adhesion and invasion of human cells by S. pneumoniae, treatment of 
these activated cells with PAFr antagonist never blocks bacterium-PAFr 
interaction completely. Most studies have reported a maximum of 50% 
reduction in bacterial transcytosis with PAFr antagonists, which again indicate 
the likely relevance of PAFr-independent pathways for bacterial adherence 
and invasion i.e. virulence. 
 
More recently, Grigg et al. (Grigg et al. 2012) investigated the role of PAFr in 
adhesion of Streptococcus pneumonia to A549 cells (alveolar epithelial cell 
line), BEAS2-B cells (bronchial epithelial cell line) and HBEpC cells (human 
primary bronchial epithelial cells), exposed to cigarette smoke extract. They 
also determined the specific role of PAFr in increased adhesion of 
pneumococcus to all these cell-lines by blocking PAFr with a specific receptor 
antagonist (CV-3988). Furthermore, they quantified PAFr transcript level by 
quantitative real-time PCR and determined PAFr protein expression by flow 
cytometry. This novel study also had clinical tissue analysis section provided 
by our group, assessing PAFr expression in upper airway epithelium in limited 
biopsies from active smokers by immunostaining.  
 
These studies concluded that increased pneumococcal adhesion to cells 
exposed to cigarette smoke extract occurred as a result of increased PAFr 
expression, and PAFr antagonist attenuated pneumococcal adhesion to 
epithelial cells. Mice exposed to CSE also showed significant upregulation in 
lung PAFr mRNA transcripts. Perhaps of most interest was suggestion of at 
least a small increase in PAFr-expression in active smokers compared to 
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normal non-smoking individuals (Grigg et al. 2012), in whom PAFr expression 
was essentially absent. 
 
Suri et al. (Suri et al. 2014) induced experimental respiratory tract rhinoviral 
infection (RV16, group A HRV) in normal controls, normal smokers and 
smokers with COPD. They reported a significant increase in PAFr mRNA 
expression in airway biopsies from smokers and smokers with COPD at 
baseline, but with no change after viral infection. In contrast, RV-14 (group B 
HRV) infection has been reported to stimulate S. pneumoniae adhesion to 
airway epithelial cells via upregulation of PAFr (Ishizuka et al. 2003), and RV-
16 infection significantly increased expression of host cell adhesion 
molecules, including PAFr, both at the gene and protein levels, in nasal 
epithelial cells. In the later study, increase in bacterial adherence was also 
found (Wang, Kwon & Jang 2009). 
 
2.3.1.5 PAFr as a potential therapeutic target for treatment of COPD 
exacerbations 
 
If one can summarize the evidence as suggesting that the major respiratory 
pathogens associated with COPD exacerbations, S. pneumoniae and H. 
influenzae, specifically bind to epithelial PAFr for colonisation of the lower 
respiratory tract, then PAFr represents a putative target for non-antibiotic 
therapies for both chronic COPD and especially exacerbated COPD (Bandi et 
al. 2001; Grigg et al. 2012; Ring, Weiser & Tuomanen 1998; Swords et al. 
2000). As alluded to above, there are already several known antagonists of 
PAFr function, which could be categorized based on their chemical properties 
(Table 3).  
 
In assays with rabbit platelet and rabbit polymorphonuclear leukocyte 
membranes, the antagonist, L659989 ((2R,5R)-2-(3-methoxy-5-
methylsulfonyl-4-propoxyphenyl)-5-(3,4,5-trimethoxyphenyl)oxolane) 
competitively inhibited [3H]PAF binding with a low equilibrium inhibition 
constant (Ki) of 1.1 nM (Hwang et al. 1988). It was approximately 10-fold less 
active towards human platelet, human polymorphonuclear leukocyte and 
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human lung membranes, with a Ki of 14.3 nM indicating that it displayed a 
degree of specificity with regard to receptors from different hosts. L659989 
was also a potent inhibitor of PAF-induced aggregation of rabbit platelets and 
degranulation of rat (50% effective dose (ED50) of 4.5 nM) and human (ED50 
10 nM) neutrophils and was active following oral administration to female rats 
(ED50 0.2 mg/kg) (Ponpipom et al. 1988). 
 
In terms of effectiveness in humans, the PAFr antagonist CV-3988 ([2-
methoxy-3-(octadecylcarbamoyloxy)propyl] 2-(1,3-thiazol-3-ium-3-yl)ethyl 
phosphate) in humans, in doses ranging from 750 to 2,000 µg/kg, reduced 
platelet sensitivity for PAF (Arnout et al. 1988). In terms of drug tolerability, 
the drug did not cause any significant adverse events at these concentrations. 
However, clinically insignificant hemolysis was observed, possibly due to the 
detergent-like properties of the drug (Arnout et al. 1988). Serious adverse 
events were similarly not found with WEB 2086 (5mg-100mg daily), though 
small fluctuations of blood pressure and pulse were found in the treatment 
groups (Adamus et al. 1990). 
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Table 3. Known classes of PAFr-antagonists  
Category Name Structure Reference 
1. Nitrogen 
heterocyclic 
compound 
SR27417 
 
(Bastos da Silva et 
al. 2000; Herbert et 
al. 1993) 
 WEB2086 
 
(Dent et al. 1989; 
Dent et al. 1989) 
2. PAF analogue CV3988 
 
(Terashita, Imura & 
Nishikawa 1985) 
(Arnout et al. 1988) 
 L659989 
 
(Hwang et al. 1988; 
Ponpipom et al. 
1988) 
3. Dihydropyridines PCA4248 
 
(Ortega et al. 1990) 
(Fernandez-
Gallardo et al. 
1990) 
4. Natural 
medicines BN52021 
 
(Desquand et al. 
1986) 
5. Others 52770 RP 
 
(Terashita et al. 
1992) 
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Existing PAFr antagonists may therefore provide specific inhibitors of PAFr-
bacterial interactions. Indeed, Cundell and colleagues demonstrated that the 
potent PAFr antagonist L659989 inhibited the adhesion of S. pneumoniae to 
cytokine-activated primary human umbilical vein endothelial cells in vitro 
(Cundell et al. 1995). This translated into the blocking by L659989 of S. 
pneumoniae adherence to IL-1-activated lung epithelium and progression to 
pneumonia in a rabbit model of infection (Cundell et al. 1995). Although most 
of the modern long acting bronchodilator and steroid inhaled medications now 
available for COPD treatment claim some effect in decreasing exacerbation 
rates, little is known about how they work in doing this. Follow-up work is now 
needed to examine the capacity of PAFr antagonists and their structural 
analogues to selectively target the use of PAFr as a gateway for infection of 
the lower respiratory tract of COPD patients by H. influenzae and S. 
pneumoniae.  
 
Furthermore, and as explained earlier, most exacerbations involve microbial 
infection (Bandi et al. 2003; Sapey & Stockley 2006; Sethi 2004), so whether 
these agents may affect host PAFr expression, bacterial ChoP expression, or 
the interaction between them, need to be investigated. In summary, all living 
organisms, including bacterial respiratory pathogens, have evolved strategies 
to survive within their specific niches. Inflammatory mediators, including PAF 
with its likely auto up-regulation of its own receptor, seem to be key pro-
inflammatory components involved in countering foreign bacterial invasion. 
However, several pathogens, especially S. pneumoniae and H. influenzae 
have evolved mechanisms to specifically adhere to PAFr and use this to avoid 
innate immune attack, and also to potentially colonize the airway epithelial 
surface. In normal airway epithelium, we believe that PAFr expression is 
essentially absent, but is enhanced by cigarette smoking. Further work in 
COPD was needed and provided in this thesis. 
2.3.2 Intercellular adhesion molecule-1 (ICAM-1) 
 
Human ICAM-1 (CD54; a transmembrane glycoprotein) is a member of the 
immunoglobulin (Ig) superfamily that contains five Ig-like domains, a 
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transmembrane domain, and a short cytoplasmic tail (Springer 1990); it is 
thought to be expressed constitutively on a wide variety of cells (including 
leukocytes, endothelial cells and respiratory epithelial cells) (Roebuck & 
Finnegan 1999), but it is also further inducible by the inflammatory mediators 
TNF-α, IL-1β and IFN-γ, and inhibited by glucocorticoids (Hubbard & Rothlein 
2000). Membrane-bound integrin receptors such as, LFA-1 and Mac-1 on 
leukocytes, CD43, soluble fibrinogen and hyaluronan, matrix factor 
hyaluronan, rhinoviruses, and Plasmodium falciparum malaria-infected 
erythrocytes serve as ligands for ICAM-1.  
 
Physiologically, ICAM-1 plays a number of key roles. It stabilizes cell-cell 
interactions and it also facilitates leukocyte per-endothelial transmigration 
from blood into inflamed tissues possibly leading to initiation of antigen-
specific immune responses (Lehmann et al. 2003; van de Stolpe & van der 
Saag 1996). ICAM-1 functions in the T-cell-mediated host defense system, 
and also as a co-stimulatory molecule on antigen-presenting cells to activate 
MHC class II restricted T-cells, and on other cell types in association with 
MHC class I to activate cytotoxic T-cells. 
 
The regulation of ICAM-1 at transcriptional level has been reviewed (van de 
Stolpe & van der Saag 1996), and It has been suggested that the expression 
of ICAM-1 is transcriptionally regulated through one of four pathways: NF-kB, 
gamma interferon–Janus kinase/signal transduction-activating transcription 
(JAK/STAT), mitogen-activated protein (MAP) kinase/activator protein 1 
(AP1), and, indirectly, protein kinase C (PKC) (Roebuck & Finnegan 1999). 
The ICAM-1 promoter contains several enhancer elements, but notably 
nuclear factor-kappa B (NF-κB), which mediates effects of 12-O-
tetradecanoylphorbol-13-acetate (TPA), IL-1, lipopolysaccharide (LPS), TNF-
α, and glucocorticoids. Because of this complexity, the regulation of ICAM-1 
expression is cell specific and depends upon the availability of 
cytokine/hormone receptors, signal transduction pathways, transcription 
factors, and post-transcriptional modification (Jahnke et al. 1995). Moreover, 
ICAM-1 is subsequently shed by cells and is detected in plasma as soluble 
(s)ICAM-1, and is found to be increased in many pathological conditions 
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including malignancies (e.g., melanoma and lymphomas), many inflammatory 
disorders (e.g., asthma and autoimmune disorders), atherosclerosis, 
ischemia, certain neurological disorders, and allogeneic organ transplantation 
(van de Stolpe & van der Saag 1996).  
 
In addition to all of the above, there is strong evidence that ICAM-1 serves as 
an important receptor for major group of human rhinoviruses (HRV) (Greve et 
al. 1989), and for some coxsackie viruses (Marlin et al. 1990). For my studies, 
I focused on the potential role of cigarette smoke on the expression pattern of 
ICAM-1, which could potentially facilitate the adhesion and pathogenesis of 
HRV to host epithelial cells. 
 
2.3.2.1 Human Rhinovirus 
 
Human rhinoviruses (HRV), first isolated in the 1950s from individuals with 
common cold symptoms, represent one of the most serologically diverse 
groups of pathogenic picornaviruses (over 160 serotypes have already been 
identified) (Bochkov & Gern 2016). HRVs are classified into three species on 
the basis of phylogenetic relationships and sequence divergence: HRV-A, 
HRV-B, and HRV-C (Kuroda et al. 2015; McIntyre et al. 2013). 
 
HRVs are positive-sense, single-stranded-RNA (ssRNA) viruses of 
approximately 7,200 base pairs. The viral genome consists of a single gene 
whose translated protein is cleaved by virally encoded proteases to produce 
11 proteins. Four proteins, VP1, VP2, VP3, and VP4, make up the viral capsid 
that encases the RNA genome, while the remaining nonstructural proteins are 
involved in viral genome replication and assembly. The VP1, VP2, and VP3 
proteins account for the virus' antigenic diversity, while VP4 anchors the RNA 
core to the capsid. There are 60 copies each of the four capsid proteins, 
giving the virion an icosahedral structure, with a canyon in VP1 that serves as 
the site of attachment to cell surface receptors.  
 
As noted earlier, more than 90% of known HRV serotypes, the “major group,” 
utilize the cell surface receptor ICAM-1, while the “minor group” attaches to 
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and enters cells via the low-density lipoprotein receptor (LDLR). Some of the 
major-group HRVs also use heparan sulfate as an additional receptor 
(Palmenberg, Rathe & Liggett 2010). In short, HRV-A and -B bind to ICAM-1 
on respiratory epithelial cells while HRV-C uses cadherin-related family 
member 3 (CDHR3) to accomplish cellular entry (Bochkov et al. 2015; 
Staunton et al. 1989) 
 
2.3.2.2 Respiratory infections by HRV infection  
 
HRVs chiefly cause upper respiratory tract (URT) infections, but may also 
infect the lower respiratory tract (LRT), in both children and adults (Hayden, 
FG 2004; Winther 2011). A number of studies using molecular techniques 
(RT-PCR) to detect HRVs have established respiratory viral infections as a 
major risk factor for acute exacerbations of asthma and COPD in both adults 
and children, frequently leading to hospital admission. HRV is also associated 
with wheezing illnesses in children, cardiopulmonary disease, and fatal 
pneumonia in immune-compromised patients. While other respiratory viruses, 
such as influenza virus and respiratory syncytial virus (RSV), cause a 
destruction of airway epithelial cells, HRV is not associated with destruction of 
the epithelial lining in nasal biopsies from subjects with natural ‘colds’ (n=29), 
determined by light or scanning electron microscopy (Winther et al. 1984).  
 
Increased nasal ICAM-1 expression has been reported on the respiratory 
epithelium of allergic subjects (Gorska-Ciebiada et al. 2006). Malmstrom et al. 
observed that HRV was frequently found in the lower airways in infants 
(n=201; age 3-26 months) with recurrent respiratory symptoms. The presence 
of HRV was associated with increased resistance to airflow, which predicted 
subsequent asthma in later life (Malmstrom et al. 2006). HRV was detected by 
both immunohistochemistry and the indirect in-situ RT-PCR (n=20), in more 
bronchial biopsies of asthmatics (73%) than in non-asthmatic subjects (22%). 
Again, presence of HRV was associated with more airway obstruction, higher 
numbers of blood eosinophils and leukocytes, and eosinophilia in bronchial 
mucosa (Wos et al. 2008). Experimental HRV infection of human participants 
(n=19) reported the presence of virus in cells from nasal lavage (all subjects), 
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sputum (all subjects), bronchoalveolar lavage (26%), bronchial brushings 
(28%), and biopsy specimens (36%) (Mosser et al. 2005). Results from in-
vitro primary cell culture models confirm that HRV infects lower airway 
tissues, and suggested viral replication in lower airway epithelial cells 
(Schroth et al. 1999), and a major role of ICAM-1 in the infective process 
(Terajima et al. 1997).  
 
RNA-sequencing (RNA-seq) analysis of HRV-infected air-liquid interface (ALI) 
human airway epithelial cell cultures from 6 asthmatic and 6 non-asthmatic 
donors identified sets of host genes transcription associated with increased 
inflammatory pathways, epithelial structure and remodeling and cilium 
assembly and function (CCL5, CXCL10, CX3CL1, MUC5AC, CDHR3, 
CCRL1) (Bai et al. 2015). 
 
As stated, HRV is an important trigger for acute exacerbations in COPD 
(AECOPD). Two prospective studies of patients hospitalized with AECOPD 
found that picornaviruses were the most common viral infection detected by 
RT-PCR in nasal lavage fluid, nasopharyngeal swab, or induced sputum 
specimens, occurring in 36 to 50% of cases (Kherad et al. 2010; Rohde et al. 
2003). HRV prevalence and load at exacerbation was found to be significantly 
higher than in the stable state (53.3% versus 17.2%). COPD patients detected 
with HRV at exacerbation also had a higher exacerbation frequency per year 
compared with patients without HRV. However, secondary bacterial infection 
was common at about 14 days post-HRV infection (George et al. 2014), 
suggesting an interaction with PAFr regulation perhaps (Avadhanula, 
Rodriguez, Devincenzo, et al. 2006). Mallia et al. experimentally infected 13 
COPD patients and 13 non-obstructed smoker controls with HRV and 
reported significant reductions in post-bronchodilator peak expiratory flow and 
carbon monoxide diffusion capacity from baseline to HRV infection in COPD 
patients but no change in controls. The authors also found increased 
neutrophil elastase and IL-8 levels in sputum supernatants and IL-6 levels in 
BAL in COPD patients infected with HRV. Although pulmonary AMs from BAL 
fluid have demonstrated deficient IFN-β responses in COPD patients 
compared to controls, there was only a non-significant trend toward reduced 
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levels of IFN-α and IFN-γ production. Interestingly, there was no change in 
TNF-α levels in either group (Mallia et al. 2011). Human bronchial epithelial 
cells exposed to airway secretions from subjects with bronchiectasis showed 
an increase in ICAM-1 mRNA and protein levels, in TNF-α-dependent manner 
(Chan et al. 2008).  
 
Quint et al. examined serum IP-10 as a potential biomarker of HRV infection 
and reported that COPD patients (n=136) had higher serum IP-10 levels than 
age-matched controls without COPD (n=70), which also correlated with 
sputum HRV viral load. In the same study during 2-years of follow-up, the 
authors reported that serum IP-10 levels increased significantly from baseline 
during HRV-positive AECOPD and demonstrated no change during HRV-
negative exacerbations (Quint et al. 2010).  
 
Cigarette smoke exposure seems to be one of the most important risk factors 
for increased levels of cytokines and subsequent upregulation of ICAM-1, 
which could predispose smokers and COPD patients to frequent HRV-
induced exacerbations.  
 
2.3.2.3 Effect of cigarette smoke on ICAM-1 
 
Small-airway epithelial cells from physiologically normal smokers (n=22) 
showed significantly higher levels of IL-8 and ICAM-1 mRNA than the non-
smokers (n=17), suggesting that cigarette smoke is likely to increase epithelial 
ICAM-1 expression (Takizawa et al. 2000). Clinical studies have 
demonstrated elevated level of serum soluble (s)ICAM-1 in COPD-smokers 
(n=142) compared to non-COPD active smokers (n=55) (Lopez-Campos et al. 
2012). An in-vitro study using primary human bronchial epithelial cells (HBEC) 
from COPD-smokers and non-smoking control participants reported a 
significantly increased release of sICAM-1 and IL-1β in cells exposed to CS, 
compared to control air-exposed cells. In addition, exposure to CS also led to 
increased permeability in the cell culture layer from currently smoking 
participants (Rusznak et al. 2000). As stated in earlier sections, IL-1β further 
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increases ICAM-1 expression on both the airway epithelial cells and 
endothelial cells. 
 
HRV itself up-regulates membrane-bound ICAM-1 expression via a NF-κβ-
dependent mechanism in both primary bronchial epithelial cells (12-fold) and 
the A549 respiratory epithelial cell line (3-fold) (Papi & Johnston 1999). Anti-
ICAM-1 antibody (14C11), administered topically or systemically, has been 
shown to inhibit major group HRV replication in vitro, as well as HRV-induced 
inflammation, pro-inflammatory cytokine induction and lung virus RNA levels 
in a mice model (Traub et al. 2013), confirming a crucial role for ICAM-1 as a 
viral facilitator. Interestingly, anti-ICAM-1 antibody (14C11) did not prevent cell 
adhesion via human ICAM-1/LFA-1 interactions in vitro, suggesting the 
epitope targeted by 14C11 was specific for viral entry. 
 
Although most attention has been on HRV, evidence indicates that ICAM-1 
also serves as an adhesion molecule for Haemophilus influenzae (via 
bacterial P5 fimbriae), which is the main bacterial pathogen in COPD, again 
especially in AECOPD (Sethi & Murphy 2008). Thus, ICAM-1 is an attractive 
target to block not only for virus-receptor binding, but also to check ICAM-1-
mediated NTHi adhesion to respiratory cells. 
 
Despite the importance of ICAM-1 in exacerbations of COPD, its expression 
in the epithelium of COPD patients has not previously been directly 
investigated in large or small airways, which could be crucial for 
understanding the susceptibility for viral infections in the natural history of 
COPD. As mentioned earlier, approximately 90% of HRV bind specifically to 
ICAM-1 as their cellular receptor; so it is certainly is an attractive target for 
development of therapies. 
2.3.3 Other receptors 
 
The initial sensing of infection is mediated by innate, germline-encoded, 
pattern recognition receptors (PRRs) for sensing the presence of 
microorganisms, by recognizing structures conserved among microbial 
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species, which are called pathogen-associated molecular patterns (PAMPs). 
Recent evidence also indicates that PRRs are capable of recognizing 
endogenous molecules released from damaged cells, termed damage- 
associated molecular patterns (DAMPs). PRRs include transmembrane 
proteins, including toll-like receptors (TLRs), as well as cytoplasmic proteins 
such as RIG-I-like receptors (RLRs) and NOD-like receptors (NLRs) (Table 4). 
The specific roles of PRRs have been reviewed previously (Akira, Uematsu & 
Takeuchi 2006; Kumagai & Akira 2010; Takeuchi & Akira 2010). 
 
TLRs are largely found on innate immune cells and structural cells. These 
receptors act through a common intracellular signaling pathway to increase 
the expression of inflammatory cytokines (TNF-α, IL-1, IL-12), chemokines 
(IL-8, MCP-1, RANTES), endothelial adhesion molecules (E-selectin), co-
stimulatory molecules (CD80, CD86), and antiviral cytokines (IFN-α, IFN-β) 
(Chaudhuri et al. 2005; Hammad et al. 2009; Zuo et al. 2015). Several 
investigators have also reported reduced TLR expression in COPD on airway 
inflammatory cells, which would lead to limited pathogen identification and 
clearance, facilitating bacterial colonization, viral invasion and increasing the 
risk of exacerbations (von Scheele et al. 2011), especially when the 
PAFr/ICAM-1 are increased at the same time. 
 
Novel studies suggest that the antiviral response of the host is dependent 
upon the recognition of a variety of viral components, especially genetic 
material, e.g., RNA by host-cytoplasmic proteinases released by the 
cytoplasmic helicase proteins RIG-I (retinoic-acid-inducible protein I) and 
MDA5 (melanoma-differentiation-associated gene 5). RIG-I is essential for the 
production of interferons in response to RNA viruses including rhinovirus, 
influenza, and RSV whereas MDA5 is critical for picornavirus detection. 
Additionally, genetically modified RIG-I-/- and MDA5-/- mice are highly 
susceptible to infection with all these RNA viruses compared to control mice 
(Kato et al. 2006). In a recent finding, severe COPD patients demonstrated a 
diminished cytokine response (granulocyte colony stimulating factor and IL-
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1β) to PAMPs (Fan et al. 2016), which could potentially lead to impaired 
pathogen clearance from patients with advanced disease. 
	
Table 4. Pattern recognition receptors (PRRs) and their ligands. 
Reproduced with permission from Takeuchi and Akira (2010). Copyright Elsevier.	
PRRs Localization Ligand Origin of the ligand 
Toll-like receptors (TLR) 
TLR 1 Plasma membrane Triacyl lipoprotein  Bacteria  
TLR 2 Plasma membrane Lipoprotein  Bacteria, viruses, parasites, self  
TLR 3 Endolysosome dsRNA Virus 
TLR 4 Plasma membrane LPS Bacteria, viruses, self 
TLR 5 Plasma membrane Flagellin Bacteria 
TLR 6 Plasma membrane Diacyl lipoprotein Bacteria, viruses 
TLR 7 (Human TLR8) Endolysosome ssRNA  Bacteria, viruses, self 
TLR 9 Endolysosome CpG-DNA Bacteria, viruses, parasites, self 
TLR 10 Endolysosome Unknown   Unknown  
TLR 11 Plasma membrane Profilin-like molecule   Protozoa 
Retinoic acid-inducible gene (RIG)-I-like receptors (RLRs) 
 
RIG-I (Retinoic acid-
inducible gene) Cytoplasm Short dsRNA 
RNA viruses, DNA 
virus 
MDA5 (mela- noma 
differentiation-
associated gene 5) 
Cytoplasm Long dsRNA RNA viruses (Picornaviridae) 
LGP2  Cytoplasm Unknown RNA viruses 
NOD-like receptors (NLRs) 
NOD-1 Cytoplasm 
Peptidoglycan (g-D-
glutamyl-meso- 
diaminopimelic acid) 
Bacteria 
NOD-2 Cytoplasm 
Peptidoglycan (muramyl 
dipeptide) 
Bacteria 
    
Investigators have reported that Moraxella catarrhalis, which binds to a 
basement membrane glycoprotein, namely laminin through ‘Ubiquitous 
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surface proteins’ (UspA1 and UspA2). The effect of chronic smoking on lower 
airway epithelial membrane integrity is well documented that exposes the 
basement membrane. Interestingly, the laminin layer in the basement 
membrane is significantly thicker in smokers than in non-smokers (Amin et al. 
2003; Tan, Forsgren & Riesbeck 2006). We have focused on two microbial 
adhesion molecules, namely, PAFr (bacterial) and ICAM-1 (predominantly 
viral). 
 
2.4 Current COPD therapeutics 
 
The current treatment for COPD is a stepwise process, which firstly aims to 
alleviate symptoms, before additional pharmacological agents are used to 
target inflammation and reduce the severity and quantity of exacerbations. 
Therapeutic strategies in COPD need to be tailored to the patient’s condition, 
and are guided by symptoms, disease manifestations and complications, 
especially the patient’s risk of experiencing exacerbations (GOLD 2015). Both 
oral and inhaled medications have been used for patients with stable disease 
to reduce dyspnea and improve exercise tolerance, but overwhelmingly 
inhaled treatment is now dominant. Most of the medications used are directed 
at the following 4 potentially reversible causes of symptoms and airflow 
limitation in a disease state that has largely fixed obstruction: 
 
• Bronchial smooth muscle contraction  
• Bronchial mucosal congestion and edema/ mucus hypersecretion 
• Airway inflammation 
• Increased airway secretions 
 
Treatment has often started with short-acting bronchodilators (e.g. beta2-
agonist such as salbutamol) to relieve a patient’s breathlessness, however 
these have largely been replaced by long-acting bronchodilators and now 
frequently a combination of long-acting beta agonist and long-acting beta-
muscarinic, though the latter may be tried by itself first. In severe (Stage III) or 
very severe (Stage IV) COPD patients and/or in those with frequent 
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exacerbations, inhaled corticosteroids (ICS) are also prescribed and are 
typically administered as a combination inhaler with a long-acting beta2-
agonist bronchodilator (e.g. fluticasone propionate and salmeterol). Antibiotics 
are also widely prescribed by health professionals to treat exacerbations 
under the prevailing belief that most exacerbations are of bacterial origin, and 
to also take a cautious approach to prevent complications such as pneumonia 
(Ram et al. 2006; Vollenweider et al. 2012).  
 
Oral corticosteroid is normally used for more severe AECOPD, but then the 
definition is rather subjective. Serious adverse health effects (especially with 
the use of ICS and antibiotics in COPD) have been associated with some of 
these therapeutic strategies making COPD treatment perhaps less early than 
it once seemed. For example, heart problems have been suggested with 
LAMAs and there is more definitive evidence of increased risk of pneumonia 
with ICS. Furthermore, the inappropriate stewardship and overuse of 
antibiotics is understood to be contributing to the rising issue of multi-resistant 
bacterial strains including virulent strains of H. influenzae, M. catarrhalis, and 
P. aeruginosa, and increased treatment costs associated with COPD (Kyd, 
McGrath & Krishnamurthy 2011; Pasquale et al. 2012). 
2.4.1 Limitations with inhaled corticosteroid (ICS) therapy 	
The vast majority of COPD patients (~80%) use inhaled corticosteroids, as a 
single agent, combination inhaler with a LABA or both (Thomas et al. 2014), 
either alone or in combination with a long-acting β2 agonist (Decramer, 
Janssens & Miravitlles 2012). Clinical studies which have evaluated the effect 
of inhaled corticosteroids (ICS) on airway infections have been too small to 
detect important effect in COPD and somewhat conflicting data have been 
reported (Finney et al. 2014). More precisely, two studies using sputum 
cultures found no association between inhaled corticosteroid use and 
bacterial infection (Marin et al. 2012; Miravitlles et al. 2010). Worryingly, 
another study based on quantitative PCR (qPCR) reported that higher doses 
of inhaled corticosteroids were actually associated with greater bacterial loads 
(Garcha et al. 2012).  
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Large clinical trials have suggested that the use of inhaled corticosteroids 
(ICS) increases the risk of pneumonia in COPD patients by two to three-fold 
(Calverley et al. 2007; Cates 2013; Crim et al. 2009; Kew & Seniukovich 
2014). Findings from the TORCH study was the first to show significantly 
increased incidence of pneumonia in the ICS-treated groups, with the 
probability of pneumonia being 12·9% with placebo, 13·3% with long-acting 
β2-agonist (LABA) monotherapy, 18·3% with inhaled corticosteroid 
monotherapy, and 19·6% in the inhaled corticosteroid in combination with 
LABA group. Although ICS treatment was found to be associated with an 
increased relative risk (RR) of pneumonia of 1·52 (95% CI 1·32–1·76), but 
there was no significant increase in pneumonia mortality (Crim et al. 2009). 
Similarly, the INSPIRE study compared fluticasone combined with salmeterol 
with the long-acting muscarinic antagonist tiotropium. They reported the 
probability of having pneumonia within 2 years as 9·4% on inhaled 
corticosteroids plus long-acting β2-agonist group and 4·9% in the tiotropium-
only group (Calverley et al. 2011).  
One study reported impaired clearance of Klebsiella pneumoniae in mice due 
to fluticasone causing increased mortality (Patterson et al. 2012), and in a 
mouse model of allergic airway disease, budesonide also impaired host 
defense to Pseudomonas aeruginosa (Wang et al. 2013). Conversely, in other 
animal models and in in-vitro cell culture models, fluticasone reduced cellular 
adherence of S. pneumoniae, H. influenzae, and P. aeruginosa (Barbier, 
Agusti & Alberti 2008; Dowling et al. 1999). Use of inhaled corticosteroid in 
children with asthma was associated with increased pharyngeal carriage of S. 
pneumoniae (Zhang et al. 2013). In an observational study on COPD patients, 
prior use of ICS is reported to be independently associated with decreased 
risk of short-term mortality and use of mechanical ventilation after 
hospitalization for pneumonia (Cheng et al. 2014). Oral or systemic steroids 
are recommended for severe pneumonia in hospitals, and use of 
corticosteroids was associated with reductions in mortality (~3%), need for 
mechanical ventilation (~5%) and hospital stays (~1 day) (Siemieniuk et al. 
2015). 
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2.4.2 Effects of inhaled corticosteroids on exacerbations 	
The major therapeutic aim in COPD is to prevent exacerbations. The use of 
ICS is widespread in patients with COPD due to its ability to reduce 
exacerbations.  Several studies have concluded a beneficial effect of ICS in 
reducing the number of COPD exacerbations for patients, especially with 
advanced disease (FEV1 <50% predicted) (Calverley 2004). Other clinical 
trials strongly indicate that the use of ICS may reduce clinically relevant 
exacerbations by approximately 30% and improve health status of patients 
who have moderate to severe disease (Jen, Rennard & Sin 2012). Moreover, 
the withdrawal of ICS may likely result in increased risk of exacerbations and 
worsening of health status (Price et al. 2013).  
 
A recent Cochrane review suggested marginal positive effect of LABA/ICS 
inhalers on exacerbation rates in COPD patients in comparison to those with 
LABA alone. Data were reviewed from nine studies, which together 
randomised 9921 participants. The rate ratio was 0.76 (95%CI: 0.68 to 0.84), 
which corresponds to one exacerbation per person per year on LABA and 
0.76 exacerbations per person per year on ICS/ LABA (Ni et al. 2014). 
2.4.3 Effects of inhaled corticosteroids on quality of life (QoL) 	
COPD exacerbations have a major impact on well-being and daily quality of 
life, which is usually measured by St. George’s Respiratory Questionnaire 
(SGRQ) (Jones et al. 1992). A reduction in score of 4 is considered a clinically 
relevant subjective improvement. A worse score predicts a worse clinical 
outcome (Osman et al. 1997). Adding ICS to the pre-existing treatment has 
been shown to significantly improve QoL in patients with COPD, as well as 
some improvement in lung function and decrease in respiratory symptoms 
(Yildiz et al. 2004). However, there is limited capacity for reversibility of 
impaired lung function in COPD (Ceylan 2006). 
2.4.4 Limitations with antibiotic therapy 	
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Standard guidelines recommend antibiotic therapy or all three cardinal 
symptoms of COPD (chronic cough, dyspnea, increased sputum purulence 
and production), although there is no substantiated evidence to support this 
recommendation (GOLD 2015). There is strong evidence that long-term 
macrolide therapy may significantly reduce COPD exacerbation rates, but 
whether though an anti-inflammatory or antibiotic mechanism is not clear 
(Albert et al. 2011; Uzun et al. 2014). Short-term antibiotics are selected for 
the treatment of AECOPD episodes, according to local bacterial resistance 
patterns, although empirical therapy usually starts with the administration of a 
macrolide, tetracycline or an aminopenicilin with or without clavulanic acid, 
and all seem to work (or not) equally well.  
 
Since there is such a large question mark over both the short- and long-term 
use of antibiotics in COPD, there is a growing demand for specific non-
antibiotic treatments to prevent bacterial colonisation and AECOPD.  
 
2.5 Concluding remarks for literature review and questions for the 
present thesis 
 
There is obviously increasing interest in the role of microorganisms in the 
progression of COPD as well as their contribution to acute exacerbations. 
Indeed, the majority (70−80%) of exacerbations are recognized as related to 
infections. Notably, two respiratory bacterial pathogens (NTHi and S. 
pneumoniae) are isolated in a majority of COPD patients, both from stable 
stages of the disease and during the AECOPD. In addition, HRV have been 
implicated as a major etiological trigger in virus-induced exacerbations. 
Despite all the data, the mechanisms by which these pathogens gain access 
to the lower respiratory tract are poorly understood.  
 
The first step of a pathogenic disease is the attachment of pathogen to host 
cells, leading to colonisation, multiplication and subsequent tissue invasion. 
Several specific questions arise regarding mechanisms: Firstly, whether 
cigarette smoking leads to an increase in adhesion sites or ‘receptors’ for 
microbes on the respiratory epithelium. Secondly, how importantly the 
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demographics (e.g. age, lung function, smoking history) of an individual may 
correlate with the microbial adhesion receptors in both smokers and COPD 
patients. Thirdly, how feasible is it to develop an in vitro epithelial cell culture 
model that would mimic the smoking-induced airway epithelial cell changes, 
and whether it is possible to measure the increase of these receptors, both at 
a molecular level and protein expression level. Fourthly, whether blocking 
microbial receptors would result in reduced pathogen adhesion, with a 
potential for therapeutic application.  
 
Thus, the aims of my thesis were developed to answer some of the early 
events that could lead to lower respiratory epithelial colonization in smokers 
and COPD patients, and are summarized below; 
 
1. To assess PAFr protein expression in epithelium of large airways using 
mucosal biopsies in smokers and COPD patients. In addition, I also 
evaluated the effect of inhaled corticosteroids on the expression of 
PAFr in stored biopsies from a previous intervention study. 
2. To assess PAFr expression in the epithelium of small airways and lung 
parenchyma in smokers and COPD patients, as Small airway and 
especially lung parenchyma is more relevant to pneumonia 
development.  
3. To assess the change in PAFr expression in cultured BEAS-2B cells 
exposed to CSE, and use this as a model to evaluate the adhesion 
pattern of S. pneumoniae and NTHi in relation to PAFr expression, and 
to assess the effect of a specific PAFr antagonist (WEB-2086) on 
bacterial adhesion to CSE pre-treated BEAS-2B cells. 
4. To assess epithelial ICAM-1 expression on the epithelium of large and 
small airways, as well as lung parenchyma, in smokers and patients 
with COPD. I also evaluated the effect of CSE on ICAM-1 expression in 
the in-vitro epithelial cell culture model (i.e. BEAS-2B cells exposed to 
CSE). 
2.5.1 Hypothesis 	
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From my aims, it can be seen that my studies are focused on "host factors" 
facilitating the adhesion of major respiratory pathogens to lung epithelium, 
both in human tissue (ex vivo) acquired from Royal Hobart Hospital and in an 
in vitro epithelial cell culture model. The impetus for my interest was the 
preliminary findings from an international collaborative study (Grigg et al., 
2012), in which our group provided preliminary evidence of an increase in 
airway epithelial expression of PAFr in smokers (in both humans and mice 
model). This encouraged me to test the hypothesis that the microbial 
adhesion molecules PAFr and ICAM-1 are upregulated in airway epithelium in 
current smokers and patients with COPD, and may be highly relevant to the 
progression of this disease.  
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Chapter 3  
 
Materials and Methods 
 
3.1 Introduction  
 
For the ex-vivo study of epithelial expression of adhesins, I investigated 
current smokers with established COPD (COPD-smokers), ex-smokers with 
COPD (COPD-ex smokers), current smokers with normal spirometry (termed 
as ‘normal lung function smokers’, NLFS), and normal healthy, never-smoking 
controls (NC) by immunostaining for markers of microbial adhesion factors, in 
particular PAFr and ICAM-1. In a longitudinal analysis, I also used the 
material that had been collected in a double blind randomised controlled trial 
comparing fluticasone propionate (0.5 mg/twice daily) with placebo for 6 
months (Reid et al. 2008), and assessed the effects of ICS on the epithelial 
expression of PAFr.  
 
I used epithelial cell cultures of BEAS-2B cells to validate these 
immunohistochemical findings. Briefly, BEAS-2B cells were cultured and 
stimulated with cigarette smoke extract (CSE). The mRNA transcript levels as 
well as protein expression were quantified for both PAFr and ICAM-1. 
Bacterial adhesion was assessed in relation to PAFr staining and a specific 
PAFr-antagonist (WEB-2086) was analysed for its ability to block the bacterial 
adhesion to CSE-pretreated epithelial cells. Materials and methods for these 
studies that are presented in chapter 4, chapter 5, chapter 6 and chapter 7, 
are detailed in this chapter.  
 
3.2 Subject recruitment  
3.2.1 Ethics statements 	
The Tasmania Health & Medical Human Research Ethics Committee 
approved all studies (EC00337, H0013051 and H0012921). All subjects gave 
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written, informed consent to use their tissue, either prior to volunteer 
bronchoscopy and biopsy, or prior to lung surgery. 
3.2.2 Endo-bronchial biopsies (large airways) 	
Seventeen current smokers with established COPD (COPD-CS), 16 current 
smokers with normal lung function (NS), 15 ex-smokers with COPD (COPD-
ES) and 15 normal healthy, never-smoking controls (NC) were recruited by 
advertisement in local newspapers and placement of posters in clinic waiting 
areas in the Royal Hobart hospital, as well as on the notice boards of social 
and veterans clubs (Table 5). Potential participants were interviewed and 
examined by a respiratory physician clinically and physiologically. The 
diagnosis of COPD was made according to GOLD guidelines based on FEV1 
/FVC ratio and patients categorized into two groups on the basis of current 
versus ex-smoking history.  
 
For normal lung function current smokers the inclusion criteria were; a 
minimum 10 pack-year history of cigarette smoking with spirometry within 
normal limits, i.e., FEV1 (forced expiratory volume in one second) >80% of 
predicted, and FEV1/FVC (forced vital capacity) >70%) and no scalloping out 
of the expiratory descending limb of the flow-volume curve to suggest small 
airway dysfunction. Normal healthy volunteers had no history of respiratory 
illness or smoking and had normal lung function. 
 
In the longitudinal study of inhaled corticosteroid, a computer generated 
random numbers table was used to assign COPD participants to fluticasone 
propionate (FP) (Accuhaler; Glaxo-Wellcome, Middlesex, UK) 500 µg/twice 
daily or placebo via identical multi-dose dry powder inhaler devices for six 
months (Figure 4.1). Before and after treatment, lung function and bronchial 
biopsies were obtained. Half of the participants were current smokers and 
other half ex-smokers. This trial was registered with the Australian New 
Zealand Clinical Trials Registry (Registry No. ACTRN12612001111864). The 
details of the RCT is published previously (Reid et al. 2008).  	
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Table 5. Demographic and lung function data for participants in the cross-sectional 
study (bronchoscopy) and at baseline in the ICS intervention. 
Groups 
(numbers) 
 
NC 
(n=15) 
 
NLFS 
(n=16) 
COPD- 
smokers 
(n=17) 
COPD- ex 
smokers 
(n=15) 
ICS at 
baseline 
 (n=22) 
GOLD 
I/GOLD II‡ N/A N/A 10/7 8/7 10/12 
Male/female 7/8 12/4 9/8 9/6 8/14 
Age (years) 44 (20-68) 50 (30-66) (p=0.313) 
61 (46-78) 
(p=0.001)* 
62 (53-69) 
(p=0.001)* 60(46-69) 
Smoking 
(pack years) 0 32 (10-57) 45 (18-78) 51 (18-150) 42(18-150) 
FEV1% 
predicted 
(Post BD)† 
113        
(86-140) 
99 (78-125) 
(p=0.01)* 
83 (66-102) 
(p<0.001)* 
83 (54-104) 
(p<0.001)* 77(55-112) 
FEV1/FVC % 
(Post BD)† 
82          
(71-88) 
77 (70-96) 
(p=0.218) 
59 (46-68) 
(p<0.001)* 
57 (38-68) 
p<0.001)* 58(41-68) 
Data expressed as median and range. 
NC- Normal control; NLFS-Normal lung function smoker; COPD-CS-COPD current 
smoker; COPD-ES- COPD ex-smoker; ICS-COPD patients on inhaled corticosteroids; 
N/A-Not any 
*Significance difference from NC  
† Post BD values after 400µg of salbutamol 
‡ Diagnosis of COPD was made according to GOLD guidelines (GOLD 2013). 
 
3.2.2.1 Exclusion criteria  	
1. Subjects with a history suggestive of asthma, which included 
symptoms in childhood, related significant atopic disorders, eczema or 
hay fever, substantial day-to-day variability or prominent nocturnal 
symptoms, or a history of wheeze rather than progressive 
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breathlessness and any who had previously used ICS (oral or inhaled) 
were excluded. 
2. Significant uncontrolled comorbidities such as diabetes, angina or 
cardiac failure, and other coexisting respiratory disorders including 
pulmonary fibrosis, lung cancer and bronchiectasis. 
3. Subjects with inability to give written informed consent were also 
excluded. 
 
3.2.2.2 Inclusion criteria  	
1. Current-smokers with COPD aged at least 40 years with smoking 
history equal to or more than 15 pack-years and subsequently obtained 
BAL fluid had to be free of bacterial pathogens; FEV1 40% to 80% 
predicted, with FER (FEV1/FVC)≤70% post bronchodilator with definite 
scalloping out of the descending limb of flow-volume loop on 
spirometry. COPD ex-smokers with at least six months of smoking 
cessation were included.   
2. Normal healthy never smoking controls and current smokers with 
normal lung function recruited also underwent bronchoscopic 
examination and physiological evaluation. They were at least 18 years 
old and FEV1/FVC ratio of 70% or higher and FEV1% predicted of 80% 
or higher.  
3. None of the never-smoking controls individuals had any history of 
significant respiratory illness or smoking.  For normal lung function 
current smokers the inclusion criteria were; less than 10 pack-year 
history of cigarette smoking with spirometry within normal limits (FEV1 
(forced expiratory volume) >80% of predicted, and FEV1/FVC (forced 
vital capacity) >70%) and no scalloping out of the expiratory 
descending limb of the flow-volume curve, suggesting small airway 
dysfunction. 
3.2.3 Bronchoscopy 	
	 79	
Bronchoscopy was performed using standard techniques. Briefly, subjects 
were pre-medicated with nebulized salbutamol (5 mg) 15–30 min before the 
procedure. Sedation was achieved with intravenous midazolam (3–10 mg) 
and fentanyl (25–100 µg). Lignocaine (4%) was used for topical anesthesia 
above the vocal cords and 2% lignocaine was used to anaesthetize the 
airways below the cords, in 2 ml aliquots as required, up to a maximum of 6 
ml. Subjects were monitored by pulse oximetry throughout the procedure and 
oxygen was administered routinely. Eight biopsies from secondary carinae of 
segmental and sub-segmental bronchi in the right lower lobe were obtained. 
There were no complications from the procedures. Bronchial biopsies were 
fixed in 4% neutral buffered formalin for 2 hours and subsequently processed 
into paraffin through graded alcohol and xylene using a Leica ASP 200 tissue 
processor. 
3.2.4 Resected lung tissue (small airways) 
 
A total of thirty-six patients were included. All had primary non-small cell lung 
cancer (NSCLC), with an approximately equal distribution of squamous and 
adenocarcinoma. Patients were classified as current smokers or ex-smokers 
(at least 12 months of smoking cessation). Eighteen patients had 
demonstrated GOLD stage I/II COPD on post-bronchodilator spirometry 
(FER<70%), and ten patients had small airway disease (SAD) only, with 
scalloping of the expiratory limb of the flow-volume curve and FEF25-75<68% 
predicted. In addition, there were eight individuals who were current smokers 
with no evidence of airflow obstruction, and hence designated as smokers 
with normal lung function (NLFS). Again, those with a history of other chronic 
respiratory disorders were excluded (Table 6), including anyone with a history 
or clinical/physiological suggestion of asthma. Surgical resection material well 
away from the main tumour, and containing non-cancer affected small and 
large airways, were fixed in formalin within minutes of surgery. At processing, 
tissue blocks of small airway (<2mm internal diameter) were embedded in 
paraffin for our analyses. For the ICAM-1 expression, we merged the COPD 
groups with SAD group (table 7).  
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Sections from nine non-smoking, non-COPD subjects were included as a 
control group (NC) for comparison. We are thankful to Prof. Darryl Knight 
(University of Newcastle, Australia) and Prof. J.C. Hogg (University of British 
Columbia, Canada) for assistance in providing normal small airway tissues. 
Emeritus Professor HK Muller, a professional pathologist, inspected and 
confirmed that these tissues were normal, and without the hallmarks of 
smoking or asthma. 
Table 6. Demographic and lung function data for participants in the cross-
sectional study (resected lung tissue for PAFr). 
Study groups NC  NLFS  SAD  COPD 
smoker  
COPD- ex 
smoker 
n 9 8 10 8 10 
Male/female 6/3 3/5 2/8 4/4 6/4 
Age (years) 52 
 (42-63) 
72      
(52-79) 
63.5    
(42-84) 
63          
(59-78) 
68.5       
(56-85) 
Smoking history  N/A 23     
(0.3-60) 
40         
(0-72) 
30            
(2-50) 
33           
(18-36) 
FEV1/FVC (%)* N/A 79.5   
(70-90) 
73.4    
(69-76.7) 
66.0        
(59.9-70) 
63.9       
(54.9-69) 
FEF25-75% L/sec Post 
BD %pred. 
N/A 81.5   
(70-116) 
47.0     
(30.8-69) 
37.0         
(28-47) 
40.5       
(20-55) 
Data expressed as median and range. 
NC, Normal control; NLFS, Normal lung function smoker; COPD-CS, COPD current 
smoker; COPD-ES, COPD ex-smoker; N/A, Not any; SAD, small airway group. 
*Post BD values after 400µg of salbutamol 
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Table 7. Demographic and lung function data for participants where 
resected lung tissue was used in the ICAM-1 study. 
Study groups NC NLFS CAL 
 LA biopsy SA resected 
tissue 
  
n 9 9 8 29 
Male/female 4/5 6/3 3/5 13/16 
Age (years) 65 (52-72) 52 (42-63) 72 (52-79) 66 (42-85) 
Smoking 
history  
N/A N/A 23 (0.3-60) 32.5 (0-72) 
FEV1/FVC 
(%)* 
N/A N/A 79.5 (70-90) 68 (54.9-78) 
FEF25-75% 
L/sec Post 
BD %pred. 
N/A N/A 81.5 (70-116) 41.5 (20-69) 
Data expressed as median and range. 
CAL, chronic airflow limitation; LA, large airways; NC, Normal control; NLFS, 
Normal lung function smoker; N/A, Not any; SA, small airways.  
*Post BD values after 400µg of salbutamol 
 
3.3 Processing of biopsies and resected tissue 
 
Sections were cut at 3 µm intervals from individual paraffin blocks and stained 
with hematoxylin & eosin and morphologically assessed for quality and lack of 
damage. Following removal of paraffin and rehydration, immunostaining for 
PAFr and ICAM-1 was done. 
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3.3.1 General procedure for hematoxylin and eosin (H&E) stain 
 
1. Paraffin blocks were sectioned at 3µms after cooling in –20 freezer or 
on ice blocks 5-10 minutes.  
2. For biopsies, two sections (approximately 3µm thick) separated by 40-
50  (approximately 10 sections) were cut and put on each slide [3 
Aminopropyl triethoxy-silane APTS (Sigma A-3648) coated slides (in 
milli Q water bath with one drop of Tween 20 (ICN 103168) in water 
bath at approx 50°C)] or Dako FLEX IHC microscopic slides (Code 
K8020, Dako Denmark A/S). For resected tissue, only one section of 
tissue was used due to greater size. 
3. Slides were dried on hotplate at 56°C for one hour and overnight at 
37°C.  
4. Slides with tissue sections were placed in Mayer’s hematoxylin for 5 
minutes to elaborate nuclei, followed by rinsing in running water.  
5. Tissue sections were placed in approximately in 400ml of water with 8 
drops of ammonia 30 seconds, and rinsed well in running water. 
6. Slides were then placed in eosin solution for 2 minutes, and rinsed 
quickly in running water to remove excess eosin and then placed into 
95% ethanol for 30 seconds with agitation. 
7. Further dehydrated with 3 changes of 100% ethanol was carried out (1 
minute each).  
8. Clearing of sections was done using two changes of fresh xylene (2 
minutes each).  
9. Sections were mounted in Depex using Dako Coverslipper (Dako, 
Denmark A/S) and dried on hotplate overnight. 
3.3.2 General procedure for PAFr and ICAM-1 staining 
 
1. Paraffin blocks were sectioned at 3µms after cooling in –20 freezer or 
on ice blocks 5-10 minutes.  
2. For biopsies, two sections (approximately 3µm thick) separated by 40-
50  (approximately 10 sections) were cut and put on each slide [3 
Aminopropyl triethoxy-silane APTS (Sigma A-3648) coated slides (in 
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milli Q water bath with one drop of Tween 20 (ICN 103168) in water 
bath at approx 50°C)] or Dako FLEX IHC microscopic slides (Code 
K8020, Dako Denmark A/S). For resected tissue, only one section of 
tissue was used due to greater size. 
3. Slides were dried on hotplate at 56°C for one hour and overnight at 
37°C.  
4. Slides were labelled using printed labels and marked on the edges with 
wax pen. 
5. Dewaxing of sections was done in “xylene” (twice for 5 minutes each) 
in fume hood.  
6. Hydration to water was carried out using 100% ethanol followed by 
95% then 70% (3 minutes each) followed by rinsing the sections well in 
running tap water (2 minutes). 
7. Antigen retrieval was performed in PT Link (Dako, Denmark A/S): for 
PAFr, sections were kept at 95°C at high pH buffer for 20 minutes: for 
ICAM-1, a temperature of 100°C at high pH buffer for 15 minutes was 
used. 
8. After antigen retrieval, the slides were cooled down to room 
temperature and transferred to Dako Autostainer Plus (Dako, Denmark, 
A/S), in which a program template for staining was made. 
9. For both PAFr and ICAM-1, sections were placed in 3% H2O2 in 
distilled water for 20 minutes and washed in distilled water for 2 
minutes to block endogenous peroxidase activity. For ICAM-1 staining, 
the sections were also blocked with non-specific non-serum protein 
block (X0909, Dako, Denmark A/S) for 10 minutes. 
10.  Sections were rinsed in working Tris HCl buffer for 2 minutes after 
each treatment.  
11. Primary antibodies were applied to the sections; PAFr (11A4, clone 21, 
Cayman Chemicals, Michigan, USA, Catalogue No 160600, 1/80 
dilution for 1 hour) and ICAM-1 (Merck Millipore Corporation, Merck 
KGaA, Darmstadt, Germany, Catalogue No MAB2130, 1/250 dilution 
for 90 minutes at 20°C, post heat retrieval). A negative control was also 
used: for PAFr-isotype-matched immunoglobulin IgG2a (X0931, Dako, 
Denmark A/S). For ICAM-1- isotype-matched immunoglobulin IgG1 
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(X0943, Dako, Denmark A/S). Lung sections from previous biobank 
were used as positive controls for confirmation of staining. 
12. Sections were rinsed well using Tris HCl (thrice, 5 mins each). 
13. Apply EnVision+ system-HRP labelled polymer (catalogue number 
K4001; Dako, Denmark A/S) reagent to sections for 30 mins and rinsed 
with Tris HCl buffer. 
14. DAB+ (catalogue number K3468; Dako, Denmark A/S) was applied to 
sections for 10 minutes and rinsed well using Tris HCl (twice) followed 
by distilled water. 
15. The slides were taken out of Autostainer and put in Mayers 
haematoxylin to elaborate nuclei for 3-5 minutes, then rinsed in running 
water. 
16. Sections were placed in approximately 400 ml of water with 6-8 drops 
of ammonia for 30 seconds, and rinsed well in running water. 
17. Dehydration was carried out in 95% ethanol, then two changes of 
100% ethanol (2 minutes each).  
18. Clearing was done in two changes of xylene (2 minutes each). 
19. Sections were mounted in Depex using Dako Coverslipper (Dako, 
Denmark A/S) and dried on hotplate overnight. 
 
3.4 Biopsy section quantification  
 
Computer-assisted image analysis was performed with a Leica DM 2500 
microscope (Leica Microsystems, Germany), Spot Insight-12 (Spot Imaging 
Solutions, USA) digital camera and Image Pro Plus 7.0 (Media Cybernetics, 
USA) software. Firstly, as many pictures as possible were taken of the tissue 
from the area of interest (for this study it was mainly epithelium, Rbm, lamina 
propria, sub-mucosal glands and lung parenchyma), avoiding overlapping of 
tissue. All image analyses were done using the above described image 
analyser. Randomly selected images (five for EBBs and eight for resected 
tissue) from the total number of images were used for desired measurements. 
3.4.1 Quantification of PAFr expression 
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Epithelial PAFr expression in large and small airways was expressed as the 
percentage of epithelium with PAFr expression. PAFr-expressing cells in 
airway reticular basement membrane (Rbm) and were quantified and 
normalized over length of Rbm. Alveolar epithelial PAFr positive cells (both 
type I and type II pneumocytes) were quantified and normalized over the 
length of parenchymal wall. We also observed macrophages staining positive 
for PAFr and an additional quantification of PAFr expressing inflammatory 
cells was done which was normalized over the length of alveolar wall.  
3.4.2 Quantification of ICAM-1 expression 
 
ICAM-1 expression in both the large and small airway epithelium was 
expressed as the percentage of ICAM-1-expressing cells out of the total cells. 
Moreover, ICAM-1 expression was differentiated between being basal or 
global. An additional quantification of ICAM-1 expression in the goblet cells 
and sub mucosal glands was done in large airways only, with staining 
intensity evaluated as: 0, negative; 1, weak; 2, moderate for <20% of cells; 3, 
moderate for >20% of cells; 4, strong for >20% of cells. ICAM-1-expressing 
cells in airway reticular basement membrane (Rbm) were also quantified and 
normalized over the length of Rbm.  For alveolar ICAM-1 expression, the 
number of type I and type II pneumocytes expressing the antigen were 
quantified as percent of total alveolar epithelial cells. The length of alveolar 
wall quantitated was approximately 6,500 µm, which was equivalent to around 
50 cells/mm of alveolar wall. 
 
The cell distribution of staining was also noted qualitatively. All slides were 
coded and randomised by an independent person and then counted in a 
single batch by me blinded to subject and diagnosis, with quality assurance 
on randomly selected slides provided by a professional academic pathologist 
(Professor H.K. Muller). 
 
3.5 In vitro epithelial cell culture 
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A primary immortalised cell line of bronchial epithelial cells, BEAS-2B 
(CellBank, Australia), which is commonly used as an in vitro model for 
studying bacterial infections was used in this study. BEAS-2B culture work 
was conducted using an Ultima Class II Fume Safety Cabinet (LAF 
technologies, Australia) under sterile conditions. Cells were maintained at 
37°C, 5% CO2 in bronchial epithelial cell growth medium (BEGM; Lonza, 
Switzerland) supplemented with a bullet kit containing bovine pituitary extract, 
epinephrine, gentamicin, human epithelial growth factor, hydrocortisone, 
insulin, retinoic acid, and transferrinprovided by the manufacturer (Lonza, 
Switzerland). Sterile sealed 75-cm2 cell culture flasks (T75 flask; Corning, 
USA) were incubated in 4 mL of collagen (Life Technologies, USA) and PBS 
at a 1:30 ratio for 45 minutes. The solution was then aspirated before the 
addition of cell-containing solution.  
 
BEAS-2B cells were obtained from liquid nitrogen storage, thawed at 37°C 
and suspended in 4 mL of pre-warmed culture media. The cell suspension 
was centrifuged (Beckman Coulter, USA) at 1500 RPM for 5 minutes at room 
temperature to separate cells from the cryoprotectant diluent dimethyl 
sulfoxide (DMSO; Sigma Aldrich, USA). 
 
Upon subculture, cells were incubated at 37°C, 5% CO2 for 5 minutes in 2.5 
mL Trypsin-EDTA solution (Sigma Aldrich, T3924, USA) supplemented with 
0.5% Polyvenylpyrrolidine (PVP; Sigma Aldrich, PVP40, USA) and 
mechanically agitated to ensure detachment of cells. The cell suspension was 
transferred to sterile centrifuge tubes and neutralised via the addition of fresh 
culture media, equivalent to four times the volume of solution and centrifuged 
at 1500 RPM for 5 minutes. Following centrifugation, the supernatant was 
aspirated, with the cell pellet mixed in fresh culture media at a concentration 
of 1.6 x 105 cells per mL. Cells were  then utilisedseeded in fresh T75 flasks, 
sterile clear-flat bottom 24-well plates (Corning, USA), sterile Millicell EZ-Slide 
8-well glass plates (EMD Millipore, USA) at a concentration of 1.6 x 105 
cells/mL, or sterile clear bottom 96-well plates (Sigma Aldrich, USA). The 
chosen cell density was optimised to ensure a monolayer of cells was present 
in each assay. Culture media was aspirated and replenished every 2 days 
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before subculture at 80-90% confluence for each experiment. Cells from 18 
passages or less were used for all experiments. 
 
Cell density was quantified using an improved Neubauer haemocytometer 
(Hausser Scientific, USA). A 10 µL aliquot of cell-containing solution was 
mixed thoroughly with Trypan Blue (Sigma Aldrich, USA) at a 1:1 
concentration. 10 µL of this solution was pipetted between a glass cover slip 
and haemocytometer via capillary action. The haemocytometer’s grid was 
seen using an Olympus Light Microscope (Olympus; Tokyo, Japan) at 200x 
magnification. Four sections of the counting chamber were used to count 
cells, with each section having a total volume of 0.1 mm3 per section (1 µL). 
The average cell count was multiplied by two to account for the dilution factor 
before being multiplied again by 10 000 to calculate the number of cells per 
mL. Only viable cells, which were unstained by Trypan Blue, were counted 
and incorporated into cell-density calculations. 
3.5.1 CSE-stimulation of epithelial cell culture 
 
CSE was prepared in accordance with procedures previously outlined (Grigg 
et al. 2012) and stored at -20°C as 100% stock solutions. CSE was diluted in 
culture media to a concentration of 1%, which has previously been optimized 
to facilitate a two-fold upregulation in PAFr expression (Grigg et al. 2012). 
BEAS-2B cells were exposed to 1% CSE solution for 4 hours, at 37°C, 5% 
CO2. 
3.5.2 Bacterial strains and growth conditions (for PAFr dependent 
adhesion assay) 
 
Clinical isolates of S. pneumoniae (strain 132), and non-typeable 
Haemophilus influenzae (NTHi) (strain RHH3) were obtained from the 
respiratory tracts of patients at the Royal Hobart Hospital, Tasmania. NCTC-
4560 (ATCC 19418), an NTHi reference strain, was also used in this study. All 
bacterial isolates were recovered from frozen stocks (-20°C) and cultured at 
35°C, 5% CO2 without shaking. S. pneumoniae was grown overnight in Brain 
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Heart Infusion broth (BHI, Oxoid, CM1135, USA) and diluted in fresh BHI to 
an optical density at 600 nm (OD600) of 0.08. using a calibrated Eppendorf 
BioSpectrophotometer (Eppendorf, USA). Bacterial suspensions were 
incubated at 35°C, 5% CO2 with measurements taken hourly until stationary 
phase was ascertained. The bacterial number was confirmed by plating serial 
dilutions of the starting inocula and performing colony-forming unit (CFU) 
counting after incubating for 24 hours at 35°C, 5% CO2. NTHi isolates were 
grown on Chocolate Agar plates (Oxoid, CM0271, USA) and colonies were re-
suspended in Phosphate Buffered Saline (PBS; Life Technologies, USA). 
Serial dilutions were plated onto Chocolate Agar for subsequent CFU 
determination. For each bacterial strain, a multiplicity of infection (MOI) in the 
range of 10-50 bacteria per BEAS-2B cell was used. We aimed to fully define 
the effect of CSE and PAFr antagonist on S. pneumoniae adhesion and PAFr 
in BEAS-2B cells, then investigate the other major pathogen, NTHi. 
 
After overnight incubation, S. pneumoniae, and NTHi were individually 
suspended into PBS to achieve an OD600 nm of between 0.12 - 0.18 OD600 
nm. The suspension was centrifuged at 6000 RPM for 5 minutes to create a 
cell pellet. The supernatant was then aspirated, with each bacterial pellet 
suspended in 2 mL of carbonate buffers containing Fluorescein isothiocyanate 
(FITC; 1 mg/mL, Sigma Aldrich, USA). For experiments with S. pneumoniae, 
FITC-carbonate buffers consisted of Sodium Carbonate (NaCO2: 0.05 M) and 
Sodium Chloride (NaCl: 0.1 M) diluted in sterile deionised water (dH20). 
Following protocols outlined by Avadhanula et al., strains of NTHi were 
suspended in sterile dH20 comprising Sodium Chloride (0.1 M), Sodium 
Carbonate (0.09 M) and Sodium Bicarbonate (Na2CO3: 0.015 M) (pH 9.2) 
(Avadhanula, Rodriguez, Ulett, et al. 2006). All bacteria were suspended in 
FITC buffer for 1 hour at 4 oC before being centrifuged at 6,000 RPM for 5 
minutes and resuspended in PBS twice. This was done to ensure no free 
FITC was remaining in solution before the final bacterial pellet was added to 
BEGM lacking gentamicin, which was also chosen to ensure culture media did 
not affect bacterial viability. Thus, FITC-labelled bacteria in BEGM without 
gentamicin was inoculated into wells and incubated for 1 hour at 37 oC, 5% 
CO2. To ensure FITC did not affect the viability of bacterial strains, serial 
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dilutions of the starting inocula were plated on Chocolate agar and 
retrospectively analysed in triplicate. 
 
An infection assay was adapted from previous collaborations between the 
CRE Breathe Well Group and Grigg and colleagues at Barts and the London 
School of Medicine and Dentistry (United Kingdom) along with previous NTHi 
adhesion assays using the BEAS-2B cell line (Avadhanula, Rodriguez et al. 
2006; Grigg et al. 2012; Mushtaq et al. 2011). Bacterial adhesion assays were 
performed on S. pneumoniae 132, and NTHi strains NCTC-4560 and RHH3 
using sterile Millicell EZ-Slide 8-well glass plates (EMD Millipore, USA). Cell 
monolayers were exposed to several treatments, with comparisons made 
between untreated-BEAS-2B cells, CSE-treated cells, as well as untreated 
and CSE-treated cells inoculated with bacteria. The effect of adding PAFr 
antagonists prior to infection on bacterial adhesion to CSE-treated cells was 
also measured. All bacterial adhesion assays were run as three biological 
replicates. 
3.5.3 Treatment with PAFr antagonists 
 
WEB-2086 was dissolved in dimethyl sulfoxide (DMSO) and added to culture 
media at a 1:1000 dilution or less to ensure DMSO concentrations were less 
than 1%. Ten-fold serial dilutions of each compound were completed (10 µM, 
1 µM, 100 nM, 10 nM) to determine the anti-infective properties of PAFr 
antagonist and stored as frozen stocks at -20°C before being warmed to 37°C 
prior to use. Cell monolayers were washed once with PBS for 5 minutes, prior 
to PAFr antagonist inoculation. Cells were then exposed to PAFr antagonist 
dilution and incubated for 1 hour at 37°C, 5% CO2 before being carefully 
aspirated. 
3.5.4 Fixation of cells and preparation of antibodies (anti-PAFr and anti-
ICAM-1) 
 
After exposure to bacteria, cells were washed in PBS and fixed with 4% 
paraformaldehyde (Sigma Aldrich, USA) for 20 minutes at room temperature 
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and rinsed in PBS for five minutes three times. Cells were treated with two 
five-minute washes of ice-cold acetone and aspirated. After blocking with 1% 
Bovine Serum Albumin (Oxoid, USA), 1% Triton-X-100 (Sigma Aldrich, USA) 
in PBS (PBST) for 30 minutes at room temperature, cells were incubated with 
a 1:100 dilution of anti-PAFr monoclonal antibody (Cayman Chemicals, USA) 
overnight at 4°C in the dark, or 1:100 conjugated anti-PAFr polyclonal 
antibody (Cayman, USA) for 90 minutes at room temperature in the dark. For 
ICAM-1 protein staining, fixed cells were incubated with an anti-ICAM-1 
antibody (1/250). 
 
After thorough rinsing with PBS, 1:500 dilution of AlexaFluor 594-conjugated 
Goat Anti-Mouse secondary antibody (Molecular Probes, USA) diluted in 1% 
BSA, PBST for one hour at room temperature was used on cells previously 
incubated with anti-PAFr monoclonal antibody (Cayman Chemicals, USA). 
Similarly, a 1/500 dilution of AlexaFluor 498-conjugated goat anti-mouse 
secondary antibody (Molecular Probes, USA) in blocking buffer for 1 hour at 
room temperature was used to illustrate anti-ICAM-1 monoclonal antibody. 
 
After incubation, three five-minute PBS washes were completed before 4', 6- 
diamidino-2-phenylindole (DAPI; Life Technologies, USA) at a concentration 
of 1:5000 in PBS was incubated in the dark at room temperature for 15 
minutes when using either anti-PAFr or anti-ICAM-1 antibody. The cells were 
washed three times with PBS before slides were mounted with Fluorescent-
mounting Media (Dako, Denmark A/S). 
3.5.5 Microscopy and image analyses 
 
Micrographs were analysed using an Olympus BX50 Fluorescence 
Microscope (Olympus; Tokyo, Japan) with NIH elements microscopy software 
(Nikon; Tokyo, Japan) and CoolSnap Hq2 CCD camera (Photometrics, USA). 
Five images were taken per well using each immunofluorescence channel to 
take pictures of DAPI (eukaryotic cell nuclei; 30 ms exposure, 405 nm), PAFr 
(PAFr expression; 1-3 second exposure, 594 nm) and FITC (bacteria; 1-3 
second exposure, 488 nm) signals using the 40× lens. NIH elements imaging 
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software (Nikon; Tokyo, Japan) was used to perform eukaryotic and bacterial 
cell counts, whilst image merging was completed using Adobe Photoshop 
C56 software (Adobe Systems, California, USA). Cell tracing was achieved 
using Image-Pro Plus 7.0 software (Media Cybernetics, Inc., USA). 
3.5.6 BEAS-2B cell viability assay 
 
Cells were passaged into sterile clear-flat 96-well plates (Sigma Aldrich, 
CLS3340, USA) with each PAFr antagonist diluted to concentrations used 
within bacterial adhesion assays and added as triplicates to incubate for 1 
hour. Alamar Blue (Life Technologies, USA) was then added into each well at 
a 10% concentration before hourly absorbance readings (585 nm) until 24 
hours using a Spectromax Spectrophotometer Microplate Reader (Molecular 
Devices, USA). A positive control of 100% reduced Alamar Blue via 
autoclaving was also used in experiments. Cell viability data is representative 
of three biological replicates and expressed as IC50 values based upon 
calculations from manufacturer’s guidelines (Life Technologies, USA). 
3.5.7 In silico analyses of PAFr antagonist compound docking 
 
I am grateful to Dr. David Gell (protein biochemist) and Mr. Rory L. Fairbairn 
(honors student) for performing these in silico analyses. To understand the 
binding of ligands to PAFr, a 3-dimensional molecular model of the PAFr 
protein was generated. The software package, MODELLER (Andej Sali, San 
Francisco, CA 94143, USA) was used to create a PAFr protein structure 
based upon the known X-ray crystal structures of related proteins (Caboni et 
al. 2014; Gazos-Lopes et al. 2014; Gui et al. 2007). The program takes as 
input: (1) an alignment of the PAFr amino acid sequence with sequence (or 
sequences) of G32 protein coupled receptor(s) of known structure; (2) the 
atomic coordinates of known structures in Protein Data Bank (pdb) format 
(Marti-Renom et al. 2000; Sali & Blundell 1993).  
The software package, MODELLER (Andej Sali, San Francisco, CA 94143, 
USA) (Sali & Blundell 1993) was used to create a PAFr protein structure 
based upon the known X-ray crystal structures of other G-protein coupled 
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receptors (GPCRs), namely, neurotensin receptor type 1 (pdb 4buo, 2.75 Å 
resolution), bovine rhodopsin (pdb 1u19, 2.2 Å resolution), and an engineered 
nociception/orphanin FQ receptor (pdb 4ea3, 3.0 Å resolution). A second 
model was obtained using the I-TASSER web server and a database of 
structural models including all 1,026 GPCRs in the human genome (Zhang et 
al. 2015), which identified C-C chemokine receptor 5 (CCR5; pdb 4mbs, 2.7 Å 
resolution) as a template with significant similarity to PAFr. Ligand docking 
was performed using AUTODOCK VINA software (Molecular Graphics 
Laboratory, California, USA) (Trott & Olson 2010). Atomic coordinate files for 
WEB-2086 and PAF in Protein Data Bank (PDB) format were generated using 
OPEN BABEL (O'Boyle et al. 2011) and input files for docking were prepared 
using AUTODOCK TOOLS (Sanner 1999). Docking results were visualized 
and molecular graphics generated using PYMOL (Schrödinger, USA). 
3.5.8 Quantitative real-time PCR (qPCR) for PAFr mRNA analysis 
 
Cells were seeded into a sterile clear-flat bottom 24-well plate (Corning, USA). 
The unstimulated cells and cells exposed to CSE (1%, 4 hours). RNA was 
prepared using the ReliaprepTM Mini RNA cell Miniprep system (Promega, 
Australia) with total RNA quantified by Nanodrop 1000 (Thermo Scientific, 
USA). Complementary DNA (cDNA) was then collected via Promega cDNA 
synthesis kit (Promega, Australia). Transcript level of PAFr was assessed by 
a commercially available primer (Qiagen, Germany, Catalogue#PPH05820C), 
whilst  ICAM-1 was assessed (H_ICAM1_1, Sigma Aldrich, USA) was 
determined by qPCR using the Corbett Rotor-Gene 6000 system (Qiagen, 
Germany). Reaction volumes in qPCR assay were 15 µL in 0.1 mL tubes 
containing 100 pg of template, 0.5 µL PAFr primer (10 mM, Qiagen, 
Germany), and 7.5 µL SensiFast SYBR (Bioline, BIO-98005, Australia). 
Thermocycling controls were run as previously described (Latham, Zhang & 
Tristram 2015). Briefly, this consisted of an initial melt at 95°C for 3 minutes 
before 40 cycles at 95°C for 10 seconds, 60°C for 10 seconds, and 72°C for 
10 seconds. Data acquiring was completed at 72oC, with melt curve collection 
between 60°C and 95°C. The relative change of expression was normalised 
to all three-reference genes (18S, β-Actin, β2-Microglobulin) using 
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comparative analysis according to the manufacturer’s guidelines (Qiagen, 
Germany). Data shown is representative of two separate experiments with 
two replicates. 
 
3.6 Statistical analysis 
 
For cross-sectional data, the distributions were generally skewed in an 
upward direction, so results are presented as medians and ranges; non- 
parametric analyses of variance were performed (Kruskal-Wallis Test 
comparing medians across all the groups of interest) and specific group 
differences were then explored as appropriate according to prior hypotheses 
using the Mann–Whitney U test. To be highly conservative, we have also 
applied a Bonferroni correction for multiple comparisons. We also performed 
regression analysis for PAFr expression against age, FEV1 (%predicted), and 
smoking history in the normal smokers and COPD groups. Associations 
between variables were assessed using Spearman's rank test. Linear 
regression analyses for potential confounders were undertaken and 
differences between groups in gender balance, age, and atopy were found to 
be non-contributory. We also performed regression analysis for both PAFr 
and ICAM-1 expression against age, FEV1, and smoking history in both the 
normal smoker controls and COPD patients and CAL groups separately. For 
in vitro studies, data are expressed as mean ± standard error using Microsoft 
Excel Statistics package (Microsoft, United States of America). Comparisons 
between groups were completed using one-way analysis of variance 
(ANOVA), and unpaired two-tailed t tests using GraphPad Prism (GraphPad 
Software Inc., United States of America). In this work statistical analyses with 
p < 0.05 were considered significant. 
Statistical analyses were performed using SPSS 21.0 for Mac, 2012 (IBM 
Corporation, Armonk, NY, USA) and GraphPad Prism 6.0 (2012) for 
Windows, (GraphPad Software Inc., La Jolla, CA, USA), with a two-tailed p-
value ≤0.05 being considered statistically significant. 
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Chapter 4  
 
Large airway epithelial platelet activating factor receptor (PAFr) 
expression is markedly upregulated in Chronic Obstructive Pulmonary 
Disease 
 
4.1 Introduction 	
Emphasis has been laid on the importance of lower respiratory tract bacterial 
colonization in the pathogenesis of COPD, its subsequent long-term 
progression and acute exacerbations, and so infection is likely to be one of 
the important factors driving inflammatory processes in the airways (Cabello 
et al. 1997; Erkan et al. 2008; Patel et al. 2002). However, the mechanisms 
underlying the initial bacterial epithelial adherence and subsequent acute and 
chronic infections remain elusive. Haemophilus influenzae and Streptococcus 
pneumoniae are the most important pulmonary bacteria during both stable 
phase of disease and exacerbations of COPD (Banerjee, Khair & 
Honeybourne 2004; Murphy et al. 2004; Soler et al. 1999). Moreover, complex 
interactions between the host, microbes (both bacteria and viruses) and 
environmental pollution are associated with exacerbations that are marked by 
substantial increases in inflammatory markers in the airways (Hurst et al. 
2006; Sapey & Stockley 2006). 
 
Large intervention trials and follow-up pharmaco-epidemiology studies have 
recommended the use of inhaled corticosteroids (ICS) to reduce frequency of 
exacerbations and improve quality of life in more severe COPD patients, and 
it has become an established therapy (Calverley et al. 2007). Although ICS 
therapy undoubtedly has some positive effects, it is accompanied by an 
increase in the risk of lower respiratory tract bacterial infections in COPD 
patients, especially with Streptococcus pneumoniae, which increase in 
incidence over time (Cates 2013; Ernst et al. 2007; Singh, Amin & Loke 
2009). 
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In an international collaborative study, our group recently demonstrated 
increased Platelet Activating Factor receptor (PAFr)-expression and PAFr-
dependent Streptococcus pneumoniae adhesion to epithelial cells in culture 
exposed to cigarette smoke extract (CSE), and provided at least very 
preliminary evidence of an increase in airway epithelial expression of PAFr in 
normal smokers (Grigg et al. 2012).  
 
PAFr is a G-protein-coupled epithelial cell membrane receptor that naturally 
binds the phosphorylcholine ligand on the eukaryotic pro-inflammatory 
chemokine PAF. Of all bacteria, Streptococcus pneumoniae (also 
Haemophilus and Pseudomonas) cell walls specifically express 
phosphorylcholine (ChoP), which out-competes PAF to bind to the PAFr. This 
initiates bacterial uptake by the host cell in a β-arrestin-dependent pathway 
(Cundell et al. 1995; Radin et al. 2005; Swords et al. 2000). 
 
In addition, PAFr-deficient mice are less likely to develop invasive 
pneumococcal infections as compared to their wild-type counterparts 
(Rijneveld et al. 2004). PAFr-dependent pneumococcal adhesion is also 
upregulated by several other factors in addition to cigarette smoke, including 
acid, respiratory viral infection, interleukin (IL)-1α and exposure to particulate 
matter (Grigg 2012). This all fits with the pattern of infection and deterioration 
seen in COPD. 
 
In this chapter, I have extended our previous cross-sectional observations, to 
analyse the expression of airway epithelial PAFr in another batch of normal 
smoker tissue, but also in groups of COPD subjects (smokers and ex-
smokers) not on ICS. I also took the opportunity to assess PAFr expression in 
a group of similar COPD subjects who had been involved in a trial of ICS 
therapy for 6 months (see page 74). 
 
4.2 Overview of materials and methods 	
The subjects involved are detailed in pages 74-75. We employed classical 
immunohistochemical methods to evaluate PAFr expression in the large 
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airway epithelium in bronchial biopsies collected from well phenotyped 
participants (detailed in chapter 3, page 74-82). 
 
Figure 4.1. Study design for ICS intervention study.  
Thirty four COPD patients; two week run-in period; then bronchoscopy and 
airway biopsy; then patients randomized 2:1 into receiving fluticasone 
propionate or placebo for 6 months by using a computer generated random-
numbers table; finally, bronchoscopy and airway biopsy repeated. Tissue 
analysis done blinded to subject status (n=6 in the intervention arm and n=3 in 
placebo arm were excluded from analysis due to lack of tissue at second 
time-point).  
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4.3 Results 
4.3.1 PAFr expression in cross-sectional study 	
Immunostaining was prominent only in the apical part of the bronchial 
epithelium of NLFS, but staining was darker and more generalized, apparently 
around the perimeter of cells, in the COPD groups. There was negligible PAFr 
staining in normal controls. These staining patterns are illustrated in Figure 
4.2. 
Image analysis confirmed that there was no difference in PAFr expression 
between COPD-smokers and COPD-ex smokers study groups (p=NS), but 
the difference between both COPD groups, and NLFS (Median 0.0%, Range 
0-4.9%) was significant, i.e., COPD-smokers (p<0.005; Median 1.03%, Range 
0-21.8%), COPD-ex smokers (p<0.002; Median 3.6%, Range 0-15.5%). NLFS 
also showed significantly higher PAFr when compared to NC (Median 0.0%, 
range 0-0%). PAFr expression in the ICS treated group was very similar to the 
other COPD groups, so no formal statistical testing was done (Figure 4.3). In 
the NLFS group, only 7 of the 16 epithelia stained detectably, while in the two 
COPD groups combined, 24 had detectable staining out of 27 (Χ2 test; 
p<0.001), as five samples from COPD groups (2/17 COPD-smokers and 3/15 
COPD-ex smokers) did not have enough tissue for analysis.  
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Figure 4. 2. Platelet activating factor receptor (PAFr) expression in epithelium 
of large airways.  
(A) A representative bronchial biopsy from a never smoker showing low PAFR 
staining that is below the cutoff threshold for positivity (Republished with 
permission from BMJ Publishing Group Ltd [18]). (B) Typical lung function 
smoker, showing positive staining (arrowed). (C) Typical COPD- smoker 
showing extensive PAFr staining. (D) Typical COPD- ex smoker showing 
brown staining (arrowed). Original magnification x400. Scale bar = 50 µm.  
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Figure 4. 3. Percentage of epithelium showing PAFr expression in cross-
sectional study. 
The COPD group after ICS is showed for completeness and is obviously quite 
similar to the COPD groups. The p values include a Bonferroni correction 
(p<0.001). Horizontal Bars represent median. 
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The regression analyses showed that age and FEV1 (% predicted) had no 
significant effects on PAFr-expression (r=0.23 and r=0.11 respectively). 
However, for pack-years of smoking in the ex-smoking COPD group, there 
was quite a strong relationship (r=0.56; p<0.05), but this was not seen in the 
currently smoking COPD subjects (r=0.09; p<0.81) (figure 4.4). 
 
 
 
Figure 4.4. Correlations of epithelial PAFr expression in COPD groups and 
smoking history in pack-years.  
(A) COPD-smoker. (B) COPD-ex smoker. 
(pack years = Number of pack of 20 cigarettes each smoked on average per 
day x number of years of smoking). 
r=0.09
p<0.81
A
r=0.56
p<0.05
B
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4.3.2 PAFr expression in central airways obtained in a placebo-
controlled ICS intervention study 	
There was considerable variation in PAFr expression within the COPD groups 
both before and after the treatment phase. The median percent epithelial 
expression rose in both the groups, by approx. 3-fold in the ICS limb (p<0.15) 
but also approx. two fold in the placebo group over time (figure 4.5). Although 
the final median level in the ICS groups was greater than in the placebo 
group, this was neither significant nor were the changes in expression over 
this time between the groups (p<0.4). It is possible, because of the small 
number of paired tissues that were available to us, that we are seeing a Type-
2 statistical error and so a power calculation using non-transformed data was 
undertaken for a potential real increase in epithelial PAFr expression with ICS, 
which indicated that for these estimates of effect size, a bronchoscopic study 
of over 200 subjects per group would be needed to show a significant positive 
effect of ICS on PAFr expression.  
 
Figure 4.5. Relative PAFr expression in the ICS intervention study.  
Horizontal Bars represent median. 
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4.4 Discussion 	
In the present study, I found that in vivo expression of PAFr is significantly 
upregulated in the central airways in COPD patients as compared to smokers 
with normal lung function and even more when compared to normal 
individuals. Expression in COPD current and ex-smoker was similar, but quite 
variable in both groups. This might suggest that smoking cessation may be 
ineffective in down-regulation of PAFr once COPD has developed. 
Alternatively, it is possible that especially high expression of PAFr in some 
smokers is both a risk factor for COPD development in the first place and its 
progression even after smoking has ceased.  
 
Overall, my data on the effects of ICS were negative, with at the very most 
only modest evidence that ICS up-regulates PAFr expression, though it 
certainly does not decrease it over 6 months, as was suggested in earlier in 
vitro and animal models (Barbier, Agusti & Alberti 2008). This study may have 
been relatively short to demonstrate relevant effect of ICS on PAFr 
expression, as a 2-year timescale has usually been taken in monitoring 
Pneumococcal disease in COPD patients treated with ICS. Thus, incidence of 
pneumonia in patients on ICS escalates over years rather than weeks or 
months (Cates 2013). It is also possible that the effects of ICS could be more 
marked in peripheral airways or lung parenchymal epithelium where the 
clinical problem of pneumonia occurs while our biopsies were taken only from 
relatively central airways. Pneumonia occurs at a rate of approximately 1% 
per year in severe COPD patients on ICS (Kew & Seniukovich 2014), and it is 
not known whether there is a specific aberration only in this small group of 
individuals affected, or whether some generic change occurs in all COPD 
subjects given ICS but which manifests clinically only in a small percentage. 
This issue needs further work. 
 
The relationship between cigarette smoking and infection/colonization with 
Streptococcus pneumoniae and NTHi has been well documented and 
exposure to tobacco smoke is considered as a major risk factor for invasive 
pneumococcal disease (Arcavi & Benowitz 2004; Nuorti et al. 2000). 
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Persistence of chronic inflammation and continuous deterioration of lung 
function following smoking cessation may be attributed to chronic colonization 
and invasion of lung tissue by respiratory bacterial pathogens, again most 
commonly S. pneumoniae and H. influenzae (Arcavi & Benowitz 2004). 
Bacterial adherence to lung epithelium and subsequent tissue invasion is 
thought to be a crucial step in the pathogenesis of respiratory infections. The 
major respiratory bacterial pathogens are equipped with the surface ligand, a 
mimic of platelet activating factor (PAF), known as phosphorylcholine (ChoP), 
which is capable of binding to epithelial PAFr. Especially virulent strains of S. 
pneumoniae have been shown to adhere its bacterial cell surface ChoP 
especially firmly with epithelial surface PAFr (Cundell et al. 1995; Grigg 2012; 
Swords et al. 2000). I suggest that my data on PAFr expression in the airway 
epithelium in COPD may be relevant to this, as out of an estimated 109 
different bacterial species (Curtis, Sloan & Scannell 2002), it is only these two 
species particularly (and also Pseudomonas aeruginosa, which is more 
relevant in cystic fibrosis) that express the ChoP ligand. 
 
In a collaborative study with Grigg et al. (Grigg et al. 2012), our group has 
described significant increased in PAFr-dependent pneumococcal adhesion, 
PAFr transcript level and PAFr protein expression in epithelial cell cultures 
exposed to cigarette smoke extract (CSE). Moreover, a specific PAFr 
antagonist attenuated pneumococcal adhesion. In the same study we showed 
enhanced airway epithelial PAFr expression in smokers airways for the first 
time. My study takes this observation further and confirmed much greater up-
regulation of PAFr expression in the COPD groups than in normal smokers. In 
contrast, Suri et al. reported no difference in PAFr mRNA transcript levels 
between normal smokers and smokers with COPD. However, they did not 
quantify the PAFr immunoreactivity on bronchial biopsies, and ultimately it is 
protein expression on the epithelial surface that will matter functionally (Suri et 
al. 2014), which might reflect post-transcriptional modification changes rather 
than transcription control. Moreover, the micrograph provided by Suri et al. 
seemed to have more PAFr expression in their normal controls than we have 
found, but the most staining did actually appear to be in COPD, consistent 
with our finding. These data raise the need for ex-vivo epithelial cultures from 
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such patients to see if functionally there is greater bacterial adhesion in COPD 
airways in the group with greatest PAFr expression. 
 
The regression analysis in the two cross-sectional COPD groups produced 
interesting outcomes. There was no relationship between either age or 
severity of airflow obstruction and PAFr-expression, but pack-years of 
smoking was strongly related, at least in COPD patients who no longer 
smoked. The lack of this relationship in current smokers suggests that this 
aggregate long-term effect was confounded by an additional effect of current 
smoking. Thus, both current smoking and history of smoking seem important, 
but since only a minority of smokers develop COPD, there must also be in 
addition an individual susceptibility, presumably at a genetic or epigenetic 
level. 
 
The role that inhaled corticosteroids (ICS) can play in COPD has been 
extensively studied in recent years and ICS have been shown to be especially 
effective at reducing exacerbation rates (Calverley et al. 2007). Other 
described benefits are more tentative, such as reduction in rate of decline in 
lung function, decreased cancer rates (Celli et al. 2008; Parimon et al. 2007) 
and decreased mortality (Calverley et al. 2007). However, a paradoxical effect 
is that ICS therapy also increases the risk of lower respiratory bacterial 
infections, especially with S. pneumonia (Calverley et al. 2007; Singh, Amin & 
Loke 2009), an effect that worsens over time (Cates 2013). An association 
between ICS and increased risk of hospitalizations due to pneumonia in 
elderly COPD patients with a high mortality rate has also been reported (Ernst 
et al. 2007). Animal models also demonstrate a similar effect of elevated risk 
of pneumonia with administration of ICS (Patterson et al. 2012). 
 
On the basis of my current data, I cannot say that this increased infective risk 
of ICS is related to enhanced expression of respiratory epithelial PAFr, but it 
remains a possibility. A much larger clinical study would be needed to 
determine this, but such a large bronchoscopic investigation is rather unlikely 
to occur. A better approach may be to see if corticosteroids have any effect on 
human primary epithelial cell cultures in this regard. It is notable that PAFr 
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expression seemed to increase in both ICS and placebo treated COPD 
subjects over 6 months. Patients are recruited into such studies when 
especially well and free from infection, and this apparently spontaneous 
change may be a regression back to their more usual status of increased 
vulnerability. 
 
There were several limiting issues in this study, especially the small numbers 
of samples available in the ICS intervention study. Secondly, only large 
airways were studied, but the next chapter extends my analysis to small 
airway samples and alveolar epithelium obtained at lung resection. Strengths 
of the present investigation include fairly robust numbers in the main cross-
sectional study that followed on from the rather small smoking effect 
published previously using this same tissue bank (Grigg et al. 2012). The data 
for the normal lung function smokers analysed here were obtained de-novo 
and by me, as a completely separate operator, but are very similar to that 
published earlier 
 
4.5 Conclusion 
In summary, airway epithelial PAFr expression is significantly up-regulated in 
smokers but is especially marked in COPD subjects, irrespective of whether 
they are current smokers or not. This opens up a very significant potential to 
explain the pathogenesis and evolution of COPD, but it now needs further 
study, especially clinical follow-up. However, PAFr expression could be very 
important in the etiology of chronic and invasive infection with Streptococcus 
pneumoniae and Haemophilus influenzae. Whether the increased expression 
of PAFr is a contributing cause of COPD or a result of it especially needs 
further investigation. 
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Chapter 5  
 
Platelet-activating factor receptor (PAFr) is upregulated in small airways 
and alveoli of smokers and COPD patients 
 
5.1 Introduction 	
As discussed earlier, the most common “colonizers” in the stable state of 
COPD are S. pneumoniae and NTHi (Chapter 2). The risk of mortality and 
morbidity escalates when patients encounter frequent AECOPD, which are 
mostly of microbial origin. 
 
In the previous chapter, I showed significantly increased expression of PAFr 
in the epithelium of central airways of both COPD-smokers and COPD-ex-
smokers compared to smokers with normal lung function, which was found to 
be independent of age or FEV1. I did find a strong relationship between PAFr-
expression and pack-years of smoking in the COPD ex-smokers suggesting 
that smoking cessation is ineffective in affecting this chronic phase of PAFr 
upregulation once COPD has developed. Alternatively, it is possible that high 
expression of PAFr in some smokers may be a risk factor for development of 
COPD in the first place (chapter 4). 
 
PAFr-protein expression in small airways has not previously been explored. 
Published evidence has established that the small conducting airways (<2mm 
in diameter) are the primary site of the majority of smoking-related airways 
obstruction in COPD (Burgel 2011; Cosio, Saetta & Agusti 2009). However, 
the extent and heterogeneity of pathological processes in small airways are 
yet to be fully understood, including the effects of smoking on the regulation of 
microbial adhesion sites, including PAFr. Since both S. pneumoniae and NTHi 
utilize PAFr for host epithelial adhesion, its upregulation in small airways 
could be especially important for inducing chronic infection and secondary 
inflammation and remodeling at this site. 
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In the present study, I have investigated whether PAFr expression is 
upregulated in epithelium of small airways and alveoli in smokers and patients 
with COPD, as well as a group with only small airway obstruction.  
 
5.2 Overview of materials and methods 	
I employed classical immunohistochemical methods to evaluate PAFr 
expression in the large airway epithelium in bronchial biopsies collected from 
well phenotyped participants (as detailed in methodology chapter 3, page 77-
83). 
 
5.3 Results 
5.3.1 Small airway epithelial PAFr expression  	
Epithelial expression was increased in NLFS (p<0.01) compared to normal, 
but most markedly increased in both COPD-smokers and COPD-ex smokers 
(figure 5.1 A, B, C & figure 5.2A). Moreover, there was significant upregulation 
in PAFr expression in COPD smokers (p<0.05) when compared to NLFS. In 
NLFS, epithelial staining was mainly apical, but in the other groups, heavy 
PAFr expression was observed throughout the airway epithelium. For all 
current smoker groups, together or separately, there were positive 
relationships between pack-year smoking history and PAFr expression 
(r≥0.5), strongest in the normal lung function smokers (r=0.9; p<0.002) (figure 
5.3). 
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.Figure 5.1 Platelet activating factor receptor (PAFr) expression in epithelium 
of small airways and lung parenchyma.  
(A-C) and lung alveoli (D-F). (A,D) Representative section of small airway 
from a never smoker showing negligible PAFr staining that is below the cut off 
threshold for positivity. (B,E) Typical normal lung function smoker showing 
positive staining (showed by black arrow). (C,F) Typical COPD-smoker 
showing extensive PAFr staining (arrowed; black circle in F shows carbon 
deposition). A-C: Magnification x400; D-F: Magnification 200x. The small 
airway disease group stained similarly to COPD. 
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Figure 5.2. Percentage of small airways epithelium showing PAFr expression 
in cross-sectional study. 
Data were log-transformed so the differences between groups are potentially 
large.  
*p<0.01 compared to NC. 
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Figure 5.3. Correlations between epithelial PAFr-expression in small airways 
and smoking history in pack-years. 
(A) for all currently smoking individuals. (B) COPD-ex smokers. 
r=0.9
p<0.002
A
r=0.36
p<0.3
B
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5.3.2 PAFr positive cells in the airway Rbm  	
The Rbm in both COPD groups was relatively hyper-cellular compared to 
normal, as previously observed (Sohal et al. 2010). The only significant 
increase in PAFr stained cells was observed in COPD-smokers (p<0.007; 
median: 1.0 PAFr positive cells/mm of Rbm; range: 0.7-10.3), compared to 
normal tissue (figure 5.4).  
 
Figure 5.4. PAFr-expressing cells in Rbm of small airways in cross-sectional 
study.  
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5.3.3 PAFr positive cells in the alveolar epithelium  	
PAFr positive cells were significantly increased (p<0.01) in all the clinical 
groups compared to normal tissue. Overall, approximately 15-20% of total 
epithelial cells (both type I and type II pneumocytes) were found to be positive 
across all the disease groups (figure 5.1 D, E, F & figure 5.5). The percentage 
of PAFr expressing cells in alveoli of normals was negligible.  
 
Figure 5.5. Quantification of PAFr-expressing cells in lung alveolar epithelial 
cells. All comparisons verses NC. 
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5.3.4 PAFr positive inflammatory cells in the lung alveolar interstitium  	
PAFr expression was present on inflammatory cells, even in the normal 
controls, mainly on macrophages, but these were always lightly stained. 
There was no statistically significant increase in either COPD group compared 
to normal. However, the number of PAFr-expressing macrophages was 
significantly increased in the interstitium in normal lung function smokers 
compared to normal tissue (p<0.008) (figure 5.6).  
 
 
Figure 5.6. PAFr-expressing inflammatory cells in interstitium. 
Data was log-transformed so the differences between groups are potentially 
large.  
  
5.4 Discussion 
 
This is the first comprehensive report of PAFr-protein expression in the 
epithelium of the small airways and lung parenchyma in smokers and patients 
with COPD. I found increased PAFr expression in the epithelium of both small 
airways and alveoli in smokers, but especially in the small airways in COPD 
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patients. I also found that the number of PAFr positive cells increased in the 
reticular basement membrane in COPD-smokers; most of these cells had 
fibroblast-like phenotype, as reported previously by our group in investigation 
of EMT in smoker airways (Sohal, S. S., Mahmood & Walters 2014; Sohal, S. 
S. et al. 2014). These findings could be crucial for understanding the 
vulnerability of smokers to airway infections specifically with NTHi and S. 
pneumoniae. 
 
Increased expression of PAFr in smokers’ large airway epithelium has been 
previously reported by Grigg et al. (Grigg et al. 2012). Previous evidence has 
indicated that environmental pollution (Mushtaq et al. 2011), acid exposure 
(Ishizuka et al. 2001), infections (both viral and bacterial) (Ishizuka et al. 
2003), cytokines (IL-1α and TNF-α) (Cundell et al. 1995) could all elevate 
epithelial PAFr expression, which is also associated with increased 
pneumococcal invasion in both cultures and animal models (Iovino et al. 
2013; Sohal et al. 2014). Epithelial expression of PAFr in the small airways of 
smokers and COPD smokers is comparable to my previous findings in large 
airways (chapter 4; page 95-98), suggesting a smoking effect on upregulation 
of PAFr throughout the airway tree, but intensified in smoking-related 
obstructive disease. 
 
The regression analysis in the smokers and COPD groups produced 
interesting outcomes. I did not find any relationship between either age or 
severity of airflow obstruction in COPD groups and small airway epithelial 
PAFr-expression. However, pack-years of smoking were strongly related to 
PAFr protein levels in all current smokers. These observations in small 
airways are quite different from those in the large airways (presented in 
chapter 4).  The study populations were different between the two studies, 
which could account for these variations but since the inclusion criteria were 
similar this is unlikely. Thus, both current smoking and a history of smoking 
seem important for epithelial PAFr expression. 
 
The importance of PAFr in chronic epithelial infection and invasion is 
documented in detail in other models, which is extensively discussed in 
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chapter 2 (pages 44-55). Also, bacterial ChoP interaction with host epithelial 
PAFr is likely to be important for both bacterial adherence and then invasion 
of host cells and tissues (Weiser, Shchepetov & Chong 1997). The interaction 
between this bacterial wall ligand (ChoP) and epithelial surface PAFr seems 
to be quite specific as only pathogens expressing ChoP are able to ‘anchor’ to 
PAFr. In addition to the role of PAFr in increasing the risk of infection, host 
PAFr and its activation has been shown to potentially enhance lung cancer 
progression and so may be implicated in some major features of COPD, i.e. 
airway infection and malignancy (Hackler et al. 2014) 
 
I also observed PAFr expression on the surface of macrophages, and whether 
these receptors may possibly provide shelter to pathogens against 
inflammatory attack needs to be investigated. I did not find significant increase 
in PAFr positive inflammatory cells (phenotypically macrophages) in the 
alveoli of COPD groups compared to normal, as reported by others (Barnes 
2008). However, there was an increase in physiologically normal smokers, 
consistent with recent reports in large airways (Sohal, S.S. et al. 2015), 
potentially due to an activated innate response to pathogenic bacteria. 
 
Previous animal studies suggest PAFr to be a putative target for non-antibiotic 
therapies for treating COPD exacerbations by preventing specific binding of S. 
pneumoniae and H. influenzae to the respiratory epithelial surface (Cundell et 
al. 1995; Grigg et al. 2012; Swords et al. 2000). Existing PAFr antagonists 
were developed as potential anti-inflammatory agents in treating asthma but 
were not found to be effective. The potential role of PAFr-antagonist in 
reducing bacterial adhesion to respiratory cells in a PAFr-dependent manner 
will be discussed in the next chapter. 
 
The strengths of the present study include the use of relevant human tissue, 
with fairly robust numbers in our cross-sectional study, following up from my 
previous observation (chapter 4) that assessed PAFr expression in large 
airways only. I have only analyzed mild to moderate COPD patients, as I 
wanted to look at pathogenic mechanisms in early disease. I assessed 
epithelium of both small airways and alveoli to get a comprehensive overview 
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of the respiratory tract. There are also a few limitations to this study. Firstly, it 
is cross-sectional at a single time point and longitudinal studies are required 
to see how variable the PAFr expression is even within individuals and if it 
relates to the natural history of smokers’ airway disease and likelihood of 
AECOPD. I have analyzed PAFr-expression only at the final protein level so 
far, though ultimately that is what counts. Secondly, the control subjects were 
relatively younger, but their ages overlapped with our clinical samples. There 
was no relationship between PAFr expression and age in any group.  
 
In conclusion, epithelial PAFr expression is upregulated in both small airways 
and alveoli in smokers, but is especially increased in small airway epithelium 
in COPD-smokers. There is a uniform increase in PAFr expression in alveolar 
epithelium in smokers/COPD but not in lung interstitial inflammatory cells. 
Increased expression of PAFr in the respiratory tract could be a crucial risk 
factor for acute and chronic infections with specific respiratory bacterial 
pathogens in smokers and especially in COPD. Translational research in this 
area is still in its infancy but has huge potential to modify clinical management 
of COPD, and indeed open up a new anti-PAFr therapeutic avenue. 
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Chapter 6  
 
An antagonist of the Platelet-Activating Factor receptor inhibits 
adherence of both non- typeable Haemophilus influenzae and 
Streptococcus pneumoniae to cultured human bronchial epithelial cells 
exposed to cigarette smoke 
 
6.1 Introduction 		
As mentioned in chapter 1, tobacco smoking is the most important causative 
factor for COPD (Fletcher and Peto 1977; Lokke et al. 2006; Lundback et al. 
2003; Taylor 2010). Exposure to cigarette smoke has been shown to 
significantly increase invasive respiratory pneumococcal infections (Nuorti et 
al. 2000). Moreover, chronic exposure of mice to cigarette smoke resulted in 
significantly higher loads of NTHi and S. pneumoniae in the lungs (Voss et al. 
2015). 
 
In chapters 4 and 5, I have shown that PAFr expression is significantly 
upregulated in the airway epithelium of both the large and small airways in 
smokers and COPD patients. NTHi and S. pneumoniae may adhere to PAFr 
expressed on the luminal surface of human respiratory tract epithelial cells 
through physico-chemical interactions with phosphorylcholine (a molecular 
mimic of platelet-activating factor) on the cell wall surface of these particular 
bacteria. 
 
As discussed in chapter 2 (page 44-55), Cigarette smoke has been shown to 
induce increased expression of PAFr in lower airway epithelial cells, which 
correlates with enhanced adhesion of S. pneumoniae (Grigg et al. 2012). In 
this work, I further investigated PAFr as an anti-infective therapeutic target 
and tested the effect of a well-characterized PAFr antagonist, WEB-2086 
(Cellai et al. 2006; Cellai et al. 2002; Kato, M et al. 2004), for its potential to 
inhibit bacterial adhesion to respiratory epithelial cells by both NTHi and S. 
pneumoniae. This may provide a novel approach for the development of 
specific inhibitors of PAFr-bacterial interactions. This area needs urgent 
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attention as it could transform the therapeutics of COPD-related airway 
infection as a driver of disease progression.  
 
6.2 Overview of materials and methods 	
I employed in vitro epithelial cell culture, quantitative real-time PCR (qPCR), 
immunofluorescence microscopy to evaluate PAFr expression and bacterial 
adhesion to both CSE treated BEAS-2B cells and controls. I am grateful to Mr. 
Rory L. Fairbairn, who assisted me carrying out this work. BEAS-2B bronchial 
epithelial cells were selected for use in this work based on their previous 
application in the study of PAFr expression in response to cigarette smoke 
exposure (Grigg et al. 2012). I assessed the effect of a specific, commercially 
available PAFr-antagonist on the adhesion pattern of bacterial strains to both 
CSE-treated BEAS-2B cells and control cells. Moreover, I worked with Dr. 
David Gell to carry out in-silico analyses to investigate the specific binding site 
of PAF (natural ligand of PAFr) and PAFr, and also the specific PAFr-
antagonist (WEB-2086) to assess if the compound could be enhanced for 
better binding and increased inhibition of ChoP expressing bacterial strains. 
The specific methods are detailed in methodology section (chapter 3, page 
83-91). 
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6.3 Results 
6.3.1 Cigarette smoke extract (CSE) treatment upregulates PAFr 
expression in bronchial epithelial cells  	
Epithelial cells treated with 1% CSE exhibited significantly higher PAFr 
expression per cell compared to untreated cells as measured by 
immunofluorescence (p<0.0001) (Figure 6.1). PAFr mRNA expression 
(relative to three housekeeping genes) was 2.93 ± 0.18 (n = 4) in BEAS-2B 
cells exposed to CSE, and 2.28 ± 0.33 (n=4) in control cells (Figure 6.1). 
 
 
Figure 6.1 Cigarette smoke extract increases PAFr-expression in BEAS-2B 
bronchial epithelial cells.  
(A) Untreated BEAS-2B cells. (B) Microscopy of BEAS-2B cells exposed to 
CSE (1%, 4 hours). All micrographs show BEAS-2B cells with PAFr 
expression (anti-PAFr monoclonal antibody; 1:100, red) and nuclei stained 
with DAPI (1:5000, blue). Magnification = 400x. (C) Percentage area of PAFr 
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compared to cell nuclei area was measured using area of interest cell-tracing 
calculations. (D) PAFr mRNA expression relative to housekeeping genes. 
Bars represent standard error of the mean. 
6.3.2 CSE significantly increases NTHi and S. pneumoniae adherence 
to BEAS-2B cells 	
Exposure of BEAS-2B cells to 1% CSE for 4 hours significantly enhanced 
epithelial cell binding of S. pneumoniae and of both NTHi strains (Figure 6.2). 
Regression analyses were performed on levels of epithelial PAFr expression 
against bacterial adhesion. This demonstrated that there was a linear 
relationship between an increase in PAFr protein levels and elevated levels of 
adhesion to CSE-pretreated lung cells for all three bacterial strains (r≥0.9; 
p<0.0001) (Figure 6.3).  
 
Figure 6.2 Cigarette smoke extract increases the adhesion of NTHi strains 
and S. pneumoniae to BEAS-2B cells (n=4).  
(A) Control BEAS-2B cells showing few FITC-tagged S. pneumoniae 132 cells 
adhering to BEAS-2B cells. (B) BEAS-2B cells exposed to CSE (1%) show 
increased attachment of FITC-tagged S. pneumoniae to BEAS-2B cells. All 
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micrographs show BEAS-2B cells with PAFr expression (anti-PAFr 
monoclonal antibody; 1:100, red) and nuclei stained with DAPI (1:5000, blue). 
Magnification=400x. (C) S. pneumoniae clinical isolate 132. (D) NTHi 
reference strain NCTC-4560. (E) NTHi clinical isolate RHH3. Bars represent 
standard error of the mean. 																															
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Figure 6.3 Correlations between change in PAFr protein expression and 
change in the number of adherent bacteria to BEAS-2B cells.  
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6.3.3 WEB-2086 reduces the adhesion of S. pneumoniae and NTHi to 
CSE-treated bronchial epithelial cells 	
WEB-2086 decreased S. pneumoniae adhesion to CSE-treated BEAS-2B 
cells back to control levels at a concentration of 100 nM (p=0.0058) (Figure 
6.4).  WEB-2086 at 10 µM, but not lower concentrations, also reduced 
adhesion of the reference strain of NTHi to CSE-treated cells to control levels 
(p<0.0001) (Figure 6.4). Adhesion of the clinical strain of NTHi to CSE-treated 
BEAS-2B cells was reduced to control levels by WEB-2086 at a concentration 
of 1 µM. WEB-2086 was non-toxic to epithelial cells even at the highest 
concentration tested i.e. IC50>10 µM. 
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Figure 6.4 Inhibitory effect of WEB-2086 on the adhesion of bacterial strains 
to CSE-treated BEAS-2B cells.  
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(A) BEAS-2B cells exposed to CSE (1%) showing attachment of FITC-tagged 
S. pneumoniae clinical isolate 132. (B) Reduced attachment of S. 
pneumoniae bacterial cells to CSE-treated BEAS-2B cells due to application 
of PAFr antagonist, WEB-2086. (C) Significant reductions in S. pneumoniae 
adhesion to CSE-treated cells were observed in the presence of 100 nM, 1 
µM and 10 µM WEB-2086. (D) A significant reduction in NTHi reference strain 
(NCTC-4560) adherence to CSE-treated was observed in the presence of 10 
µM WEB-2086. (E) Significant reductions in NTHi clinical isolate (RHH3) 
adherence to CSE-treated cells were observed in the presence of 1 µM and 
10 µM WEB-2086. Bars represent standard error of the mean. 
 
6.3.4 Docking WEB-2086 to a molecular model of PAFr 	
Initial models of PAFr produced by MODELLER and I-TASSER were very 
similar (r.m.s. deviation of 3 Å over 295 Cα atom pairs), and predicted that the 
same set of amino acids would contribute to the ligand binding site. A final 
consensus model of PAFr was generated in MODELLER using NTR1 and 
CCR5 as template structures (Figure 6.5A), taking advantage of regions of 
local high sequence/structure similarity to each template. The natural PAF 
ligand and WEB-2086 were docked to the model using the AUTODOCK Vina 
package. In a search of the whole molecular surface, both PAF and WEB-
2086 consistently docked into the same deep cavity on the predicted 
extracellular face of the PAFr model (Figure 6.5A). The cavity is substantially 
larger than the WEB-2086 compound (Figure 6.5B) and a fine-grained 
docking search of this pocket identified a number of potential docking poses.  
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Figure 6.5 In silico analyses of PAFr structure and ligand binding.  
(A) Ribbon representation of the molecular model of the PAFr receptor 
(residues 8–309), based on the template structures of NTR1 (PDB 4buo) and 
CCR5 (PDB 4mbs). The expected extracellular face is towards the top of the 
page. The docking pose for WEB-2086 with the highest predicted binding 
affinity is located in a deep cleft in the central axis of the receptor. (B) Surface 
representation of the central ligand binding cleft in the PAFr model, shown 
from above. WEB-2086 is shown in stick representation. 
 
6.4 Discussion 	
In the present study, I found that in vitro exposure to cigarette-smoke extract 
increased PAFr expression and adhesion of NTHi and S. pneumoniae to 
bronchial epithelial cells. Regression analysis identified a correlation between 
PAFr expression and levels of bacterial adherence. As PAFr expression 
increased on the surface of the epithelial cells, the number of NTHi and S. 
pneumoniae cells binding per BEAS-2B cell increased linearly. 
 
Addition of PAFr antagonist (WEB-2086) reduced the adherence of both 
respiratory bacterial pathogens down to control levels, but large range of 
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effective doses depending on bacterial strains. Interestingly, the adherence of 
the S. pneumoniae clinical isolate was inhibited at a lower concentration of 
PAF antagonist compared to the NTHi strains tested. There were no 
consistent differences in the slope of the relationship between PAFr receptor 
upregulation and bacterial attachment, for the different strains tested, to 
suggest an inter-species difference in PAFr-dependent bacterial adhesion. A 
larger number of isolates of both species would need to be investigated to 
ascertain any species- or strain-specific susceptibility to WEB-2086, but it 
should be noted that varying levels of adhesion to airway epithelial cells have 
been observed across different clinical isolates of NTHi (Marti-Lliteras et al. 
2011). 
 
This is the first study reporting the efficacy of WEB-2086 in specifically 
reducing NTHi adherence to CSE pre-treated lung cells. This is also true for 
pneumococci although a similar inhibitory effect was observed for WEB-2086 
in an epithelial cell culture model of pneumococcal infection in which PAFr 
was upregulated by particulate air pollution (Mushtaq et al. 2011). The 
available data suggest that exposure to cigarette smoke may promote 
infection of the lung epithelium of COPD patients by the main bacterial drivers 
of AECOPD, NTHi and S. pneumoniae, via upregulated PAFr, though 
changes in ChoP expression may also play a part. I have also discussed the 
variation in ChoP expression that may lead to altered NTHi adherence and 
invasion, and reduced resistance to pulmonary clearance (chapter 2, page 44-
55).  
 
In this work, I tested a well-evaluated PAFr antagonist for its ability to inhibit 
the binding of NTHi and S. pneumoniae to CSE pre-treated airway epithelial 
cells. WEB-2086 was effective in significantly reducing the adhesion of both 
respiratory pathogens to CSE-exposed bronchial epithelial cells with 
demonstrated PAFr upregulation. Interestingly, the bacterial adhesion seen in 
the presence of WEB-2086 was comparable to control levels observed for the 
cultured epithelial cells for which PAFr expression had not been induced 
through CSE exposure. In terms of drug tolerability, PAF antagonists, 
including WEB-2086, have been shown to be safe in both animals and 
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humans, even at high doses over several months (Cellai et al. 2006; Cellai et 
al. 2002; Kato, M et al. 2004). Similarly, I did not find WEB-2086 to be toxic to 
BEAS-2B cells even at the highest effective level.  
 
There are a few limitations to this study. I used a commercial airway epithelial 
cell line, and further work is now needed on the anti-infective effects of 
WEB2086 using primary human cells, especially from smokers. Secondly, the 
ligand-docking studies are reliant on an in silico model of PAFr which was 
derived from the tertiary structure of related GPCRs. X-ray crystallographic 
work is required to confirm the specific PAFr-WEB2086 interactions.  
 
In summary, I investigated the anti-adhesion activity of WEB-2086 towards 
NTHi and S. pneumoniae, two major respiratory pathogens on airway 
epithelium primed by CSE to upregulate PAFr expression. I demonstrated 
strong association between PAFr upregulation and bacterial adhesion; the 
latter of which was reduced to control levels in the presence of the PAFr 
antagonist WEB-2086. Understanding the events leading to the colonisation 
of the lower respiratory tract of COPD patients with NTHi and pneumococcus, 
and to subsequent increased local and systemic inflammation, may lead to 
translation into new management strategies for COPD. Given the apparent 
tolerance of WEB-2086 in human subjects and its ability to block adhesion of 
S. pneumoniae and NTHi to respiratory epithelial cells, I am now keen to see 
clinical exploratory proof-of-concept studies of PAF antagonists undertaken in 
healthy individuals, and then in COPD patients to ascertain if they positively 
affect day-to-day symptoms as well as prevent or ameliorate AECOPD. PAFr-
antagonists represent a potential non-antibiotic, anti-infective drug for 
therapeutic interventions in COPD patients, especially perhaps those who are 
prone to frequent AECOPD, and indeed in smokers more generally who are 
vulnerable to episodes of pneumonia. 
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Chapter 7  
 
The main rhinovirus respiratory tract adhesion site (ICAM-1) is 
upregulated in smokers and patients with chronic airflow limitation 
(CAL) 
 
7.1 Introduction 
 
COPD is seriously complicated by viral as well as bacterial infections. Viruses 
are detected in 40 to 60% of COPD exacerbations (AECOPD) in PCR-based 
studies (Sykes, Mallia & Johnston 2007), and are associated with more 
severe exacerbations in terms of symptoms, resulting in longer recovery times 
and greater likelihood of hospitalization. Human rhinoviruses (HRVs) make up 
approximately 50% of all viruses isolated from COPD patients (Greenberg, SB 
et al. 2000). Furthermore, HRV prevalence and load at COPD exacerbations 
are significantly higher than in the stable state (George et al. 2014). In COPD 
patients experimentally infected with HRV, the sputum viral load correlates 
with sputum neutrophilia and interleukin-8 levels (Mallia, P. et al. 2011), i.e., 
the activation of the innate immune system characteristic of these AECOPD 
episodes. 
Respiratory tract epithelium is the primary target for viral pathogens and 
ICAM-1 has been reported as the major surface receptor for HRVs in ~60% 
serotypes, essential for host-cell entry, while low-density-lipoprotein receptor 
and related molecules serve as an entry receptor for only 10% of HRV 
serotypes (Ledford et al. 2004). Very recently, a novel receptor (CDHR3) has 
been suggested to be relevant to HRV-C attachment (Bochkov et al. 2015), 
although its relevance to HRV infection has not been fully established. 
ICAM-1 is a member of the immunoglobulin (Ig) superfamily that contains five 
Ig-like domains, a transmembrane domain, and a short cytoplasmic tail 
(Springer 1990). I have extensively discussed the characteristics of ICAM-1 in 
chapter 2 (page 57-63). The importance of ICAM-1 in physiologically normal 
smokers has been reported previously (chapter 2, page 57-63). Moreover, 
anti-ICAM-1 antibody has been shown to inhibit major (group A and B) HRV 
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replication in vitro, as well as HRV-induced inflammation and lung virus RNA 
levels in mice model (Traub et al. 2013), confirming a crucial potential role for 
ICAM-1 as a viral facilitator. However, the expression of ICAM-1 has not been 
directly investigated in large or small airways in COPD patients, which could 
be crucial for understanding the susceptibility to and effect of viral infections in 
the natural history of COPD.  
Evidence indicates that ICAM-1 also serves as an adhesion molecule for 
Haemophilus influenzae (via bacterial P5 fimbriae), which is the main bacterial 
pathogen in COPD, again especially in AECOPD (Sethi & Murphy 2008). 
Thus, ICAM-1 is an attractive target to block not only virus-receptor binding, 
but also contribute to perhaps checking ICAM-1-mediated NTHi adhesion to 
respiratory cells. This is of particular interest as there is some existing work in 
the field, but looking at only healthy smokers rather than COPD. 
In the present study, I have taken a somewhat new direction for human work, 
and tested the potential for clinical relevance of some of these previous 
observations. I have investigated whether ICAM-1 expression is upregulated 
in the epithelium of both the large and small airways, and also in the alveoli, in 
both “normal” smokers and in patients with airflow obstruction, including 
individuals with established COPD. 
7.2 Overview of materials and methods 	
I employed classical immunohistochemical methods to evaluate PAFr 
expression in the large airway epithelium in bronchial biopsies collected from 
well phenotyped participants (as detailed in methodology section, chapter 3). 
 
7.3 Results 
7.3.1 ICAM-1 expression in epithelium of large and small airways 	
Compared to normal controls, epithelial staining was increased in the apical 
areas (large airways: p<0.006; small airways: p<0.004) in NLFS, whereas in 
the CAL group, heavy ICAM-1 expression was observed throughout the 
airway epithelium (large airway: p<0.001; small airway: p<0.001), including 
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both the apical and basal cells, though basal cell staining was heaviest 
(Figure 7.1 & Figure 7.2). ICAM-1 expressing cells were significantly 
increased in the epithelium of CAL group, both in the large (p<0.007) and 
small airways (p<0.02), when compared to NLFS group. For all current 
smoker groups (NLFS and CAL analysed separately), there were positive 
relationships between pack-year smoking history and ICAM-1 expression, for 
both the large and small airways (r=0.50; p<0.03) (Figure 7.3). 
 
 
Figure 7.1 Intercellular adhesion molecule-1 (ICAM-1) expression in 
epithelium of large and small airways.  
(A, D) Representative section of small airway from a never smoker showing 
negligible ICAM-1 staining. (B,E) Typical normal lung function smoker 
showing positive staining (showed by black arrow). (C,F) Typical COPD-
smoker showing extensive ICAM-1 staining (black arrow). 
Magnification=x400. BC: basal cells; EC: epithelial cells; GC; goblet cells. 
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Figure 7.2 Quantification of ICAM-1-expressinf cells in cross-sectional study. 
(A) Large airway epithelium	
(B) Small airway epithelium	
(C) Lung alveolar epithelial cells	
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Figure 7.3 Correlations between total epithelial cells positive for ICAM-1 with 
pack-years of smoking history. 
(A) Large airway epithelium	
(B) Small airway epithelium	
(C) Lung alveolar epithelial cells	
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7.3.2 ICAM-1 positive cells in the airway Rbm 	
The Rbm in smokers and especially in COPD has been reported as hyper-
cellular (Sohal, Sukhwinder S. et al. 2010), and this was true in this study 
also. However, the only significant increase in the number of ICAM-1 
expressing cells in the Rbm was observed in small airways of the CAL group 
(p<0.02). These ICAM-1 positive cells were especially related to cells with a 
morphological fibroblast-like phenotype Figure 7.4, though the number of 
individuals with high ICAM-1 expression in large airways did seem greater in 
NLFS and especially in CAL in large airways. 
 
 
Figure 7.4 ICAM-1 expressing cells in Rbm.  
(A) Large airway. (B) Small airway. 
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7.3.3 ICAM-1 expression in the goblet cells and sub mucosal glands in 
the large airways 	
A novel finding that we did not expect, was that goblet cells in the large 
airways of NLFS (p<0.05) and CAL (p<0.004) patients showed intense ICAM-
1 expression compared to control tissues (Figure 1 & Figure 4). In addition, 
the staining intensity was significantly higher for the CAL group (p<0.04), 
compared with NLFS and NC groups combined. Similarly, we observed 
increased ICAM-1 positivity in the submucosal glands in tissues from the CAL 
group compared with both controls sets (p<0.05), and there was also higher 
staining intensity (p<0.03) (Figure 5).  
 
Figure 7.5 Photomicrograph showing ICAM-1 expression.  
(A-B) lung alveolar epithelium. (C-D) submucosal glands. (A) Representative 
sections from a never smoker. (B) Typical COPD-smoker showing positive 
staining in alveolar epithelial cells (mainly type II). (C) normal lung function 
smoker. (D) COPD-smoker showing extensive ICAM-1 staining in submucosal 
glands. Magnification: A-B=x100; C-D=x200.  
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Figure 7.6 Quantification of ICAM-1 expression in goblet cells and 
submucosal glands in the cross-sectional study.  
(A) ICAM-1 expressing goblet cells in large airway epithelium. (B) Intensity of 
ICAM-1 staining of goblet cells in large airway epithelium. Only ICAM-1 
positive goblet cells are included in this comparison. (C) ICAM-1 expressing 
submucosal glands. (D) Intensity of ICAM-1 staining of submucosal glands. 
7.3.4 ICAM-1 expression in the alveolar cells in lung parenchymal 	
Overall, approximately 15-30% of total epithelial cells, most frequently but not 
exclusive type II cells, were found to be positive in both the NLFS (p<0.008) 
and CAL (p<0.007) groups, compared with normal tissue; on an average, 
approximately 4% cells were positively stained for ICAM-1 in the control group 
(Figure 2 & 4).  
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7.3.5 Cigarette smoke extract (CSE) treatment upregulates ICAM-1 
expression in bronchial epithelial cells 	
ICAM-1 mRNA expression (relative to three housekeeping genes) was 
increased in BEAS-2B cells exposed to CSE (p<0.03; n=4) compared to 
control cells (Figure 6). Moreover, CSE exposure significantly increased 
ICAM-1 protein expression per cell compared to untreated cells (p<0.003) 
(Figure 6).  
Figure 7.7 Photomicrograph showing ICAM-1 expression in bronchial 
epithelial cells.  
(A) BEAS-2B control cells. (B) BEAS-2B cells pretreated with CSE (1%, 4 
hours). (C) CSE 1% increases ICAM-1 transcript level, assessed by 
quantitative RT-PCR and normalised for three housekeeping gene. (D) CSE 
(1%) also increases protein expression on cultured epithelial cell culture, 
quantified by computerized image analysis software. Magnification=400x. 
(Blue: nuclear stain DAPI; Green: Alexa Fluor 488 showing ICAM-1 stain). 
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7.4 Discussion 	
This is the first comprehensive report of increased ICAM-1 protein expression 
in epithelium of both the large and small airways in smokers but especially in 
patients with chronic airflow limitation (CAL), including individuals with definite 
COPD. There is some up-regulation in the alveolar epithelium of the lung 
parenchyma but this is less marked than in the airways, and with no 
difference between normal smokers and obstructed smokers or ex-smokers. I 
also found increased ICAM-1 expression in goblet cells in large airway from 
smokers and CAL patients. Furthermore, ICAM-1 expression in the 
submucosal glands was increased in CAL group compared to smokers.  
I analysed all individuals with airflow obstruction together as a single group, 
as there was no obvious difference in regard to ICAM-1 expression in the 
respiratory tract between those with SAD only and those with more advanced 
and classic COPD. Moreover, ICAM-1 expression, both at the mRNA and 
protein level, was upregulated in cultured bronchial epithelial cells exposed to 
cigarette smoke extract. These findings, taken as a whole may be crucial for 
understanding the vulnerability of smokers and especially patients with airflow 
obstruction to airway infections, specifically with HRV and NTHi, although for 
the latter, platelet-activating factor receptor (PAFr) upregulation may be of 
even greater importance (chapter 4 and chapter 5). Clinical relevance of 
increased ICAM-1 expression in the pathogenesis of smoking-related airway 
diseases including COPD has been suggested previously, but mainly through 
indirect evidence, which is summarized on pages 57-63. Briefly, HRV has 
been detected in lower airway specimens such as sputum from children with 
wheezy bronchitis (Horn, Reed & Taylor 1979), and brushed cells from 
allergic volunteers experimentally infected with RV16 (Gern et al. 1997) by 
RT-PCR and culture. Moreover, compared with normal control, cultured 
airway epithelial cells from patients with COPD showed increased 
susceptibility to RV infection, and also higher levels of mRNAs encoding 
ICAM-1 (Schneider et al. 2010). Mechanistically, HRV itself upregulated 
membrane-bound ICAM-1 expression via NF-κβ-dependent mechanisms, in 
normal primary human bronchial epithelial cell cultures (Papi & Johnston 
1999).  
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In this study, I did not find any correlation between cellular ICAM-1-expression 
in the airway and either age or lung function in CAL group, but ICAM-1 
expression in both the large and small airways was significantly correlated 
with smoking history, with a wide range of pack-years represented.  
My data also suggest that in addition to respiratory epithelium, large airway 
goblet cells and submucosal glandular cells may also be involved in HRV 
pathogenesis. Empirically, airway viral infection results in mucus 
hypersecretion, which may play a role in the pathogenesis of severe airway 
obstruction in AECOPD. Notably, I showed increased ICAM-1 expression in 
goblet cells and submucosal glands in the large airway of smokers, but 
especially so in CAL patients. Furthermore, the intensity of staining of these 
cells was markedly heavier in the CAL group. Previous research has shown 
that HRV infection could upregulate ICAM-1-mRNA and inflammatory 
cytokines in submucosal gland cells, and, an anti-ICAM-1 antibody blocked 
both RV infection as well as post-infection production of these cytokines in 
submucosal gland cells (Yamaya et al. 1999). Thus, airway goblet and 
submucosal glands may be an important potential target of RV infection, and 
given that there is marked hypertrophy and hyperplasia of this glandular 
tissue in COPD, it again adds to the vulnerability of these patients to HRV at 
acute exacerbations. 
In addition to being a receptor for the majority of HRV serotypes, ICAM-1 may 
also serve as an adhesion receptor for Haemophilus influenzae (Avadhanula, 
Rodriguez, Devincenzo, et al. 2006). Blocking cell surface ICAM-1 with 
specific antibody significantly reduced the adhesion of NTHi to A549 
respiratory epithelial cells (Avadhanula, Rodriguez, Ulett, et al. 2006). It has 
been shown that NTHi itself upregulates ICAM-1 expression as incubation of 
respiratory epithelial cells with NTHi increased ICAM-1 expression by four-
fold, both at the mRNA and surface protein levels (Frick et al. 2000). 
Pretreatment of bronchial epithelial cells (BEAS-2B) and primary bronchial 
epithelial cells in culture with NTHi significantly up-regulated ICAM-1 and 
enhanced adhesion of HRV to these cells (Gulraiz et al. 2015). These studies 
in relation to NTHi did not take into account the possibility of co-regulation of 
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ICAM-1 with Platelet Activating Factor receptor (PAFr), which we have 
previously suggested to be the main airway adhesion site for pathogenic 
Haemophilus with a high correlation (chapter 6, page 120). Work on potential 
interactions between these two adhesion systems is now urgently needed, 
which could lead to novel non-antibiotic, anti-infective therapeutic strategies 
that could break some of these postulated vicious cycles involving microbial 
adhesion molecules. 
In this study, I have found that alveolar epithelial cell ICAM-1 expression was 
increased equivalently in smokers and the CAL group, with type II cells being 
the predominant cell type affected. Empirically, staining was much less 
marked than in the airways. Burns et al also previously reported increased 
ICAM-1 expression in type II pneumocytes in mice lung tissue exposed to S. 
pneumoniae (Burns, A R, Takei & Doerschuk 1994), potentially facilitating 
CD18-dependent neutrophil emigration into sites of acute inflammation. They 
did not explore the possibility of increased microbial vulnerability, which is 
likely to exist, though the major potential for infection would seem to be 
airways, which fits with clinical experience. 
The strengths of the present study include the use of abundant and relevant 
human tissue in well phenotyped individuals with mild-to-moderate obstructive 
airway disease, focusing on pathogenic mechanisms in relatively early 
disease with few confounding factors such as chronic bacterial infection or 
emphysema. I had robust numbers to give sufficient power to detect these 
findings, and this was confirmed by the strong statistical outcomes.  
There are also a few limitations. Firstly, the study was cross-sectional at a 
single time point and longitudinal studies would be better able to track the 
variability of ICAM-1 expression within individuals and if this relates to viral 
infectivity and the natural history of smoking-related airway disease and 
especially AECOPD prospectively. Secondly, our control subjects were 
somewhat younger on average than the clinical groups, but ages over-lapped 
substantially between groups and there was no suggestion of a relationship 
between ICAM-1 expression and age within any group. Finally, there was no 
microbiological component; we need to investigate variability in viral 
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adherence to respiratory epithelial cells in relation to ICAM-1 expression. 
In conclusion, epithelial ICAM-1 expression is upregulated throughout the 
respiratory tract in smokers, but is especially marked in subjects with chronic 
airflow obstruction, even when mild, and then in both the large and small 
airways. ICAM-1 expression in goblet cells and submucosal glands is also 
markedly increased in smokers and patients with CAL. There is an increase 
but less marked than in the airways in ICAM-1 expression in alveolar 
epithelium, especially in Type-2 cells, but this is only a smoking effect. 
Increased expression of ICAM-1 in the respiratory tract, and mostly so in the 
airways, could be a crucial risk factor for infection in the respiratory tract with 
this common viral agent in smokers and especially in AECOPD. Whether this 
increase in ICAM-1 expression encourages NTHi adherence to human 
airways and lung tissue needs further assessment. Translational research in 
this area is still in its infancy but has huge potential to provide new therapeutic 
targets to modify clinical management of smoking-related airflow limitation. 
Thus, further clinical research on novel anti-ICAM-1 therapies is now 
warranted. 
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Chapter 8  
 
Summary and Conclusions 
8.1 Overview of results 	
Respiratory tract infections are acknowledged to be one of the important 
contributing factors in episodes of acute exacerbations in COPD (AECOPD). 
There is also growing evidence that chronic bacterial colonization also plays a 
key role in the progression of COPD. My thesis reports novel findings from 
investigations of microbial receptors in lung tissues, especially airway 
epithelium, collected from smokers and COPD patients. I propose that 
increased expression of highly strategic adhesion sites for microbes are major 
pathological changes contributing to increased susceptibility of these 
individuals to chronic airway colonization and persistence of pathogens in the 
host. These changes in the airways were not described as comprehensively in 
the literature before, and I believe this thesis will significantly improve the 
current understanding of airway infections in COPD, and potentially lead to 
new therapeutic approaches.  
 
My thesis is divided into seven main sections. First two chapters outline the 
current evidence on the role of microbial infections in COPD. Third chapter 
details the methodological approach employed, and also contains the 
demographics of study participants. There are four main chapters elaborating 
my study results. In the first two results section (chapter 4 and chapter 5), I 
investigated the PAFr-protein expression in the respiratory tract epithelium 
(large and small airways plus lung parenchyma) of smokers and COPD 
patients, which was compared to physiologically healthy smokers and healthy 
non-smokers. I also quantified PAFr-expressing inflammatory cells in the 
parenchymal tissue. These ex-vivo findings using human tissues led me to 
investigate the effects of cigarette smoke extract in an in-vitro epithelial cell 
culture model (using commercially available BEAS-2B cells). In chapter 6, I 
confirmed that CSE increased PAFr mRNA transcripts as well as protein in 
these cells. This increase in PAFr significantly correlated with bacterial (for 
both NTHi and S. pneumoniae) adhesion to CSE-pretreated epithelial cells. 
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Furthermore, blocking PAFr expressed on CSE-treated epithelial cells 
reduced the absolute number of bacterial cells adhering to BEAS-2B cells.  
Finally in the last data chapter (chapter 7), I demonstrated an increase in the 
major adhesion receptor (ICAM-1) for ~60% HRV serotypes, in the epithelium 
of large and small airways, as well as lung parenchyma in smokers and 
patients with chronic airflow limitation (CAL), the majority with frank COPD. 
Again, I confirmed these findings in smoking-induced epithelial cell culture 
model (at both mRNA level and protein expression pattern). The summary of 
each chapter is briefly discussed below. 
 
8.1.1 PAFr-expression in large airways 	
This was the first study to comprehensively report PAFr-expression in large 
airway epithelium in COPD patients with full appropriate controls. This study 
was cross-sectional and I studied the bronchial biopsies from well phenotyped 
study groups, which was a major strength of the study (chapter 4). I 
demonstrated that PAFr expression was significantly increased in smokers, 
but especially so in subjects with COPD. Moreover, the increase in PAFr-
protein expression correlated with smoking history, and further, smoking 
cessation in COPD does not reduce the PAFr-expression levels back to 
normal. In this chapter, I was also able to utilize tissue material from a 
previous randomized control trial to assess the effect of ICS (1000mcg/day 
Fluticasone/placebo for 6 months) on PAFr-expression. I found that median 
PAFr-expression was increased after six months of ICS therapy in COPD 
patients, although statistically non-significant. This observation could be quite 
important and should encourage future research, given the fact that risk of 
pneumonia is increased in COPD patients on ICS therapy for reasons not 
really understood. The risk of lower airway bacterial infections in smokers and 
COPD patients could potentially be due to increased expression of PAFr, at 
least in some individuals.  
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8.1.2 PAFr-expression in small airways  	
This was also the first study to report on PAFr-expression in the epithelium of 
both the small airway and alveoli in COPD patients (chapter 5). A total of 45 
individuals participated in this study. Epithelial PAFr-protein expression was 
increased in small airways of smokers, but especially marked in patients with 
COPD. I also evaluated the PAFr-expression in lung parenchyma (both type I 
and type II alveolar epithelial cells), and found that PAFr-expressing alveolar 
epithelial cells were increased in smokers, compared to normal controls. 
However, this was not further enhanced in COPD patients. I also observed 
some PAFr-expressing inflammatory cells in the lung parenchyma, but these 
were not increased in COPD patients. Again, pack-years of smoking were 
strongly correlated with small airway epithelial PAFr-expression in all current 
smokers. Thus, both current smoking and a history of smoking seem 
important for PAFr expression.  
 
8.1.3 Effect of a PAFr antagonist in reducing the attachment of 
respiratory bacterial pathogens  	
I developed an in vitro epithelial cell culture model to confirm whether 
cigarette smoke extract affects PAFr-expression, and subsequent whether 
bacterial adhesion to cells (chapter 6). I found that treatment of bronchial 
epithelial cells (BEAS-2B) with CSE increased PAFr-expression, which was 
indeed significantly associated with increased bacterial (both NTHi and S. 
pneumoniae) adhesion. The levels of PAFr-protein expression significantly 
correlated with the number of bacteria adhering to epithelial cells pre-treated 
with CSE. Moreover, a specific PAFr-antagonist, WEB-2086 reduced the 
epithelial adhesion by both these bacteria to levels observed for non-CSE 
exposed cells. Moreover, WEB-2086 was found to be non-toxic towards the 
bronchial epithelial cells. In collaboration with a protein biochemist, I was able 
to carry out in silico analyses of PAFr protein, which allowed identification of 
the binding pocket for PAF/WEB-2086 in the predicted PAFr tertiary structure. 
WEB-2086 represents an innovative class of candidate drugs for inhibiting 
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PAFr-dependent lung infections by the main bacterial drivers of smoking-
related COPD. 
 
This was the first study to report competitive inhibition of WEB-2086 towards 
NTHi adhesion to CSE-treated BEAS-2B cells. WEB-2086 represents an 
innovative class of candidate drug for inhibiting PAFr-dependent lung 
infections by the main bacterial drivers of smoking-related COPD (Figure 8.1). 
 
Proof of concept clinical studies are needed, but first we need more data from 
well phenotyped clinical groups but using human airway primary cultures. It is 
also important to know whether currently used medications affect PAFr 
upregulation; how most of them have benefits long term in COPD is rather 
enigmatic. 
 
 
Figure 8. 1 Platelet activating factor receptor (PAFr) as a potential therapeutic 
target. 
Reproduced with permission form Shukla et al. (2015). Copyright Taylor and 
Francis 2015. 
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8.1.4 ICAM-1 expression  	
The final analysis involved the assessment of epithelial ICAM-1 expression in 
both the large and small airways, as well as lung parenchyma, of smokers 
and patients with chronic airflow limitation (CAL) (chapter 7). The CAL group 
included both frank COPD (smokers and ex-smokers) and subjects with small 
airway narrowing only. I found that ICAM-1 expression was upregulated 
throughout the respiratory tract (both large and small airway epithelium) in 
smokers, but was especially marked in subjects with chronic airflow 
obstruction, even when mild including CAL. Notably, I also showed increased 
ICAM-1 expression in goblet cells and submucosal glands in the large airway 
of smokers, but especially so in CAL patients. Furthermore, the intensity of 
staining of these cells was markedly heavier in the CAL group.  
Assessment of ICAM-1 in lung parenchyma was also undertaken. There was 
an increase, but less markedly so than in the airways, in ICAM-1 expression 
in alveolar epithelium, especially in Type-II alveolar epithelial cells, but this 
was only a smoking effect, i.e. no extra expression in CAL/COPD. Similar to 
PAFr expression, epithelial ICAM-1 expression in both large and small airway, 
was significantly correlated with pack-years of smoking history in both normal 
epithelium, ‘healthy’ smokers and CAL subjects. 
Finally, ICAM-1 expression, both at the mRNA and protein level, was 
upregulated in cultured bronchial epithelial cells (BEAS-2B) exposed to 
cigarette smoke extract. 
These findings taken on a whole may be crucial for understanding the 
vulnerability of smokers and especially CAL patients to airway viral infections, 
specifically with major group HRV (group A and B), but also potentially with 
NTHi. 
 
8.2 Concluding remarks 	
In my thesis, I hypothesized that airway epithelial microbial receptors (namely 
PAFr and ICAM-1) would be upregulated in physiologically ‘normal’ smokers 
and especially in COPD patients. I showed that this is the case, and further 
validated my ex-vivo lung tissue data with in-vitro epithelial cell culture 
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studies. I have provided detailed quantitative information on both the major 
microbial receptors in smokers and COPD and their relation to smoking 
history. The expression patterns for both PAFr and ICAM-1 seemed to be 
highly variable within each study groups, but it was significantly different 
between phenotypic groups. Moreover, quitting smoking does not seem to 
completely normalise the adhesin-profile, especially in COPD subjects.  
Thus, “classic” respiratory pathogens (both bacteria and viruses) seem to 
have evolved extremely important strategies to survive within their respective 
niches, by specifically adhering to attachment proteins such as PAFr and 
ICAM-1. The initial pathogen binding to the airway epithelial surface may aid 
in chronic colonization/acute infection of the host.  
My project also presented experimental evidence that it is possible to block 
PAFr in epithelial cell cultures in a way that reduces adherence of bacterial 
pathogens to these cells. This opens the possibility that these receptors could 
be targeted therapeutically in COPD, and even in Pneumococcal pneumonia. 
Translational research in this area is still in its infancy but has huge potential 
to provide new therapeutic targets. 
The knowledge gained during my PhD studies at University of Tasmania will 
enable me to develop strategies to further understand the microbial 
pathogenesis in COPD. I now plan to collect primary lung epithelial cells from 
human volunteers (normal controls, normal smokers and COPD patients); it 
would be useful to assess the PAFr expression pattern as well as investigate 
the effects of COPD medication (LABA, LAMA and ICS combinations) on 
these cells. Furthermore, infection assays will be carried out to further 
investigate the efficacy of PAFr-antagonist (WEB-2086) and novel compounds 
that colleagues in Hobart have designed. The investigation of molecular 
mechanisms involved in the adhesion of bacterial pathogen to host cell will be 
investigated in mouse models. Another major research aspect that needs to 
be investigated is the variability of both the amount and localization of ChoP 
on the cell wall of clinical isolates of NTHi in the same cohort of patients over 
time, and how these factors correlate with the natural history of COPD. ChoP 
gene (Lic A-D) mRNA expression in NTHi clinical isolates, longitudinally 
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obtained from COPD patients over one/two years, and would enable me to 
assess this bacteria-associated ChoP variability in the pathogen. Moreover, 
collection of clinical data would allow correlation of variation in ChoP 
expression with disease trajectories. Furthermore, additional studies on PAFr-
expressing macrophages, which I reported in chapter 5, could be really 
valuable, as this particular aspect of the host immune system has not been 
investigated to date, and it could be interesting to see whether PAFr- 
expression on macrophages aids in clearance of bacterial pathogens or 
impairs bacterial clearance from the host. 
Although the investigation of novel anti-PAFr/ICAM-1 therapies are 
challenging, this is now essential in order to better manage bot chronic 
infection in COPD airways ell as AECOPD while avoiding the real risk of 
increasing antibiotic-resistance in major bacterial pathogens, such as S. 
pneumoniae and non-typeable H. influenzae. I intend that all these potential 
studies, leading from my PhD outcomes, will project my career forwards, but 
to do this effectively I will need to cultivate an interest in this work among 
clinical colleagues that I work with in the future. 
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Appendix 
A1. ICAM-1 expression in large and small airway epithelium. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A.1. Epithelial ICAM-1 expressing cells (A) large airways; (B) small 
airways. 
NC: normal control; NLFS: normal lung function smoker; SAD: small airway 
disease; COPD-CS: COPD-current smoker; COPD-ES: COPD ex-smoker 	
